Clinical Practice Guideline

Management of Asthma in Children and Adults

2009

VA/DoD Evidence Based Practice
VA/DoD CLINICAL PRACTICE GUIDELINE FOR MANAGEMENT OF ASTHMA IN CHILDREN AND ADULTS

Department of Veterans Affairs
Department of Defense

Prepared by:

The Management of Asthma Working Group

With support from:
The Office of Quality and Performance, VA, Washington, DC
&
Quality Management Division, United States Army MEDCOM

QUALIFYING STATEMENTS

The Department of Veterans Affairs (VA) and the Department of Defense (DoD) guidelines are based on the best information available at the time of publication. They are designed to provide information and assist decision-making. They are not intended to define a standard of care and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably, and appropriately, occur when providers take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation.

Version 2.0 – 2009
INTRODUCTION

The Clinical Practice Guideline for Management of Asthma in Children and Adults was developed under the auspices of the Veterans Health Administration (VHA) and the Department of Defense (DoD) pursuant to directives from the Department of Veterans Affairs (VA). VHA and DoD define clinical practice guidelines as:

“Recommendations for the performance or exclusion of specific procedures or services derived through a rigorous methodological approach that includes:

- Determination of appropriate criteria such as effectiveness, efficacy, population benefit, or patient satisfaction; and
- Literature review to determine the strength of the evidence in relation to these criteria.”

The intent of these guidelines is to:

- Reduce current practice variation and provide facilities with a structured framework to help improve patient outcomes
- Provide evidence-based recommendations to assist providers and their patients in the decision-making process concerning the diagnosis and management of patients with asthma
- Identify outcome measures to support the development of practice-based evidence that can ultimately be used to improve patient healthcare outcomes.

2009 UPDATED VERSION OF THE GUIDELINE

This clinical practice guideline updates the 1999 version of the DoD/VA Guideline on Management of Asthma for Adults and Children Age 6 years and over. The current guideline incorporates the two sections of the 1999 guideline into one document. Where evidence suggests differences in the management between adults and children, age-specific recommendations are provided. The objective of the DoD/VA Working Group in developing this guideline was to incorporate information from existing national recommendations into a format that would maximally facilitate clinical decision-making.


The DoD/VA Working Group (WG) reviewed these two guidelines and made the decision to adopt several of their recommendations. The Working Group developed a revised comprehensive clinical algorithm that incorporates the diagnosis and management of asthma in both children and adults. Additional recommendations were added addressing specific issues that the Working Group considered to be of importance to patients in the healthcare system of the VA and DoD. Hence, this DoD/VA updated version of the Asthma guideline includes evidence-based recommendations for routine primary care and additional recommendations suggesting specific actions for diagnosis and treatment of exercise-induced asthma in active young adults. These specific recommendations may better serve providers caring for service persons with asthma among the active duty population.

The guideline/algorithms are designed to be adapted to an individual facility’s needs and resources. They will also be updated periodically or when relevant research results become available. The guideline should be used as a starting point for innovative plans that improve collaborative efforts and focus on key aspects of care. Except in very unusual circumstances, the recommendations outlined in this guideline should also serve as a framework to the care that is provided or recommended in specialty care settings.
BACKGROUND

Asthma is a chronic inflammatory disease of the lungs characterized by episodic and reversible airway obstruction. During the 1990s, rates of asthma increased in all age and racial groups, from an average of 30.7 per thousand to 53.8 per thousand in 1994. In 1998, asthma affected an estimated 17.3 million people in the United States, including over 4.8 million children. In 2005, asthma affected more than 22 million persons. In children, asthma is one of the most common chronic diseases, affecting more than 6 million children (current asthma estimates, 2006 National Health Interview Survey (NHIS), Centers for Disease Control and Prevention (CDC). [http://www.cdc.gov/asthma/nhis/06/table3-1.htm]

In 1995, asthma accounted for more than 5,000 deaths, 1.87 million emergency department visits, and over 100 million restricted activity days. There have been important gains since and the number of deaths due to asthma has declined, even in the face of an increasing prevalence of the disease (NHIS 2005). Fewer patients who have asthma report limitations to activities, and an increasing proportion of people who have asthma receive formal patient education (Department of Health and Human Services [DHHS], Healthy People 2010 midcourse review). Hospitalization rates have remained relatively stable over the last decade, with lower rates in some age groups but higher rates among young children 0–4 years of age. There is some indication that improved recognition of asthma among young children contributes to these rates. However, the burden of avoidable hospitalizations remains.

With the appropriate use of available therapies, asthma exacerbations and their consequences can be effectively controlled. The purpose of this clinical practice guideline is to help clinicians and patients make appropriate decisions about asthma care. This guideline can assist primary care providers or specialists in the diagnosis and initial management of symptoms, follow-up management, assessment of the ongoing clinical situation, emergency management of acute exacerbations, determination of appropriate treatment, and delivery of individualized interventions.

Goals of the Guideline

- Update the recommendations for the diagnosis of asthma in children and adults
- Update the recommendations for the management of asthma in children and adult.
- Address the diagnosis and management of asthma in the active duty population (including deployed, non-deployed)
- Review the evidence regarding the assessment of severity definition of disease control (addressing risk and impairment) and the use of peak flow meters
- Review the evidence regarding intervention for asthma (new treatment strategies, combination therapies, non-pharmacologic treatment, education, and written ongoing treatment plans involving the patient)
- Review the evidence and address the management of exercise-induced bronchospasm (EIB)
- Review the evidence regarding outpatient management of acute exacerbation of asthma.

---

Target population

The guideline will offer best practice advice on the following:

- Diagnosis and management of asthma in adults:
  - Special consideration for active duty members
  - Special consideration for diagnosis and management in the elderly (over age 65) or other co-morbidities
- Diagnosis and management of asthma in children.

Audiences

Primary care and allied health professionals who have direct contact with patients with asthma (in the outpatient setting), and make decisions concerning routine management of their care.

Development Process

The development process of this guideline follows a systematic approach described in “Guideline-for-Guidelines,” an internal working document of VHA’s National Clinical Practice Guideline Counsel. Appendix A clearly describes the guideline development process.

The literature was critically analyzed and evidence was graded using a standardized format. The evidence rating system for this document is based on the system used by the U.S. Preventative Services Task Force (USPSTF). (See Appendix A – Development Process.)

Evidence Rating System

<table>
<thead>
<tr>
<th>Rating</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A strong recommendation that the clinicians provide the intervention to eligible patients. Good evidence was found that the intervention improves important health outcomes and concludes that benefits substantially outweigh harm.</td>
</tr>
<tr>
<td>B</td>
<td>A recommendation that clinicians provide (the service) to eligible patients. At least fair evidence was found that the intervention improves health outcomes and concludes that benefits outweigh harm.</td>
</tr>
<tr>
<td>C</td>
<td>No recommendation for or against the routine provision of the intervention is made. At least fair evidence was found that the intervention can improve health outcomes, but concludes that the balance of benefits and harms is too close to justify a general recommendation.</td>
</tr>
<tr>
<td>D</td>
<td>Recommendation is made against routinely providing the intervention to patients. At least fair evidence was found that the intervention is ineffective or that harms outweigh benefits.</td>
</tr>
<tr>
<td>I</td>
<td>The conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention. Evidence that the intervention is effective is lacking, or poor quality, or conflicting, and the balance of benefits and harms cannot be determined.</td>
</tr>
</tbody>
</table>

Lack of Evidence – Consensus of Experts

Where existing literature was ambiguous or conflicting, or where scientific data were lacking on an issue, recommendations were based on the clinical experience of the Working Group. These recommendations are indicated in the evidence tables as based on “Working Group Consensus.”

This Guideline is the product of many months of diligent effort and consensus building among knowledgeable individuals from the VA, DoD, and academia, and a guideline facilitator from the private sector. An experienced moderator facilitated the multidisciplinary Working Group. The draft document was discussed in two face-to-face group meetings. The content and validity of each section was thoroughly reviewed in a series of conference calls. The final document is the product of those discussions and has been approved by all members of the Working Group.

The list of participants is included in Appendix H to the guideline.
Implementation

This guideline is not intended to be construed or to serve as a standard of medical care. Standards of care are determined on the basis of all clinical data available for an individual patient and are subject to change as scientific knowledge and technology advance and patterns of care evolve.

The guideline and algorithm should serve as a guide that providers can use to determine best interventions and timing of care for their patients to optimize quality of care and clinical outcomes. This should not prevent providers from using their own clinical expertise in the care of an individual patient. Guideline recommendations are intended to support clinical decision-making but should never replace sound clinical judgment. The ultimate judgment regarding a particular clinical procedure or treatment plan must be made by the provider, following discussion of the options with the patient or parent, in light of the diagnostic and treatment choices available.

Although this guideline represents the state of the art practice at the time of its publication, medical practice is evolving and this evolution will require continuous updating of published information. New technology and more research will affect and improve patient care in the future. The clinical practice guideline can assist in identifying priority areas for research and optimal allocation of resources. Future studies examining the results of clinical practice guidelines such as these may lead to the development of new practice-based evidence.

Outcomes

- **Control Symptoms:** Nighttime awakenings; need for Short-Acting Beta Agonists (SABA) for quick relief of symptoms; work/school days missed; ability to engage in normal daily activities/desired activities

- **Optimize (normal) lung function:** Forced Expiratory Volume in 1 Second (FEV1); FEV1/Forced Vital Capacity (FVC); peak flow

- **Reduce risk of exacerbation**

- **Minimize adverse effects**

- **Utilization of healthcare**

- **Working knowledge of the asthma action plan**

- **Patient satisfaction**
Content of the Guideline

The guideline consists of an algorithm that describes the step-by-step process of the clinical decision-making and intervention that should occur throughout the diagnosis, treatment, and follow-up of asthma patients. General and specific recommendations for each step are included in the annotation section. The links to these recommendations are embedded in the relevant specific steps in the algorithm.

Each annotation includes a brief background, discussion of the research supporting the recommendations and the rationale behind the grading of the evidence as well as the determination of the strength of the recommendations (SR). The SR is indicated in brackets for each of these recommendations. Readers should note that the grade relates to the strength of the evidence and not necessarily to the clinical importance of the recommendation.

Recommendations that are based on the clinical experience of the Working Group are not followed by an “SR” grade. A complete bibliography of the references used in this guideline can be found in Appendix I.
## Guideline Update Working Group*

<table>
<thead>
<tr>
<th>VA</th>
<th>DoD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald Curran, MD</td>
<td>Arthur Blain, MD</td>
</tr>
<tr>
<td>Carlos Daughaday, MD</td>
<td>Deborah Bray, RN, MSN</td>
</tr>
<tr>
<td>Debbie Khachikian, PharmD</td>
<td>Christina Colluraburke, LCDR, MC, USN</td>
</tr>
<tr>
<td>Michael Littner, MD</td>
<td>Darrel Dodson, LTC, MC, USA</td>
</tr>
<tr>
<td>Gregory Sees, RRT, RPSGT</td>
<td>Trina Davenport, HM2, USN</td>
</tr>
<tr>
<td>Rees Lee, CDR, MC, USN</td>
<td>Daniel P. Hsu, LTC, MC, USA</td>
</tr>
<tr>
<td>Julie Liss, PharmD</td>
<td>Wayne Schriner, DO, MPH</td>
</tr>
<tr>
<td>John Manning, CDR, NC, USN</td>
<td>Henry Wojtczak, CAPT, MC, USN</td>
</tr>
<tr>
<td>Michael Morris, COL, MC, USA</td>
<td>Jane Jacknewitz-Woolard, RN</td>
</tr>
<tr>
<td>Jack M. Markusfeld, COL, MC, USA</td>
<td></td>
</tr>
</tbody>
</table>

Office of Quality and Performance, VHA  
Carla Cassidy, RN, MSN, NP

Quality Management Division  
U.S. Army Medical Command  
Ernest Degenhardt, RN, MSN, ANP-FNP  
Angela Klar, RN, MSN, ANP-CS

Facilitator  
Oded Susskind, MPH

Research Team – Evidence Appraisal  
RTI International North Carolina  
Linda Lux, MPA  
Meera Viswanathan, PhD  
Kathleen Lohr, PhD

Healthcare Quality Informatics, Inc.  
Rosalie Fishman, RN, MSN, CPHQ  
Joanne Marko, MS, SLP

*Bolded names are Co-Chair of the Guideline Working Group.  
Additional contributor contact information is available in Appendix H.
TABLE OF CONTENTS BY TOPICS

INTRODUCTION ............................................................................................................................................................. 2

Guideline Update Working Group ......................................................................................................................................... 7

Algorithms ........................................................................................................................................................................... 13

Annotations ............................................................................................................................................................................ 16

1. DEFINITIONS ............................................................................................................................................................... 16

ALGORITHM A: ASSESSMENT AND DIAGNOSIS ................................................................................................. 17

2. ESTABLISHING THE DIAGNOSIS OF ASTHMA ............................................................................................... 17

2.1 Medical History and Physical Exam ......................................................................................................................... 17

2.2 Chest Radiograph ....................................................................................................................................................... 18

2.3 Exclude Alternative Diagnoses ............................................................................................................................ 19

2.3.1 Full Pulmonary Function Testing (Exclude Alternative Diagnoses) ................................................................. 22

2.3.2 Spirometry with Bronchodilators (Airflow is partially reversible) ........................................................................ 24

2.3.3 Bronchoprovocation Testing – Airway Hyperresponsiveness ................................................................................ 26

2.3.4 Other Diagnostic Tests .......................................................................................................................................... 27

2.3.5 Allergy Testing ....................................................................................................................................................... 27

2.4 Indication for Specialty Consultation ....................................................................................................................... 29

ALGORITHM B: INITIATION OF THERAPY ....................................................................................................................... 31

3. CO-MORBIDITIES FOR ASTHMA ............................................................................................................................. 31

3.1 Gastroesophageal Reflux Disease (GERD) ................................................................................................................. 31

3.2 Allergic Rhinitis/Sinusitis ............................................................................................................................................... 32

3.3 Obesity ........................................................................................................................................................................... 33

3.4 Obstructive Sleep Apnea .............................................................................................................................................. 34

4. SEVERITY CLASSIFICATION .................................................................................................................................. 35

5. INITIAL TREATMENT .................................................................................................................................... 38

5.1 Establishing Patient-Provider Partnership .............................................................................................................. 38

5.2 Reduction of Exposure to Risk .................................................................................................................................. 38

5.3 Co-morbid Conditions ............................................................................................................................................... 40

5.4 Medication .................................................................................................................................................................. 41

5.5 Patient Education ....................................................................................................................................................... 43

5.6 Plan for Improving Activity Level (Asthma at Work/School/Daycare) ................................................................. 44

5.7 Psychosocial Assessment ........................................................................................................................................... 46
ALGORITHM C: FOLLOW-UP ............................................................................................................................ 47

6. MONITORING FOR CONTROL AND FOLLOW-UP ............................................................................................. 47
  6.1 Assessment of Control ................................................................................................................................... 47
  6.2 Adjustment of Treatment .......................................................................................................................... 50

7. FOLLOW-UP OF PATIENT WITH STABLE ASTHMA ............................................................................................ 52
  7.1 Indications for Consultation/Referral to Specialist .................................................................................... 53

INTERVENTIONS ............................................................................................................................................... 54

8. PHARMACOTHERAPY ....................................................................................................................................... 54
  8.1 Step Care Approach ................................................................................................................................... 54
  8.2. Medication ................................................................................................................................................ 55
      8.2.1 Quick Relief ............................................................................................................................................. 55
      8.2.2 Long-term Controllers ............................................................................................................................. 56
      8.2.3 Combination ........................................................................................................................................... 62
  8.3 Use of Devices (MDI without Chambers), Training Technique .............................................................. 63

9. ENVIRONMENTAL CONTROL ............................................................................................................................ 65
  9.1 Inhaled Allergens ....................................................................................................................................... 65
  9.2 Inhaled Irritants ......................................................................................................................................... 67
  9.3 Occupational Exposure .............................................................................................................................. 67

10. OTHER INTERVENTIONS ................................................................................................................................. 69
  10.1 Smoking Cessation ................................................................................................................................... 69
  10.2 Nutrition .................................................................................................................................................. 70
  10.3 Weight loss .............................................................................................................................................. 71
  10.4 Complementary and Alternative Medicine (Meditation, Acupuncture) .................................................. 72

11. SELF-MANAGEMENT/PATIENT EDUCATION .................................................................................................. 73
  11.1 Patient and Family Education (Self-Management) .................................................................................. 73
  11.2 Strategies to Deliver Patient and Family Education ................................................................................. 75
  11.3 Optimal Self-Management Tools ............................................................................................................ 76

12. ACUTE EXACERBATION .................................................................................................................................. 79
  12.1 Indication for Immediate Triage .............................................................................................................. 79
  12.2 Assessing Severity of Exacerbation ........................................................................................................ 80
  12.3 Non-Urgent Management of Acute Exacerbations (Home or Office) ...................................................... 82
  12.4. Management of Exacerbation in the Emergency Department ............................................................. 83
  12.5 Follow-up in Primary Care after Discharge from Emergency Department ............................................. 84

13. EXERCISE-INDUCED BRONCHOSPASM ....................................................................................................... 85
13.1 EIB in the Patient with Asthma ................................................................................................................ 85
13.2 EIB in the Athlete ..................................................................................................................................... 86
13.3 Bronchoprovocation Testing .................................................................................................................... 87
13.4. EIB Treatment ......................................................................................................................................... 88
14. MILITARY (ACTIVE DUTY)-SPECIFIC ISSUES ........................................................................................ 90

APPENDICES ......................................................................................................................................................... 91
Appendix A  Guideline Development Process ........................................................................................................... 91
Appendix B-1 Details of a Comprehensive History .................................................................................................. 96
Appendix B-2 Details of a Comprehensive Physical Exam ....................................................................................... 98
Appendix C DoD Service-Specific Regulation Concerning Asthma ........................................................................ 100
Appendix D Medication Tables ...................................................................................................................................... 101
Appendix E Environmental Control .......................................................................................................................... 105
Appendix F Questions for Literature Search .......................................................................................................... 107
Appendix G Acronym List ....................................................................................................................................... 109
Appendix H Participant List .................................................................................................................................... 111
Appendix I Bibliography ......................................................................................................................................... 117

TABLES
Table 1. Clinical Features Differentiating COPD and Asthma ............................................................................... 20
Table 2. Identifying Alternative Diagnoses Based on Symptoms and Tests .......................................................... 21
Table 3. Identifying Alternative Diagnoses Based on Symptoms and Tests – Pediatric-Specific .......................... 22
Table 4. Co-morbidities of Asthma in Adults and Children .................................................................................. 31
Table 5. Initial Assessment of Asthma Severity .................................................................................................... 37
Table 6. Asthma Control (All Ages) .................................................................................................................... 49
Table 7. Step Care for Medications Required to Maintain Long-Term Control .................................................. 51
Table 8. Comparison of Inhaler Devices ........................................................................................................... 64
Table 9. Core Education and Self-Management Concepts .................................................................................. 74
Table 10. Information Included in Written Asthma Action Plans .......................................................................... 77
Table 11. Classification of Acute Exacerbation: Severity and Treatment ............................................................... 81
TABLE OF CONTENTS BY ANNOTATIONS

INTRODUCTION ..................................................................................................................................................... 2

Guideline Update Working Group ...................................................................................................................... 7

Algorithms ........................................................................................................................................................... 13

Annotations ......................................................................................................................................................... 16

1. DEFINITIONS ................................................................................................................................................ 16

ALGORITHM A: ASSESSMENT AND DIAGNOSIS .............................................................................................. 17

Annotation A-1 Patient with Symptoms or Recurrent Episodes of Cough, Wheeze, or SOB ................... 17

2. ESTABLISHING THE DIAGNOSIS OF ASTHMA ....................................................................................... 17

Annotation A-2 Obtain History and Physical Examination ......................................................................... 17

Annotation A-3 Consider X-ray in New Onset if Not Previously Obtained .............................................. 18

Annotation A-4 Non-Asthma Cause of Symptoms Identified ................................................................. 19

Annotation A-5 Assess Airway Obstruction (Spirometry) ......................................................................... 24

Annotation A-6 Refer to Specialist for Evaluation and Diagnosis ............................................................ 29

ALGORITHM B: INITIATION OF THERAPY ......................................................................................................... 31

Annotation B-1 Assess Asthma Triggers, Allergies and Co-morbidities ...................................................... 31

3. CO-MORBIDITIES FOR ASTHMA ................................................................................................................ 31

Annotation B-2 Assess and Determine Initial Asthma Severity (Impairment and Risk) ........................... 35

4. SEVERITY CLASSIFICATION ......................................................................................................................... 35

5. INITIAL TREATMENT ................................................................................................................................... 38

Annotation B-3 Establish Partnership and Goals ..................................................................................... 38

Annotation B-4 Manage Triggers and Allergens ....................................................................................... 38

Annotation B-5 Manage Co-morbidities .................................................................................................. 40

Annotation B-6 Manage Medication ........................................................................................................ 41

Annotation B-7 Educate Patient and Family ............................................................................................ 43

Annotation B-8 Educate About Asthma During Activities ................................................................. 44

Annotation B-9 Assess Needs for Family Support and Mental Health Services ;
Assess Quality of Life of the Patient ........................................................................................................... 46
ALGORITHM C: FOLLOW-UP

6. MONITORING FOR CONTROL AND FOLLOW-UP

Annotation C-1 Reassess Symptom Control
Annotation C-2 Adjust/Decrease Medication as Indicated
Annotation C-3 Schedule Follow-up Visit

7. FOLLOW-UP OF PATIENT WITH STABLE ASTHMA

Annotation C-4 Reassess Diagnosis, Consider Consultation or Referral

D. INTERVENTIONS

8. PHARMACOTHERAPY

9. ENVIRONMENT CONTROL

10. OTHER INTERVENTIONS

11. SELF-MANAGEMENT/PATIENT EDUCATION

12. ACUTE EXACERBATION

13. EXERCISE-INDUCED BRONCHOSPASM

Annotation E-1 High Suspicion of Asthma or EIB?
Annotation E-2 Consider Bronchoprovocation Testing
Annotation E-3 Manage Exercise-Induced Bronchospasm (EIB)

14. MILITARY (ACTIVE DUTY)-SPECIFIC ISSUES
B. Initiation of Therapy

1. Patient with diagnosed asthma

2. Assess asthma triggers, allergies, and co-morbidities [B-1]

3. Assess and determine initial asthma severity (impairment and risk) [B-2]

4. Initiate treatment:
   1. Establish partnership and goals [B-3]
   2. Manage triggers and allergens [B-4]
   3. Manage co-morbidities [B-5]
   4. Manage medication [B-6]
   
   Educate patient and family: [B-7]
   5. Monitoring asthma
   6. Asthma during activities [B-8]
   7. Lifestyle changes
   8. Written plan for exacerbation

5. Assess and address:
   - Needs for family support and mental health services
   - Quality of life of the patient [B-9]

6. Schedule follow-up

Initial Treatment

1. Establish patient-provider partnership [B-3]
   Describe goals of treatment
   Explain nature of asthma disease
   Utilize a variety of educational strategies

2. Manage the environment [B-4]
   Describe environment controls
   Identify triggers and allergens
   Develop environment modification plan

3. Manage co-morbidities [B-5]
   Co-morbidities contributing to symptoms
   Co-morbidities affecting adherence to treatment

4. Manage medication [B-6]
   Describe the medication plan
   Explain use of drugs and side effects
   Teach use of devices

Patient and Family Education

5. Monitoring asthma
   Describe benefit of asthma control
   Teach use of peak flow meter
   Teach recognition of asthma symptoms
   Explain use of diary and zones if part of an Asthma Action Plan

6. Asthma at work/school/day care [B-8]
   Explain exercise-induced asthma
   Plan for improving activity level
   Provide letter for school/day care

7. Lifestyle changes
   Exercise
   Weight loss
   Smoking cessation

8. Plan for exacerbation
   Describe warning signs of exacerbation
   Develop plan for episode
   Establish contact with clinic and provider

8/25/2009
Follow-up for patient with stable asthma

2

Reassess:
- Symptoms control (impairment and risk)
- Response to therapy (based on history and spirometry)
- Need for quick relief medication
- Side effects
- Adherence
- Family concerns

[C-1]

3

Is patient’s asthma (impairment and risk) controlled?

4

Adjust/decrease medication as indicated [C-2]

5

Are there co-morbid conditions contributing to symptoms?

6

Manage co-morbid conditions

5

Yes

7

Problems with adherence or appropriate technique?

8

Address adherence to medication

7

Yes

9

Problems with environment identified?

10

Develop plan to minimize exposure

9

Yes

11

Other non-asthma Dx identified?

12

Evaluate alternative Dx and treat as indicated

11

Yes

13

Increase medication as indicated [C-2]
- Reassess diagnosis
- Consider consultation or referral [C-4]

14

Provide, review and update patient education and written action plan

- Assess need for family support
- Address preventive health maintenance (See sidebar D)

10

Schedule follow-up visit [C-3]

Sidebar D: Preventive Health
- Vaccination (flu shot)
- Counseling/Education
- Monitoring for long-term medication
- Adverse effects
- Smoking cessation

11/8/2009
Annotations

1. DEFINITIONS

**Asthma** is a chronic inflammatory disorder of the airways.

**Chronically inflamed airways** are hyperresponsive; they become obstructed and airflow is limited when airways are exposed to various risk factors. These episodes are usually associated with widespread but variable airflow obstruction, which is often reversible either spontaneously, or with treatment.

**Control** is the degree to which the manifestations of asthma (symptoms, functional impairments, and risks of untoward events) are minimized and the goals of therapy are met.

**Exercise-induced asthma** involves episodes of airway obstruction in individuals who have the underlying chronic condition that is triggered by exercise.

**Exercise-induced bronchospasm or hyperreactivity** is a disorder of the airways as a result of exercise in patients who have normal baseline spirometry and are not considered to have chronic inflammation of the airways.

**Impairment** involves functional limitations the patient is currently experiencing or has recently experienced.

**Severity** refers to the intrinsic intensity of the disease process. Severity is most easily and directly measured in a patient who is not currently receiving long-term control treatment.

**Risk** is the likelihood of either asthma exacerbations, progressive decline in lung function (or, for children, reduced lung growth), or risk of adverse effects from medication.
ALGORITHM A: ASSESSMENT AND DIAGNOSIS

2. ESTABLISHING THE DIAGNOSIS OF ASTHMA

Establishing the diagnosis of asthma primarily rests on obtaining a solid clinical history suggestive of airway hyperreactivity that includes symptoms such as shortness of breath (SOB), cough, wheezing, or chest tightness and objective evidence of reversible airway obstruction by either spirometry or bronchoprovocation testing. Since many disease processes share similar clinical symptoms, the clinician should not rely solely on symptoms for diagnosing asthma and should always consider alternative diagnoses that mimic asthma. Additional imaging studies, pulmonary function testing, or biomarkers of inflammation are often required to rule out other causes. Diseases such as chronic obstructive pulmonary disease (COPD), sarcoidosis, congestive heart failure, and vocal cord dysfunction require a much different approach for diagnosis and treatment. It is imperative that the clinician carefully examine the clinical history, spirometric findings, and response to treatment to reach the correct diagnosis and to provide the proper long-term care of patients with asthma. Some evidence suggests that many patients are incorrectly diagnosed and treated for asthma when they have an alternative diagnosis.

Annotation A-2 Obtain History and Physical Examination

2.1 Medical History and Physical Exam
(Episodic symptoms of airflow obstruction or airway hyper-responsiveness are present)

BACKGROUND

A complete history and physical exam is the first step in establishing the diagnosis of asthma. Characteristic symptoms of shortness of breath, wheezing, cough, chest tightness, or nocturnal awakenings may suggest the diagnosis. The history should emphasize recurrence of symptoms with associated factors such as exercise, viral infections, or environmental exposures. Physical exam may demonstrate wheezing or suggest other diagnoses. For pediatric patients, a thorough history and physical exam is particularly important. For children too young to perform spirometry, the diagnosis of asthma is often solely based on the history and physical exam without the benefit of objective evidence. Waiting to diagnose asthma until the child is old enough to perform spirometry or other objective measures is inappropriate and unnecessarily delays treatment.

ACTION STATEMENT

Complete and document a thorough history of asthma symptoms and physical examination in all patients suspected of having asthma.

RECOMMENDATIONS

1. During the diagnostic evaluation a thorough history should be performed to include focus on the following elements (see Appendix B-1 for expanded details of the history):
   a. Characterization of symptoms related to airway obstruction or airway hyper-responsiveness to include cough, wheezing, shortness of breath, chest tightness, and sputum production
   b. In children, cough may be the only presenting symptom, while wheezing may not be present in some patients with asthma
c. The pattern of symptoms should be characterized to include onset, duration, frequency, diurnal variation, and seasonality
d. Precipitating and aggravating factors (including occupational exposure)
e. Prior diagnosis, prior symptoms, prior exacerbations, and prior therapies
f. Review of all current medications including over-the-counter and supplements
g. Family and social history.

2. In children, a thorough birth history must also be obtained. Important factors in a birth history would include evidence of maternal smoking, prematurity, chronic lung disease, bronchopulmonary dysplasia, and postnatal smoke exposure.

3. Careful review of systems for any condition which can mimic asthma, such as pulmonary emboli, congestive heart failure, congenital heart disease, viral syndromes, or hypersensitivity pneumonitis.

4. During the diagnostic evaluation, a thorough physical examination should be performed, emphasizing findings in the following areas (see Appendix B-2 for expanded details of the physical exam):
   a. Upper respiratory tract, including presence of increased nasal secretions, mucosal swelling, or nasal polyps
   b. Chest, including wheezing during normal breathing or prolonged forced exhalation, hyperexpansion of the thorax, use of accessory muscles, or chest deformity
   c. Skin, including the presence of atopic dermatitis or eczema
   d. Absence of the above findings does not exclude the diagnosis of asthma and the examination should include findings that may support alternative diagnoses (see Appendix B-2)
   e. Consider cardiac evaluation of all murmurs or evidence of cardiovascular disease before initiating, or concurrent with initiating, asthma therapy.

**DISCUSSION**

The symptom complex in any patient suspected of having asthma is paramount in recognizing and establishing treatment options for any patient. The episodic nature of asthma symptoms helps to differentiate asthma from other respiratory disorders.

The presenting symptom complex serves as the basis for the future diagnostic evaluation and for defining the severity of impairment and risk for any individual patient.

---

**Annotation A-3** Consider X-ray in New Onset if Not Previously Obtained

2.2 Chest Radiograph (Exclude alternative diagnoses)

**BACKGROUND**

The chest radiograph may be an invaluable tool for excluding other diagnoses that masquerade or complicate the diagnosis and/or treatment of asthma. A chest radiograph can provide key information regarding heart anatomy, lung parenchyma, and mediastinal structures not readily detected by physical exam. Every patient diagnosed with asthma should have at least one chest radiograph during their initial evaluation to help exclude other diagnoses. In children, chronic wheezing and cough may represent a vascular ring (suggested by a right-sided aorta), congestive heart failure, pneumonia, or a variety of other non-asthmatic diagnoses.

**ACTION STATEMENT**

Obtain a chest radiograph during the initial evaluation for asthma if not done recently.
**Recommendations**

1. In the pediatric and adolescent patients, a chest radiograph should be considered during the initial treatment period to rule out other diagnoses.

2. In the adult patient with new symptoms suggestive of asthma, a chest radiograph should always be obtained during the initial evaluation.

**Discussion**

The prevalence of other diseases in a pediatric patient with cough or wheezing makes a chest radiograph less useful during the evaluation and initial treatment of asthma in the pediatric patient.

There is a higher likelihood of other diseases found in the adult population being evaluated for asthma. In most cases, a chest radiograph during the initial evaluation will be normal but may exclude other diagnoses.

**Evidence Statements**

- Relatively few new tests have been developed that facilitate the diagnosis of asthma in children 3 years of age or younger. In clinical practice, 3 evaluations—chest radiography, sweat chloride testing, and allergy skin testing—generally serve as standards of cost-effective assessment for eliminating other illnesses and confirming a diagnosis in the asthmatic child (Strunk, 2002).

- The routine use of spirometry and bronchoprovocation testing is warranted, but other tests, such as full PFT, CXR, and cardiac and laboratory evaluations, have limited diagnostic value in the active duty patient population (Morris et al., 2002).

- The chest radiograph is generally normal in patients with asthma and therefore not useful as an asthma outcome measure (O’Connor, 1994).

**Annotation A-4 Non-Asthma Cause of Symptoms Identified**

2.3 Exclude Alternative Diagnoses (Additional studies)

**Background**

A fundamental tenet of the diagnosis of asthma is a thorough evaluation and exclusion of alternative diagnoses that may masquerade as asthma or that may co-exist and complicate the evaluation and treatment of asthma. The accurate diagnosis of asthma requires the exclusion of alternative diagnoses that may present with shortness of breath (SOB), wheezing, cough, or other symptoms suggestive of asthma. Exclusion/inclusion of alternative diagnoses starts with a thorough history and physical exam from which a differential diagnosis and a rational approach to additional testing can be developed.

**Action Statement**

Consider differential diagnoses when diagnosing asthma. Refer to a specialist when symptoms, examination, or testing suggests alternative diagnoses.

**Recommendations**

1. Alternative diagnoses should be considered in all patients, and in particular those over age 30 and under age two with new symptoms suggestive of asthma. (see Tables 2 and 3)

2. A significant history of smoking exceeding 20 pack years makes the diagnosis of COPD more likely than asthma.
3. Absence of airway obstruction on initial spirometry should prompt consideration for alternative diagnoses and additional testing.
4. Abnormalities found on Chest X-Ray (CXR) screening should prompt referral to a specialist for further evaluation.
5. When there is no clear response to initial therapy, other significant causes of airway obstruction must be considered.

**DISCUSSION**

COPD and asthma are frequently distinguishable based on history (and examination) in untreated patients presenting for the first time. Features from the history and examination (such as those listed in Table 1) should be used to differentiate COPD from asthma whenever possible.

**Table 1. Clinical Features Differentiating COPD and Asthma**

<table>
<thead>
<tr>
<th>Clinical Features</th>
<th>COPD</th>
<th>Asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoker or ex-smoker</td>
<td>Nearly all</td>
<td>Possibly</td>
</tr>
<tr>
<td>Symptoms under age 35</td>
<td>Rare</td>
<td>Often</td>
</tr>
<tr>
<td>Chronic productive cough</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Breathlessness</td>
<td>Persistent and progressive</td>
<td>Variable</td>
</tr>
<tr>
<td>Nighttime waking with breathlessness and/or wheeze</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Commonly associated with atopic symptoms and seasonal allergies</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Significant diurnal or day-to-day variability of symptoms</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Favorable response to inhaled glucocorticoids</td>
<td>Inconsistent</td>
<td>Consistent</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Symptoms</td>
<td>Test: Results</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>• See VA/DoD CPG for COPD, Sec. 2.4 (see Table 1)</td>
<td>• ABG: hypercapnia</td>
</tr>
<tr>
<td>Allergic Rhinitis</td>
<td>• Seasonal or chronic rhinorrhea/nasal obstruction</td>
<td>• Trial of antihistamines</td>
</tr>
<tr>
<td></td>
<td>• Daytime and/or morning cough</td>
<td>• Allergy testing</td>
</tr>
<tr>
<td></td>
<td>• Nasal steroids</td>
<td>• Nasal steroids</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastro-esophageal Reflux (GERD)</td>
<td>• Heartburn</td>
<td>• Trial of H2-blocker or proton pump inhibitors</td>
</tr>
<tr>
<td></td>
<td>• Irritable after feeding [children]</td>
<td>• Consider GI referral for pH probe: reflux</td>
</tr>
<tr>
<td></td>
<td>• Commonly asymptomatic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congestive Heart Failure / Coronary Artery Disease (CAD)</td>
<td>• Fatigue</td>
<td>• Echocardiogram: low LVEF</td>
</tr>
<tr>
<td></td>
<td>• Orthopnea</td>
<td>• diastolic dysfunction</td>
</tr>
<tr>
<td></td>
<td>• Paroxysmal nocturnal dyspnea</td>
<td>• BNP: Elevated</td>
</tr>
<tr>
<td></td>
<td>• Dyspnea on exertion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Edema</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weight gain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hypertension</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Coronary Artery Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vocal cord dysfunction (VCD)</td>
<td>• Poor response to asthma Rx</td>
<td>• Laryngoscopy: inspiratory vocal cord closure</td>
</tr>
<tr>
<td></td>
<td>• Inspiratory wheeze/stridor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Episodic dyspnea</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rapid onset/relief</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Emotional trigger</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergic bronchopulmonary aspergillosis (ABPA)</td>
<td>• Brownish sputum, wheezing, SOB, fever, malaise</td>
<td>• Blood: eosinophilia</td>
</tr>
<tr>
<td></td>
<td>• Blood: eosinophilia</td>
<td>• Serum precipitins to aspergillus</td>
</tr>
<tr>
<td></td>
<td>• Serum precipitins to aspergillus</td>
<td>• Very elevated IgE</td>
</tr>
<tr>
<td></td>
<td>• Recurrent fleeting infiltrates, bronchiectasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis – Multisystem inflammatory disorder; granulomatous changes primarily found in lung</td>
<td>• Asymptomatic, SOB, wheezing, cough</td>
<td>• ACE level: Elevated hypercalcemia</td>
</tr>
<tr>
<td></td>
<td>• Episodic dyspnea</td>
<td>• Non-caseating granulomas on biopsy</td>
</tr>
<tr>
<td></td>
<td>• Sudden chest pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Presence of risk factors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tachycardia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchiectasis – Airway enlargement due to previous infections</td>
<td>• Chronic productive cough, wheezing, SOB</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolus (PE)</td>
<td>• Unresponsive to bronchodilator</td>
<td>• D-dimer: elevated</td>
</tr>
<tr>
<td></td>
<td>• Hemodynamic compromise</td>
<td>• ABG: hypoxemia</td>
</tr>
<tr>
<td></td>
<td>• Sudden chest pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Presence of risk factors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tachycardia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>• Recurrent productive cough</td>
<td>• Sweat chloride test: abnormal</td>
</tr>
</tbody>
</table>

Key: ABG Arterial Blood Gas; ACE-Angiotensin-converting Enzyme; BNP-b-type Natriuretic Peptide; CT-Computed Tomography; CXR-Chest X-Ray; gE-Immunoglobulin E; LVEF-Left Ventricular Ejection Fraction.
Table 3. Identifying Alternative Diagnoses Based on Symptoms and Tests – Pediatric-Specific

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Symptoms</th>
<th>Test</th>
<th>Radiographic Finding (CT, CXR)</th>
</tr>
</thead>
</table>
| Foreign Body                                   | • Unilateral wheeze  
• Sudden onset  
• Choking history  
• Age: 6 months-6 years                                            | • Bronchoscopy              | • CXR – Unilateral hyperinflation or atelectasis  
• Failure to deflate on expiratory or decubitus CXR                |
| Bronchopulmonary dysplasia (BPD)               | • Premature birth:  
• Hx prolonged mechanical ventilation/oxygen requirement in neonatal period. If responsive to bronchodilators and steroids, treat as asthma | N/A                         | • CXR: May appear identical to asthma patients                     |
| Laryngomalacia                                 | • Inspiratory wheeze  
• Onset prior to 6 weeks of age  
• Improves when prone  
• No bronchodilator response                                         | • Laryngoscopy              | N/A                                                                |
| Subglottic stenosis                            | • Hx of intubation  
• Biphasic wheeze, loudest in neck  
• No bronchodilator response                                             | • Bronchoscopy              | N/A                                                                |
| Tracheo/ bronchomalacia                        | • Inspiratory or expiratory monophasic wheeze  
• No bronchodilator response                                               | • Bronchoscopy              | N/A                                                                |
| Bronchiolitis (asthma exacerbation caused by viruses) | • Diffused wheeze and/or bronchi                                        | • No response to beta-2 agonist  
• Respiratory Syncytial Virus testing                                   | N/A                                                                |
| Recurrent upper respiratory infection          | • Common cold symptoms                                                  | • Reduction of respiratory symptoms after bulb suction or decongestion | N/A                                                                |

2.3.1 Full Pulmonary Function Testing (Exclude Alternative Diagnoses)

**BACKGROUND**

Full pulmonary function testing including flow volume loops, lung volumes, and diffusing capacity of the lung for carbon monoxide (DLCO) may be indicated in evaluating patients suspected of having asthma. Full pulmonary function testing can assist in clarifying the differential diagnosis when spirometry demonstrates a restrictive rather than obstructive process. Full pulmonary function testing can assist in the differentiating elements of COPD, interstitial lung disease, and restrictive lung disease due to chest wall mechanics.

**ACTION STATEMENT**

Consider full pulmonary function testing for patients with significant pulmonary symptoms and restrictive spirometry, and in many cases, those with normal spirometry.
**RECOMMENDATIONS**

1. The presence of restrictive indices on spirometry (reduction in both FEV1 and FVC) should prompt the clinician to perform full pulmonary function testing to include lung volumes and diffusing capacity.
2. In those patients with confirmed restriction on full pulmonary function testing, referral to specialty care is indicated.
3. In those patients with normal spirometry and significant pulmonary symptoms, consideration should also be given to full pulmonary function testing to exclude mild reductions in vital capacity or diffusing capacity.
4. Careful review of the flow volume loop should be performed on all spirometric exams to look for the presence of truncated or flattened loops suggestive of possible upper airway obstruction.

**RATIONALE**

Spirometric evidence of asthma in an actively symptomatic patient is characterized by the presence of obstructive indices (a reduction in FEV1/FVC ratio below 95th percentile). Absence of this finding or the presence of restrictive indices suggests other causes of lung disease that can be better characterized by lung volumes and DLCO.

Normal spirometric indices may be seen in mild lung disease or in association with a secondary process (ABPA, sarcoidosis, obesity). Full studies may elucidate the presence of hyperinflation (due to COPD or asthma) or a reduction in diffusing capacity not typical for asthma. In differentiating COPD from severe asthma, the DLCO is generally not reduced in patients with severe asthma.

Normal spirometry in a patient with active symptoms typical of asthma may actually represent vocal cord dysfunction. An abnormal inspiratory flow volume loop with normal spirometry is suggestive, but not diagnostic of vocal cord dysfunction.

**EVIDENCE STATEMENTS**

- Paradoxical inspiratory vocal cord closure is a frequent occurrence in patients with symptoms of exertional dyspnea, and should be strongly considered in their evaluation. In a cross-sectional, controlled study, fifteen percent of patients studied prospectively were found to have VCD, whereas all control subjects were negative for VCD. There was minimal difference in pulmonary function testing between VCD-positive and VCD-negative patients, whereas control subjects had higher spirometric values. Twenty percent of VCD-positive patients had abnormal flow-volume loops compared with 14 percent of patients without VCD, but after methacholine, 60 percent of VCD-positive patients developed abnormal flow-volume loops. In the VCD-positive group, 60 percent had a positive methacholine response, but there was less decrease in FEV1/FVC ratio compared with either VCD-negative patients or control subjects (Morris et al., 1999).

- “Vocal cord dysfunction often mimics asthma. VCD is characterized by episodic dyspnea and wheezing caused by intermittent paradoxical vocal cord adduction during inspiration (sometimes with abnormal adduction during expiration as well). The cause of VCD is not well understood, although some patients develop VCD in response to irritant triggers, such as fumes, cold air, and exercise. Although VCD is clearly distinct from asthma, it is often confused with asthma, leading to inappropriate medication of affected individuals with anti-asthma medications. Asthma medications typically do little, if anything, to relieve symptoms if the patient has pure VCD. VCD should be considered in the differential of difficult-to-treat, atypical asthma patients. It is important to note, however, that VCD and asthma may coexist and that VCD may complicate asthma management.” (NHLBI Asthma Guidelines 2007 – page 47)
Annotation A-5  Assess Airway Obstruction (Spirometry)

2.3.2 Spirometry with Bronchodilators (Airflow is partially reversible)

**BACKGROUND**

While the diagnosis of asthma may be based on history and physical examination alone, the confidence in the diagnosis is substantially enhanced by objective techniques such as spirometry. Spirometry should be obtained on all patients older than five years of age. The classic spirometric finding in asthma is obstructive airflow changes that partially or completely normalize after bronchodilator treatment. For the purpose of diagnosis, spirometry is an essential technique that allows documentation of airflow reversibility and demonstrates baseline function prior to treatment.

**ACTION STATEMENT**

Perform spirometry (with bronchodilators if indicated) in all adult patients and older children suspected of having asthma, to establish the presence of airway obstruction as a diagnostic study, preferably prior to initiation of treatment.

**RECOMMENDATIONS**

1. Spirometry should be performed in accordance with published standards and documented in the medical record. In general, there is no minimum age for spirometry, but patients under age 5 may not be able to perform breathing maneuvers correctly. [A]

2. A diagnosis of expiratory airflow limitation can be made in accordance with validated reference values (such as National Health and Nutrition Examination Survey (NHANES) III as recommended by the ATS/ERS guidelines).

3. The presence of obstruction should be based on a forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) value less than the fifth percentile and not on the percent reduction of the FEV1. (Healthcare providers not trained in the interpretation of spirometry should have the results reviewed by a specialist.) [B]

4. If airway obstruction is present or there is suspicion of asthma, spirometry should be repeated post-bronchodilators to establish the presence and degree of reversibility of the FEV1. [B]

5. A 10-12 percent increase in the FEV1 (and > 200 ml in adults) may be considered significant airway reversibility. [C]

**DISCUSSION**

Evidence of Reversible Obstruction (in order of preference):

- Improved spirometry following bronchodilator (>12% FEV1 improvement in children and adults; for adults, FEV1 increase must also exceed 200 ml)

- Physical exam changes following bronchodilator documented by healthcare provider (examples: improved aeration and increased expiratory time on auscultation, changes in wheezing, decreased retractions/work of breathing)

- Historical improvement in respiratory symptoms following bronchodilator described by patient or caregiver (example: decreased cough, dyspnea, or audible wheeze; decrease in nighttime awakenings due to respiratory problems).

The diagnosis of asthma should be made in conjunction with an objective measurement of airway obstruction (if feasible based on age) with reversibility.

A baseline spirometry value establishes the severity of obstruction to guide future treatment strategies.
Current guidelines recommend the NHANES III reference values with interpretation based on the 95th percentile rather than previous reference values and methods of interpretation that were not normalized for race and ethnicity.

In patients who are not able to perform a spirometry test, the diagnosis of asthma can still be made based on history and physical examination findings suggesting airway hyperreactivity (such as decreased respiratory effort following a bronchodilator or improvement of symptoms following a bronchodilator).

Evidence of reversibility with borderline airway obstruction may be considered diagnostic for the presence of asthma.

EVIDENCE STATEMENTS

- “Spirometry can demonstrate obstruction and assess reversibility in patients greater than 5 years of age. Patients’ perceptions of airflow obstruction are highly variable. Spirometry is an essential objective measure to establish the diagnosis of asthma, because the medical history and physical examination are not reliable means of excluding other diagnoses or of assessing lung status. Spirometry is generally recommended, rather than measurements by a peak flow meter, due to wide variability in peak flow meters and reference values. Peak flow meters are designed for monitoring, not as diagnostic tools.” (NHLBI 2007: Summary Guidelines – page 11)

- Objective assessments of pulmonary function are necessary for the diagnosis of asthma because medical history and physical examination are not reliable means of excluding other diagnoses or of characterizing the status of lung impairment. Although physicians generally seem able to identify a lung abnormality as obstructive (Russell et al., 1986), they have a poor ability to assess the degree of airflow obstruction (Nair et al., 2005; Shim and Williams, 1980) or to predict whether the obstruction is reversible (Russell et al., 1986). Furthermore, pulmonary function measures often do not correlate directly with symptoms. One study reports that one-third of the children who had moderate-to-severe asthma were reclassified to a more severe asthma category when pulmonary function reports of FEV1 were considered in addition to symptom frequency (Stout et al., 2006). Conversely, a majority of children in another study who had mild-to-moderate asthma classified by symptoms had normal FEV1 (Bacharier et al., 2004). These findings emphasize the importance of using multiple measures and the value of pulmonary function testing in a comprehensive assessment of asthma.” (NHLBI 2007: Asthma Guidelines – page 43)

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Performance of spirometry</td>
<td>ATS/ERS, 2005</td>
<td>III</td>
<td>Fair</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>NHLBI, 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Spirometry interpretation</td>
<td>ATS/ERS, 2005</td>
<td>II-2</td>
<td>Poor</td>
<td>Small</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Hankinson et al., 1999</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Post-spirometry bronchodilator use</td>
<td>ATS/ERS, 2005</td>
<td>III</td>
<td>Fair</td>
<td>Mod</td>
<td>C</td>
</tr>
<tr>
<td>4 Bronchodilator reversibility</td>
<td>Dales et al., 1988</td>
<td>II-2</td>
<td>Fair</td>
<td>Mod</td>
<td>C</td>
</tr>
</tbody>
</table>

**LE** = Level of Evidence; **QE** = Quality of Evidence; **NE** = Net Effect; **SR** = Strength of Recommendation (See Appendix A)
2.3.3 Bronchoprovocation Testing – Airway Hyperresponsiveness

BACKGROUND

Bronchoprovocation testing may be a useful tool when attempting to demonstrate airway hyperresponsiveness in a patient with symptoms suggestive of asthma and normal baseline spirometry. A common diagnosis in adolescents and young adults who exercise regularly is exercise-induced bronchospasm (EIB). Common methods of assessing airway hyperresponsiveness include methacholine challenge testing, exercise spirometry, or eucapnic voluntary hyperventilation. These tests in particular should be conducted on patients who exhibit symptoms consistent with asthma, but the diagnosis is not established by baseline spirometry and bronchodilator studies. Bronchoprovocation testing is usually performed by a specialist familiar with the procedure and knowledgeable on indications and pitfalls with each type of testing procedure.

ACTION STATEMENT

Consider referral for bronchoprovocation testing for those patients with symptoms suggestive of asthma with 1) normal baseline spirometry (no evidence of obstruction) and/or minimal clinical response to initial treatment; or 2) symptoms primarily associated with exertion.

For further discussion of EIB, see Annotations E-1, E-2, E-3.

RECOMMENDATIONS

1. Refer patients to a pulmonary function laboratory capable of performing bronchoprovocation testing in accordance with American Thoracic Society (ATS) standards.
2. The preferred method for bronchoprovocation testing is histamine or methacholine challenge testing. Other established methods are less commonly available such as cold air or eucapnic hyperventilation.
3. Exercise challenge testing is a less sensitive test for detecting the presence of airway hyperreactivity and may be considered for symptoms primarily associated with exertion.

DISCUSSION

Normal spirometry with negative response to bronchodilator medications may be indicative of mild intermittent disease or the lack of airway hyperreactivity.

Confirmation of airway hyperreactivity by bronchoprovocation testing can help clarify the presence of asthma. Testing should be performed by a qualified physical fitness test (PFT) laboratory and interpreted by an appropriately credentialed or trained physician for the level of bronchial hyperresponsiveness.

A positive methacholine or histamine test is usually indicative of airway hyperreactivity. A negative test excludes asthma as the underlying cause of symptoms.

A negative exercise challenge test does not exclude the presence of asthma or exercise-induced bronchospasm.

EVIDENCE STATEMENTS

- “Bronchoprovocation with methacholine, histamine, cold air, or exercise challenge may be useful when asthma is suspected and spirometry is normal or near normal. For safety reasons, bronchoprovocation should be carried out only by a trained individual. A positive test is diagnostic for airway hyperresponsiveness, which is a characteristic feature of asthma but can also be present in other conditions. Thus, a positive test is consistent with asthma, but a negative test may be more helpful to rule out asthma.” (NHLBI Summary Guidelines, 2007)
2.3.4 Other Diagnostic Tests

**BACKGROUND**

Multiple biomarkers such as exhaled nitric oxide, sputum eosinophils, and serum arginase levels are available measurements of airway inflammation. However, no specific biomarkers have been validated prospectively in regards to impacting either diagnosis or response to therapy. Furthermore, the equipment required for such measurements is prohibitively expensive and performed in specialized clinical settings.

**RECOMMENDATIONS**

1. Biomarkers such as nitric oxide are not currently validated clinical indicators of asthma severity or control and should not be used in the primary care setting as a means of diagnosis or evaluating response to therapy.
2. Biomarker evaluation is best performed in specialty clinics where such testing is frequently conducted and interpreted.

**RATIONALE**

No definitive studies exist that validate the use of biomarkers to confirm asthma diagnosis or to monitor response to treatment. The NHLBI guidelines (2007) regard biomarkers as having the potential to impact asthma care in the future but do not routinely recommend these tests outside specialized clinical settings.

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Exhaled nitric oxide is not indicated in the primary care setting for diagnosis of asthma</td>
<td>Petsky et al., 2008</td>
<td>I</td>
<td>Fair</td>
<td>I</td>
</tr>
<tr>
<td>2  Exhaled nitric oxide measurements are not recommended in the primary care setting for asthma monitoring</td>
<td>Petsky et al., 2008</td>
<td>I</td>
<td>Fair</td>
<td>I</td>
</tr>
<tr>
<td>3  Measurements of sputum eosinophils are not indicated to confirm the diagnosis of asthma or measure the response to therapy</td>
<td>Gogate &amp; Katial, 2008</td>
<td>III</td>
<td>Poor</td>
<td>I</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

2.3.5 Allergy Testing

**BACKGROUND**

Allergy testing is an important tool in the evaluation and management of patients with asthma. Assessing for specific IgE can assist in demonstrating the presence or absence of atopy as well as identifying specific antigens that may trigger or contribute to symptoms. The presence of atopy is common and an important risk factor for the development of asthma. The absence of atopy, especially in children with other atypical features, may lead to a more aggressive pursuit of alternative diagnosis. Identification of atopy, specific allergic sensitization, and co-morbid allergic rhinitis can help focus strategies for education and avoidance techniques. They may also assist to identify or strengthen indications for selection of medication and immunotherapy, and may play a role in identifying patients at risk of severe or fatal episodes.
**ACTION STATEMENT**

Consider allergy testing to assist in the diagnosis of asthma.

**RECOMMENDATIONS**

1. Consider allergy testing in patients with asthma with symptoms suggesting significant co-morbid allergic rhinoconjunctivitis or if recommended by specialty referral.
2. Allergy testing may be useful in the diagnostic evaluation of asthma to: [B]
   a. Identify atopy and co-morbid allergic rhinoconjunctivitis as risk factors for the development of asthma
   b. Identify precipitating factors and/or triggers related to asthma symptoms and worsening co-morbid allergic rhinoconjunctivitis
   c. Allergy testing in children is less sensitive.

**DISCUSSION**

Allergy testing can be accomplished by either prick/puncture skin testing or serologic methods. Established practice parameters identify prick/puncture skin tests as the preferred techniques for assessing IgE-mediated hypersensitivity. Serologic testing for allergen-specific IgE can demonstrate correlation of higher kIU levels to clinical sensitivity for some allergens that is equivalent to prick/puncture tests. However, skin prick/puncture tests generally have better overall predictability and are the preferred initial diagnostic approach.

The most appropriate age to undertake allergy testing is not well defined in the literature and is often best decided in the context of the patient’s clinical presentation. Studies have identified that even children under the age of two at high risk of atopy can demonstrate allergic sensitization. Nevertheless, the use of aeroallergen skin testing to confirm and identify specific sensitizations in children under age 2 has limited application and is generally not undertaken. Skin testing for aeroallergens, in patients 5 years of age and older, has greater clinical applicability and begins to have more robust supportive data in the literature. Unfortunately, the evidence that early intervention can prevent sensitization has not been convincing. While data may include younger children, a substantial portion of the referenced literature is limited or weighted to children age 5 and above. Additionally, the identification of sensitization in patients with asthma has greater benefit and greater clinical applicability in patients with perennial symptoms.

The appropriate number of allergens to use in testing is not well defined in the literature and is often best decided with an understanding of regional botany and in the context of the patient’s clinical presentation. Nevertheless, large panels of indiscriminate tests are not supported in the literature or general standards of care. Committees of a national specialty organization have identified a panel of important relevant North American allergens that contain fewer than 40 allergens.
### EVIDENCE TABLE

<table>
<thead>
<tr>
<th></th>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Atopy and allergic sensitization are risk factors for the development of asthma</td>
<td>Hagy et al., 1976 NHLBI, 2007 Sears et al., 2003 Sporik et al., 1990</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>2</td>
<td>Allergic sensitization is commonly associated with asthma</td>
<td>Call et al., 1992 Gruchalla et al., 2002 Huss et al., 2001 NHLBI, 2007 Pollart et al., 1989 Reid et al., 1993 Rosenstreich et al., 1997</td>
<td>II-1</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>3</td>
<td>Allergy testing can identify triggers associated with asthma morbidity and mortality</td>
<td>Call et al., 1992 Gruchalla et al., 2002 NHLBI, 2007 Pulimood et al., 2007 Reid et al., 1993 Rosenstreich et al., 1997 Targonski et al., 1995</td>
<td>II-1</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

**Annotation A-6 Refer to Specialist for Evaluation and Diagnosis**

#### 2.4 Indication for Specialty Consultation

**BACKGROUND**

While the majority of patients with asthma should be diagnosed and treated at the primary care level, some patients with more severe asthma or those whose symptoms present a diagnostic dilemma may benefit from an evaluation by a pulmonologist, allergist, or other asthma specialist.

**ACTION STATEMENT**

Refer patients with atypical presentation for evaluation and diagnosis to a specialist.

**RECOMMENDATIONS**

1. Patients who are under consideration for an asthma diagnosis by their primary care provider should be referred to a subspecialist (Allergist / Immunologist, Pulmonologist, Gastroenterologist, Otolaryngologist) if any of the following are present: [C]
   a. Findings NOT consistent with typical asthma diagnosis that should prompt referral to specialty:
      - Poor growth / failure-to-thrive (especially in infants and children)
      - Cyanosis at feeding (infants and children)
      - Vomiting at feeding (infants and children)
      - Clubbing
      - Stridor / upper airway wheeze
      - Hemothysis
• Any significant chest radiograph abnormality
• Lymphadenopathy
• Persistent oxygen requirement
• Chest pain
• Pneumothorax
• Recurrent bacterial pneumonia
• Monophonic or unilateral wheeze
• Recurrent bronchitis (only for adults)
• History of anaphylaxis
• Chronic productive cough or irreversible airway obstruction on spirometry in the absence of a diagnosis of COPD

b. Signs and symptoms are atypical, or there are problems in differential diagnosis such that the primary care provider is uncertain of making an asthma diagnosis

c. Patient requires confirmation of a history that suggests that an occupational or environmental inhalant or ingested substance is provoking or contributing to asthma.

2. Patients who have significant psychiatric, substance abuse, psychosocial, or family problems that interfere with their asthma therapy may need referral to an appropriate mental health professional for counseling or treatment. [B]

3. Patient/parent requests for consultation with subspecialist.

DISCUSSION

Most patients with asthma can be successfully managed by the primary care provider, but patients with asthma are in a continuum of severity and vary in their response to medications. Situations may arise in either establishing a diagnosis or selecting the best therapy when the specialist will be of assistance.

EVIDENCE STATEMENTS

- Patients with symptoms suggestive of asthma with atypical features may require referral to an asthma specialist for accurate diagnosis.

- Significant psychiatric, substance abuse, psychosocial, or family problems that interfere with their asthma therapy have been shown to interfere with a patient’s ability to adhere to treatment (Strunk et al., 1985, 1987).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Specialist referral assists in diagnosis of asthma or alternative diagnoses</td>
<td>AAAAI, 2006 NHLBI EPR3 2007</td>
<td>III</td>
<td>Fair</td>
</tr>
<tr>
<td>2</td>
<td>Referral of patients with significant mental health illnesses to an appropriate mental health professional for counseling to improve adherence</td>
<td>Strunk et al., 1985, 1987</td>
<td>II</td>
<td>Good</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
ALGORITHM B: INITIATION OF THERAPY

Annotation B-1  Assess Asthma Triggers, Allergies and Co-morbidities

3. CO-MORBIDITIES FOR ASTHMA

BACKGROUND

Patients diagnosed with asthma should be investigated for co-morbidities regardless of age. Patients with asthma commonly have other diagnoses that exacerbate their respiratory complaints or act to trigger asthma symptoms. Failure to identify these co-morbidities may lead to difficulty fully controlling respiratory symptoms resulting in increased asthma symptoms and exacerbations. Evidence suggests that appropriate treatment of these co-morbidities can improve asthma control. A thorough history, physical exam, and focused review of systems should be obtained to determine if these co-morbidities are present and contribute significantly in an individual patient (see Table 4).

Table 4. Co-morbidities of Asthma in Adults and Children

<table>
<thead>
<tr>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic rhinitis and sinusitis</td>
<td>Gastroesophageal Reflux Disease (GERD)</td>
</tr>
<tr>
<td>Gastroesophageal Reflux Disease (GERD)</td>
<td>Allergic rhinitis and sinusitis</td>
</tr>
<tr>
<td>Allergic bronchopulmonary aspergillosis (ABPA)</td>
<td>Allergic bronchopulmonary aspergillosis (ABPA)</td>
</tr>
<tr>
<td></td>
<td>Obstructive Sleep Apnea (OSA)</td>
</tr>
</tbody>
</table>

3.1 Gastroesophageal Reflux Disease (GERD)

BACKGROUND

Gastroesophageal reflux disease (GERD) is the retrograde regurgitation of stomach contents into the esophagus and, in some individuals, the upper airway. Acid stimulation of the esophagus has been demonstrated to cause bronchospasm and involvement of the upper airway may cause laryngospasm or even aspiration events. Investigation for GERD should be a routine part of an initial asthma evaluation in all patients, regardless of age, and should be particularly addressed in those patients with frequent heartburn or nocturnal asthma symptoms.

ACTION STATEMENT

Obtain a detailed history of the frequency of heartburn symptoms and treat for GERD if symptoms or nocturnal asthma is significant.

RECOMMENDATIONS

1. Patients with asthma should be questioned about the frequency of heartburn symptoms, effectiveness of previous treatments, and the presence of symptoms such as nocturnal cough or wheezing, morning hoarseness, or sore throat even in the absence of heartburn. [B]
2. Parents of children under age 5 should be questioned about irritability after feeds, regurgitation while supine, or complaints of chest pain that may be a manifestation of GERD. [B]
3. Treatment should include specific food avoidance (especially caffeine and alcohol), avoidance of food and drink 3 hours before bedtime, elevation of head of bed, and appropriate pharmacologic therapy. [C]


DISCUSSION

GERD symptoms are prevalent in children and adults with asthma and nocturnal reflux can contribute to nocturnal asthma symptoms. Although there is no overall improvement in asthma following medical treatment, use of proton pump inhibitors decreases nocturnal symptoms, reduces exacerbations, decreases cough, and improves quality of life. Surgical treatment is reported to reduce asthma symptoms and medication use.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GERD is a common finding in patients with asthma</td>
<td>Harding, 1999</td>
<td>II-2</td>
<td>Good</td>
<td>Mod</td>
</tr>
<tr>
<td>2</td>
<td>GERD contributes to nocturnal asthma symptoms</td>
<td>Avidan et al., 2001 Cibella &amp; Cuttitta, 2001</td>
<td>II-2 II-1</td>
<td>Fair Good</td>
<td>Mod</td>
</tr>
<tr>
<td>3</td>
<td>Medical treatment for GERD reduces symptoms and exacerbations</td>
<td>Gibson et al., 2003 Kiljander et al., 1999 Littner et al., 2005</td>
<td>I</td>
<td>Good</td>
<td>Small-Mod</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

3.2 Allergic Rhinitis/Sinusitis

BACKGROUND

There is a strong association between allergic rhinitis and asthma. The majority of school-age children with asthma have co-morbid allergic rhinitis; the association remains strong in adults and wanes in the elderly. Consistent with the concept of the airway as a continuum, treatment of allergic rhinitis can improve asthma outcomes. Accumulation of fluid in the sinuses with resultant chronic nasal drainage and post-nasal drip is a common complication in asthma patients, even in young children. A common misperception among physicians is that children do not get sinusitis. In fact, the maxillary and ethmoid sinuses are present at birth and sinusitis as a co-morbidity must be considered in all patients regardless of age.

ACTION STATEMENT

Evaluate patients with asthma who have chronic nasal drainage, nasal congestion, or postnasal drip for the presence of allergic rhinitis or chronic sinusitis as a co-morbidity affecting asthma control.

RECOMMENDATIONS

1. Patients with asthma should undergo an assessment for allergic rhinitis or sinusitis that is either seasonal or year-round in variation. This assessment should include a history of seasonal variations, specific triggers, diurnal variation, and changes in the workplace. [B]
2. Physical examination of all patients with asthma should include evaluation for the presence of conjunctival inflammation, nasal mucosal inflammation, nasal discharge, polyps, and post nasal drip. [B]
3. Consideration for allergy testing should be given to patients with asthma who have allergic rhinitis and who experience year-round symptoms or difficulty controlling asthma. [B]
4. Adequate treatment of allergic rhinitis or sinusitis should be undertaken in an effort to improve asthma outcomes. Treatment may include allergen avoidance, medications, immunotherapy, or surgical therapy. [B]
RATIONALE

There is considerable evidence for the relationship of the upper and lower airways and the concept of the airway as a continuum. Epidemiologic studies support a substantial association between allergic rhinitis and asthma.

In patients with allergic rhinitis, nasal allergen challenge has been shown to induce adhesion molecule expression and inflammatory mediators in bronchial mucosa and sputum.

Treatment of allergic rhinitis and asthma with intranasal corticosteroids decreases exhaled nitric oxide and other markers of lower airway inflammation. Antihistamine therapy in the treatment of asthma reveals positive results, and intranasal steroids and second-generation antihistamines have been reported to decrease emergency department visits for asthma.

A similar manifestation of airway continuum exists in patients with sinusitis and asthma. A direct relationship can be seen between severity of sinusitis and markers of lower airway inflammation as well as decreases in pulmonary function. Improvement in respiratory symptoms in children, who have asthma and are treated with intranasal corticosteroids and antibiotics for rhinosinusitis, is accompanied by decreases in inflammatory cells and mediators in the nose.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Allergic rhinitis/sinusitis is a common finding in patients with asthma</td>
<td>Guerra et al., 2002 Linneberg et al., 2002</td>
<td>II-2</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>2  Allergy testing should be considered in patients with asthma who have allergic rhinitis symptoms</td>
<td>Dolen, 2001 Pulimood, 2007 Yunginger et al., 2000</td>
<td>II-1</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>3  Treatment for allergic rhinitis/sinusitis improves respiratory symptoms</td>
<td>Nelson, 2003 Sandrini et al., 2003 ten Brinke et al., 2002 Tosca et al., 2003</td>
<td>II-1</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

3.3 Obesity

BACKGROUND

Obesity is an increasing problem in industrialized nations and has a significant effect on the development of asthma and asthma control. There is a higher prevalence of asthma in the overweight pediatric population. Weight loss is associated with improved asthma control and should be highly encouraged in patients with asthma.

ACTION STATEMENT

Clinicians advising patients with asthma who are overweight or obese should recommend weight loss to improve overall health and possibly asthma control.

RECOMMENDATIONS

1. Weight loss should be highly encouraged in patients with asthma who are overweight or obese to improve pulmonary mechanics, decrease exacerbations, and reduce the use of steroids, especially in children who are more likely to have asthma persistence. [C]
RATIONALE

Obesity has been associated with asthma persistence and severity in both children and adults. Although obesity itself causes alterations in pulmonary physiology that can lead to dyspnea, studies have documented specific increases in asthma among overweight and obese persons.

Children with high body weight, either at birth or later in childhood, are at increased risk for future asthma. Obese and non-obese patients with asthma have similar lung function abnormalities, but co-morbidities and altered responses to medications may significantly affect asthma control in obese people.

Obesity increases the prevalence, incidence, and possibly severity of asthma, while weight loss in the obese improves asthma outcomes. Obesity also influences asthma control and the response to standard asthma therapeutics.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Obesity is associated with asthma persistence and severity</td>
<td>Flaherman &amp; Rutherford, 2006 Schaub &amp; von Mutius, 2005 Shore, 2007 Weiss, 2005</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>2 Weight loss in overweight patients with asthma improves outcomes</td>
<td>Dixon et al., 2006 Simard et al., 2004 Stenius-Aarniala et al., 2000</td>
<td>II-2</td>
<td>Fair</td>
<td>Small</td>
<td>C</td>
</tr>
<tr>
<td>3 The effects of obesity on asthma appear to be independent of diet and physical activity</td>
<td>Camargo et al., 1999</td>
<td>II-2</td>
<td>Fair</td>
<td>Small</td>
<td>C</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

3.4 Obstructive Sleep Apnea

BACKGROUND

Obesity is associated with persistent asthma and severity in both children and adults. Sleep disturbances in patients with asthma are common. In the patients with uncontrolled asthma, recurrent cough and wheeze may interrupt sleep. Obstructive sleep apnea (OSA) as a cause for sleep disordered breathing is also relatively common. In children, OSA is often a manifestation of tonsillar and adenoidal hypertrophy and surgery may be curative. Addressing OSA effectively can dramatically improve the quality of sleep and a patient’s daytime academic / work performance.

ACTION STATEMENT

Clinicians evaluating patients who are overweight or obese and have unstable or poorly controlled asthma (particularly those with nocturnal asthma or awakenings) should assess for the presence of obstructive sleep apnea.

RECOMMENDATIONS

1. Overweight patients with asthma should be questioned about their sleep habits and hygiene and in particular a history of loud snoring, excessive daytime somnolence, and witnessed apneas.

2. Patients with excessive daytime somnolence or witnessed apneas should be referred for sleep testing (polysomnography). [B]
3. Patients with unstable uncontrolled asthma and sleep apnea should be treated with continuous positive airway pressure (CPAP). Weight loss, dental appliances, and evaluation for surgery may be considered in selected patients. [C]

**RATIONALE**

Patients who have OSA and nocturnal asthma may have similar clinical presentations to include conditions such as repetitive sleep arousals associated with changes in airflow, ventilatory effort, and decreases in oxygen saturation during sleep. Moreover, asthma and OSA may coexist in a significant number of patients.

Patients who have unstable asthma and sleep apnea demonstrate improved peak expiratory flow when treated with nasal continuous positive airway pressure (CPAP).

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Overweight patients with asthma with excessive daytime somnolence or nocturnal awakening should be evaluated for obstructive sleep apnea</td>
<td>Yigla et al., 2003</td>
<td>II-2</td>
<td>Good</td>
<td>Mod</td>
</tr>
<tr>
<td>2</td>
<td>Treatment with CPAP improves patients with asthma with OSA</td>
<td>Chan et al., 1988</td>
<td>II-2</td>
<td>Fair</td>
<td>Mod</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*

**Annotation B-2**  Assess and Determine Initial Asthma Severity (Impairment and Risk)

**4. SEVERITY CLASSIFICATION**

**BACKGROUND**

Asthma is a heterogeneous disorder with a wide range of severity. An assessment of severity is essential for determining appropriate initial therapy and need for specialty referral. The system for assessing severity has been refined from previous guidelines. It now includes the domain of risk as well as current impairment from asthma. Asthma severity is classified using standardized, widely accepted terminology. This allows for clear communication among medical providers and gives a uniform framework for the assessment of asthma.

NHLBI and GINA classifications of asthma severity are based on expert consensus. In order to provide a clear and practical initial assessment of severity, elements of both guidelines were adopted in constructing the VA-DoD severity classification table (Table 5).

**ACTION STATEMENT**

Assess current impairment and risk of exacerbation as part of initial evaluation, to determine and classify the severity of the asthma.

**RECOMMENDATIONS**

1. Current impairment and risk of exacerbations should be assessed in the initial evaluation of asthma to classify severity (see Table 5).

2. A history of asthma symptoms, nighttime awakenings, need for SABA for relief of symptoms and interference with activities should be used to assess current impairment.
3. The frequency and severity of asthma exacerbations should be used in assessing the domain of risk. Lung function and psychosocial factors may also help predict risk.

4. Spirometry should be used in the initial assessment of all patients who are capable of performing an adequate expiratory maneuver. Lung function is a measure of impairment but may also predict risk.

5. Classification of severity of the disease should be based on initial assessment of the patient who is not on long-term control therapy.

**RATIONALE**

Classification of severity may be helpful in guiding initial management, but ongoing management should be based on periodic assessment of asthma control.

**EVIDENCE STATEMENTS**

- An assessment of severity based on impairment and risk should be made to determine initial therapy, but periodic assessment of asthma control should be used to determine ongoing management (NHBLI, 2007; GINA, 2007).

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classification of Severity</td>
<td>GINA, 2007</td>
<td>III</td>
<td>Poor</td>
<td>Unknown</td>
<td>I</td>
</tr>
<tr>
<td>NHLBI, 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*
### Table 5. Initial Assessment of Asthma Severity

<table>
<thead>
<tr>
<th>SEVERITY (Assess over a period of at least 4-6 weeks)</th>
<th>Intermittent</th>
<th>Classifying Asthma Severity and Initiating Therapy</th>
<th>Persistent</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Impairment</strong></td>
<td></td>
<td><strong>Mild</strong></td>
<td><strong>Moderate</strong></td>
<td><strong>Severe</strong></td>
</tr>
<tr>
<td>Symptoms</td>
<td>≤ 2 days/week</td>
<td>&gt; 2 days/week but not daily</td>
<td>Daily</td>
<td>Throughout the day</td>
</tr>
<tr>
<td>Nighttime awakenings</td>
<td>≤ 2 x/month</td>
<td>&gt; 2x/month</td>
<td>&gt; 1x/week but not nightly</td>
<td>Nightly</td>
</tr>
<tr>
<td>Use of quick-relief for symptom control</td>
<td>≤ 2 days/week</td>
<td>&gt; 2 days/week but not daily, and not more than once on any day</td>
<td>Daily</td>
<td>Several times/day</td>
</tr>
<tr>
<td>Interference with normal activity</td>
<td>None</td>
<td>Minor limitation</td>
<td>Some limitation</td>
<td>Extremely limited</td>
</tr>
<tr>
<td><strong>Lung Function:</strong></td>
<td></td>
<td><strong>FEV1</strong>:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal FEV1/FVC:</td>
<td></td>
<td>&lt; 19 yr - 85%</td>
<td>≥ 20-39 yr - 80%</td>
<td>40-59 yr - 75%</td>
</tr>
<tr>
<td>FEV1</td>
<td>&gt; 80% predicted Normal between exacerbations</td>
<td>&gt; 80% predicted Normal between exacerbations</td>
<td>60-80% predicted</td>
<td>&lt;60% predicted</td>
</tr>
<tr>
<td>Interference with normal activity</td>
<td>None</td>
<td>Minor limitation</td>
<td>Some limitation</td>
<td>Extremely limited</td>
</tr>
</tbody>
</table>
| Risk                                                 | Exacerbations requiring systemic corticosteroids (consider severity and interval since last episode) | 0-1 x/year | Age 0-4 years: 
≥ 2 exacerbations in 6 months requiring oral or intravenous corticosteroids, OR
> 4 wheezing episodes/1 year, lasting >1 day AND risk factors for persistent asthma | | Age ≥5 years and adult: 
> 2 exacerbations per year requiring oral or intravenous corticosteroids |

Modified from NHLBI 2007 and GINA 2007 guidelines.
5. INITIAL TREATMENT

Annotation B-3  Establish Partnership and Goals

5.1 Establishing Patient-Provider Partnership

BACKGROUND

A proactive partnership between the patient and provider that identifies the patient’s perception of their asthma control and quality of life will enable the development of a treatment plan that emphasizes long-term control through medications, avoidance mechanisms, and asthma self-management.

ACTION STATEMENT

Establish an interactive partnership with patient and caregiver to optimize the patient self-management of asthma.

RECOMMENDATIONS

1. Patient and parent education on asthma self-management should begin at diagnosis and be reviewed regularly.
2. Patients and parents should be familiar with, and receive education from, the entire healthcare team: physicians, nurses, pharmacists, respiratory therapists, etc.
3. Communication with the patient/parents should focus on patient-centered goals of treatment; at every visit, reinforce self-management of asthma.
4. Written asthma action plans, developed jointly between patient and provider, should focus on daily management and techniques to manage exacerbations for all patients with asthma.

RATIONALE

Reviews of NHLBI 2007 and Cochrane Review of 36 trials show that self-management education, to include a written asthma action plan, not only reduced hospitalizations, emergency department visits, and unscheduled visits to the physicians, but improved outcomes.

EVIDENCE STATEMENTS

- NHLBI (2007) clearly supports the need for a proactive partnership between patient (and/or parent) and provider.
- Review of current evidence reveals no changes to NHLBI 2007 recommendations.

Annotation B-4  Manage Triggers and Allergens

5.2 Reduction of Exposure to Risk

BACKGROUND

Asthma symptoms may be triggered by a wide variety of occupational and aeroallergen exposures or exacerbated by certain medications. Education that addresses recognition and avoidance of these triggers will
help improve long-term asthma control and decrease the frequency and severity of exacerbations. Patients with chronic asthma are at increased risk for complications from influenza and pneumococcal pneumonia.

**RECOMMENDATIONS**

1. Patients with persistent asthma should be evaluated for possible allergen and environmental triggers that can be avoided (see Section 9 - Environmental Control), including outdoor activity if levels of air pollution are high.
2. Patients should be advised to avoid non-selective beta-blocker therapy. [B]
3. Encourage avoidance of sulfite-containing foods or other foods determined by history to trigger exacerbations. [B]
4. NSAID and aspirin use in patients with nasal polyps, severe persistent asthma, or known NSAID/ASA sensitivity should be strictly avoided. [B]
5. All patients with asthma who are older than 6 months of age should receive inactivated flu vaccine to decrease the risk of complications from infection with influenza. Patient or parents should be counseled that the vaccination will not decrease the frequency or severity of exacerbations during the flu season. [A]
6. Pneumococcal polysaccharide vaccine should be administered to adults with chronic persistent asthma. [B]

**RATIONALE**

Asthma control cannot be achieved with medications alone. Avoidance of identified triggers is essential to successful management. Patients with chronic asthma are at increased risk for complications from influenza and pneumococcal pneumonia.

**EVIDENCE STATEMENTS**

- Environmental triggers, including sulfites in food, should be identified and incorporated into patient education about avoidance (NHLBI, 2007)
- Nonselective beta-blocker drugs aggravate asthma symptoms in patients with persistent asthma (NHLBI, 2007)
- A subgroup of patients with asthma may have acute attacks precipitated by ingestion of aspirin and/or NSAIDS (NHLBI, 2007)
- Influenza and other viral respiratory infections are associated with acute exacerbations and influenza vaccine may prevent some cases of influenza, although it may not prevent the number of exacerbations during the flu season (NHLBI, 2007)
- Pneumococcal polysaccharide vaccine is safe and appropriate for all adults with chronic respiratory diseases, including asthma (ACIP, 2008). The ACIP recommends that asthma should be included among the chronic pulmonary diseases (such as COPD and emphysema) that are indications for pneumococcal polysaccharide vaccine in adults aged 19 through 64.
### EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Allergen avoidance is effective in improving asthma control (see Section 9)</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
</tr>
<tr>
<td>2</td>
<td>Nonselective beta-blocker drugs, including eye drops, may precipitate asthma attacks</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
</tr>
<tr>
<td>3</td>
<td>Sulfite avoidance prevents exacerbations in patients identified with sensitivity</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
</tr>
<tr>
<td>4</td>
<td>NSAID and ASA avoidance prevents attacks in sensitive patients</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
</tr>
<tr>
<td>5</td>
<td>Inactivated influenza vaccine is safe in patients &gt; 6 months of age with asthma</td>
<td>ACIP, 2008, NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
</tr>
<tr>
<td>6</td>
<td>Inactivated influenza prevents complications of influenza in patients with asthma, but has no effect on the frequency of exacerbations during the flu season</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
</tr>
<tr>
<td>7</td>
<td>Pneumococcal Polysaccharide vaccine is appropriate for adult patients with chronic asthma</td>
<td>ACIP, 2008</td>
<td>II</td>
<td>Poor</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*

---

**Annotation B-5  Manage Co-morbidities**

### 5.3 Co-morbid Conditions

#### BACKGROUND

Multiple conditions exist that can provoke or exacerbate asthma symptoms if left untreated. Inadequate treatment of co-morbid conditions may result in false assessments of asthma severity and control, thus complicating the long-term management and increasing the risk of treatment failure (see Annotation B-1).

#### RECOMMENDATIONS

1. Patients who do not respond to typical asthma therapy should be reevaluated for the presence of unmanaged co-morbid conditions.
2. Identify and treat conditions such as allergic rhinitis, sinusitis, gastro-esophageal reflux, obstructive sleep apnea, obesity, substance abuse, depression, or other mental health disorders to ensure optimal control of asthma.

#### RATIONALE

While the association between allergen exposure and asthma symptoms is well documented, measures to avoid allergens and other triggers may decrease attacks. However, the studies of specific avoidance interventions have generally been inconclusive with regard to asthma symptoms. The treatment of other co-morbid conditions may improve the response to medications as well as adherence.
EVIDENCE STATEMENTS

- Since the 2007 NHLBI guidelines were published, no new studies were found that provided any significant new recommendations concerning identification and treatment of co-morbid conditions.
- The NHLBI guideline recommendations are incorporated into this document for identification and treatment of co-morbidities.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Co-morbid conditions should be identified and treated to ensure optimal asthma control</td>
<td>NHLBI, 2007 &amp; 1997</td>
<td>I</td>
<td>Fair</td>
<td>B</td>
</tr>
<tr>
<td>2 Treatment of GERD with Proton Pump Inhibitor (PPI) improves asthma symptoms</td>
<td>Gibson et al., 2003 Havemann et al., 2007 Littner et al., 2005 Sharma et al., 2007</td>
<td>I</td>
<td>Fair</td>
<td>C</td>
</tr>
<tr>
<td>3 Treatment of allergic rhinitis and rhinosinusitis is recommended to improve asthma control</td>
<td>Sandrini et al., 2003 Nelson, 2003 Rabago et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>4 Allergen avoidance remains recommended; however, current evidence indicates a low likelihood of significant asthma control with avoidance measures for house dust mites</td>
<td>NHLBI, 2007 Sheikh et al., 2007</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

Annotation B-6  Manage Medications

5.4 Medication

BACKGROUND

The goals of therapy are to prevent or reduce the frequency and intensity of symptoms, prevent recurrent exacerbations, prevent decline in lung function, and improve quality of life. Medications to treat asthma are categorized into long-term control medications and quick relief medications. Long-term control medications are taken daily to achieve and maintain control of persistent asthma. Quick relief medications are used to treat acute symptoms and exacerbations. The initial medication regimen is based on asthma severity, optimal delivery devices, and safety.

(For detailed recommendations and discussion of evidence, see Section 8: Intervention – Pharmacotherapy.)

RECOMMENDATIONS

1. Patients diagnosed with persistent asthma require treatment with an inhaled corticosteroid to reduce inflammation. Additional long-term control medications such as long-acting beta agonists (LABAs) or leukotriene inhibitors may be added based on initial asthma severity and subsequent assessment of control to relieve bronchospasm. **Patients must never be treated solely with long-acting beta2-agonists.**

2. Short-Acting Beta Agonists (SABAs) should be used for relief of acute asthma symptoms. An asthma action plan is needed to guide home use of SABAs. Two to six puffs of SABA may be used in
accordance with the asthma action plan. Patients who do not experience relief after 3 doses in a one hour period OR who need a dose more frequently than every 4 hours, should seek medical care.

3. To ensure adequate medication delivery, an appropriate inhaler device should be used. Device selection must include consideration of the patient’s developmental age and ability to perform proper technique (see Table 8 Comparison of Inhaler Devices).

4. A large volume spacer such as the Aerochamber should be used in patients who have difficulty using metered-dose inhalers.

(For detailed recommendations, see Section 8: Intervention – Pharmacotherapy.)

RATIONAL

Review of NHLBI (2007) and GINA (2007) guidelines and several randomized controlled clinical trials strongly support the use of inhaled steroids as the preferred first-line agent.

A Cochrane review validates the use of MDI and VHC/spacer devices in lieu of nebulized therapy in the acute setting and for administration of daily controller medications.

EVIDENCE STATEMENTS

- Published guidelines have recommended the initiation of inhaled controller medications for all patients diagnosed with persistent asthma (NHLBI, 2007; GINA, 2007).

- The recent GINA and NHLBI guidelines also support the use of MDI/HFA and other delivery devices for effective medication delivery in lieu of nebulized medication in both the daily and acute administration setting (NHLBI, 2007; GINA, 2007).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Use of inhaled corticoid steroids (ICS) in persistent asthma is beneficial</td>
<td>GINA, 2007 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>2 Additional long-acting beta agonists in conjunction with ICS may be beneficial in controlling symptoms</td>
<td>GINA, 2007 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>3 SABAs are effective for acute asthma symptoms</td>
<td>GINA, 2007 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>4 Medication delivery is improved by the use of an appropriate device</td>
<td>GINA, 2007 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>4 Holding Chambers are as effective as nebulizers for beta-agonist treatment of acute asthma in children age &lt; 5</td>
<td>Cates et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
5.5 Patient Education

BACKGROUND
Asthma self-management education is imperative and effective in attaining validated patient outcomes and improved asthma control. Targeted asthma education provided to patients and their caregivers affords asthma knowledge, skill sets for home management, action steps for changes in asthma control, and empowerment. Integration of self-management educational components by patients and their providers reduces urgent care clinic visits and hospitalizations, improves health status, reduces symptoms, lessens limitation of activity, improves quality of life and perceived control of asthma, and improves medication adherence. Reinforcement of asthma self-management education is essential at all points of contact with the patient and their caregivers.


ACTION STATEMENT
Provide formal asthma education to all patients diagnosed with asthma and reinforce self-management skills of patients and caregivers as part of each follow-up visit.

RECOMMENDATIONS

1. Patients and their caregivers should be educated regarding the essential and basic facts about asthma that includes: [B]
   a. What defines well-controlled asthma
   b. Roles of medications
   c. Appropriate technique in using inhaler devices
   d. Self-monitoring (either symptom or peak flow-based)
   e. Identification of triggers and environmental exposure control measures
   f. When and how to handle signs and symptoms of worsening asthma
   g. When and where to seek care.

2. Asthma self-management education should be incorporated into all points of contact with the patient and his/her caregivers. [B]

RATIONALE
Asthma patient education programs have been proven effective in improving asthma outcomes. The NHLBI (2007) guidelines recommendations were adopted.

EVIDENCE STATEMENTS

- Recent meta-analysis reaffirmed the positive impact of asthma education at repeated asthma visits on outcomes such as emergency department utilization rates (Coffman et al., 2008).
EVIDENCE TABLE

<table>
<thead>
<tr>
<th></th>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Assessment of asthma control and its impact on optimal treatment strategy</td>
<td>Lundback &amp; Dahl, 2007</td>
<td>III</td>
<td>Fair</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>2</td>
<td>Inhaler technique and adherence to therapy</td>
<td>Blaiss et al., 2007</td>
<td>III</td>
<td>Fair</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>3</td>
<td>Determining personal best peak flow</td>
<td>Reddell et al., 2004</td>
<td>II-2</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>4</td>
<td>Traditional and new approaches in asthma monitoring</td>
<td>Sorkness, 2008</td>
<td>III</td>
<td>Fair</td>
<td>Significant</td>
<td>B</td>
</tr>
<tr>
<td>5</td>
<td>The effects of a peak flow-based action plan in preventing exacerbations of asthma</td>
<td>Cowie et al., 1997</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>6</td>
<td>Effects of Asthma Education on Children’s use of Acute Care Services: A Meta Analysis</td>
<td>Coffman et al., 2008</td>
<td>I</td>
<td>Good</td>
<td>Significant</td>
<td>A</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

Annotation B-8    Educate About Asthma During Activities

5.6 Plan for Improving Activity Level (Asthma at Work/School/Daycare)

BACKGROUND

A major goal of asthma therapy should be maintenance of normal, age-appropriate activity levels (this includes routine exercise as well as desired extracurricular activities). Patients should exhibit minimal, if any, symptoms during exercise and should experience regular attendance at work or school.

ACTION STATEMENT

Explain exercise-induced asthma (EIA) and the plan for improving activity level, and provide a letter for school/day care.

RECOMMENDATIONS

1. Patients should be encouraged to continue regular exercise and activities of daily living. [A]
2. Ensure family members, teachers, coaches, and school nurses are aware of the basic principles of asthma symptom recognition and management for acute exacerbation.
3. All patients should have a written asthma action plan that includes instructions for recognition of worsening conditions along with actions to take at home/work/school/daycare. [A]
4. Patients should be educated about the instructions included in the action plan.
   a. Education regarding exercise-induced asthma: [A]
      - Explain that pharmacologic therapies and other strategies may improve exercise tolerance and decrease the occurrence of exercise-related symptoms
      - Use SABA 20 minutes prior to planned exertion; if symptoms appear during activity, a repeated dose of SABA may be offered as addressed in the written asthma action plan
      - Extend warm-up periods prior to exercise.
   b. Education regarding occupational asthma: [B]
      - Obtaining serial peak flow values both at work and away from work may suggest a relationship between work and asthma
• Patients with occupation-related asthma may require referral to an occupational health specialist.

5. Managing asthma during school/daycare activities:
   a. The asthma action plan for children should be provided to the school and/or daycare [C]
   b. Establish a partnership with schools and/or daycare centers to provide education programs for staff and/or peers [B]
   c. Use of medication:
      • Controller medication:
        o If possible, schedule controller medications to be given at home and not at school or daycare
        o If patient adherence is questionable, medication may need to be given at school to ensure compliance during the school year
        o When daily controller medication is required at school/daycare, the ability of school/daycare personnel to administer the medication should be determined.
      • Rescue medication:
        o Rescue medications should be available at school/daycare
        o For school-age children, determine availability of rescue medication; some school systems do not allow children to personally carry any medication
        o For daycare or young school-age children, the ability of the staff to administer medication should be determined.

EVIDENCE STATEMENTS

- Strong evidence supports the use of written asthma action plans (Gibson et al., 2003; NHLBI, 2007).
- A proactive partnership with schools and/or daycare centers should be established to improve asthma management and control in children (Gerald et al., 2006; Haltlerman et al., 2004; NHLBI, 2007).
- Evidence supports the use of SABA prior to exercise for those patients with exercise-induced asthma (NHLBI, 2007).
- Patients with occupational asthma may require management from an occupational asthma specialist (NHLBI, 2007).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Written asthma action plans should be provided to all patients</td>
<td>Gibson et al., 2003 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
</tr>
<tr>
<td>2</td>
<td>Establish a partnership with schools and/or daycare centers</td>
<td>Gerald et al., 2006 Halterman et al., 2004 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
</tr>
<tr>
<td>3</td>
<td>Use of SABA prior to exercise for patients with EIA</td>
<td>NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
</tr>
<tr>
<td>4</td>
<td>Patients with occupational asthma may require referral to an occupational asthma specialist</td>
<td>NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
5.7 Psychosocial Assessment

BACKGROUND

Psychosocial factors such as socioeconomic status, educational level of caregivers, and the presence of emotional or psychiatric disorders among family members may adversely affect asthma care. Cultural and ethnic beliefs or perceptions about asthma or other chronic illnesses may also impact compliance with an asthma care plan. Patients with depression or other psychiatric disorders often report impairments that are more significant. Social or mental health services may improve not only symptom treatment, but also patient perception of symptom control.

ACTION STATEMENT

Develop and tailor the comprehensive asthma treatment plan to the individual needs of the patient with specific sensitivity to cultural, ethnic, educational, or other social or psychological barriers to care.

RECOMMENDATIONS

1. Asthma care should be provided in an environment that is culturally and ethnically sensitive and at an educational level appropriate to the patient and caregivers. [A]
2. Socio-economic barriers to patient adherence to asthma care should be identified with the patient and caregivers, and addressed by education or appropriate referrals. [B]
3. Psychiatric disorders, to include chronic stress or depression, should be identified and patients referred as appropriate. [B]

RATIONALE

The NHLBI guidelines (2007) have expanded the importance of providing asthma care that is culturally and ethnically sensitive respecting the educational level of the patient and caregiver. Literature reveals that the home environment may impact asthma care and compliance with therapy. Patients with asthma have been found to be at higher risk for depression and other behavioral disorders that require psychiatric intervention.

EVIDENCE STATEMENTS

- Overwhelming evidence reported outcome improvements with asthma education that is culturally and ethnically sensitive, and appropriate to educational age (NHLBI, 2007).
- Expert opinion and emerging evidence suggests that psychosocial conditions may play an important role in asthma management (NHLBI, 2007; Strine et al., 2008).
- Research indicates that patients with asthma are at higher risk for depressive and/or behavioral disorders requiring treatment interventions (Kuehn, 2008; NHLBI, 2007).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosocial conditions impact asthma care</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
<td>B</td>
</tr>
<tr>
<td>and severity</td>
<td>Strine et al., 2008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with asthma are at higher risk for</td>
<td>Kuehn, 2008</td>
<td>II</td>
<td>Good</td>
<td>B</td>
</tr>
<tr>
<td>depressive or behavioral disorders</td>
<td>NHLBI, 2007</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*
ALGORITHM C: FOLLOW-UP

6. MONITORING FOR CONTROL AND FOLLOW-UP

BACKGROUND

A stepwise approach to therapy is recommended, in which the dose and number of medications and frequency of administration are increased as necessary and decreased when possible, to achieve and maintain control of asthma. Assessing both the domains of impairment and risk emphasizes the need to separately consider asthma’s effects on quality of life and functional capacity on an ongoing basis (impairment), as well as the risks asthma presents for adverse events in the future. These include exacerbations, or progressive reduction in lung growth in children. The two domains may respond differently to treatment. For example, a large study of children with asthma revealed that 30 percent of the low-dose ICS treatment group, whose levels of impairment (symptoms, SABA use, and lung function) improved, remained at risk for exacerbations requiring oral systemic corticosteroids.

The goal for therapy is to control asthma by: (NHLBI, 2007)

Reducing Impairment

- Prevent chronic and troublesome symptoms (e.g., coughing or breathlessness during the day, at night, or after exertion)
- Require infrequent use (< 2 days/week) of SABA for quick relief of symptoms, not including prevention of exercise-induced bronchospasm (EIB)
- Maintain (near) normal pulmonary function
- Maintain normal activity levels (including exercise and other physical activity and attendance at work or school)
- Meet patient and family expectations of, and satisfaction with, asthma care.

Reducing Risk

- Prevent recurrent exacerbations of asthma and minimize the need for emergency department (ED) visits or hospitalizations
- Prevent progressive loss of lung function; for children, prevent reduced lung growth
- Provide optimal pharmacotherapy with minimal or no adverse effects.

Annotation C-1 Reassess Symptom Control

6.1 Assessment of Control

BACKGROUND

Since asthma is a dynamic condition, ongoing monitoring is essential to maintain control and establish the lowest step and dose of treatment. Through proper monitoring, the control of asthma can be reassessed and the responsiveness to therapy noted. The severity and control of asthma can be further broken down into the domains of asthma impairment and risk. Specific assessment measures can be utilized in the monitoring process, including the monitoring of signs/symptoms of asthma, pulmonary function, missing days of school/work/duty, quality of life, history of asthma exacerbations, adherence to and adverse effects from prescribed medical regimens, and patient satisfaction with current asthma treatment.

ACTION STATEMENT

Continue monitoring asthma symptoms to maintain control and establish the lowest step and dose of treatment.
RECOMMENDATIONS

1. Patients with a new diagnosis of asthma, regardless of initial severity, should be seen frequently until they are on an effective regimen and demonstrate sufficient understanding of their disease management. Thereafter, patients with intermittent and mild persistent asthma should be seen at least every 6 months. Those asthma patients with more labile or persistent symptoms should have more frequent follow up. [B]

2. Every patient with asthma should be taught to recognize their asthma symptoms, and a written asthma action plan, developed in partnership with the patient, should detail the daily management (medications and environmental control strategies), and how to recognize and handle worsening asthma. The action plan is particularly recommended for patients who have moderate or severe asthma, a history of severe exacerbations, or poorly controlled asthma. The written plan can be either symptom or peak flow-based; evidence shows similar benefits for each. [B]

3. Periodic pulmonary function tests or spirometry to assess asthma control should be performed: [A]
   a. At the initial evaluation
   b. After treatment and stabilization
   c. If symptoms worsen
   d. If change of medication is considered.

4. Periodic spirometry should be considered in patients with controlled symptoms to assess changes in airways function.

5. Providers should consider giving patients a peak flow device and including peak flow values in written action plans for adults. Peak flow devices would be especially useful in patients with moderate-severe asthma, poor perceivers of symptoms, and those with frequent asthma exacerbations. Peak flow devices may help the patient and provider assess changes in therapy and detect changes in disease state.

6. Self-assessment tools should be considered in monitoring patients with asthma. Examples include: [B]
   a. Asthma Control Test (ACT) scores used for assessment of symptoms over the past 4 weeks
   b. Quality of life monitors to determine a patient’s satisfaction with asthma control and care.

7. Patient adherence and inhaler technique should be evaluated at every asthma visit.

8. Adherent patients with poorly controlled asthma or intolerance of medications should be referred to a specialist.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>QE</th>
<th>Overall Quality</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma monitoring</td>
<td>Sorkness et al., 2008</td>
<td>III</td>
<td>Fair</td>
<td>Small</td>
<td>B</td>
</tr>
<tr>
<td>Peak flow and asthma action plans</td>
<td>Cowie et al., 1997 Reddell et al., 2004</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>Asthma control tests (ACT)</td>
<td>Schatz et al., 2006</td>
<td>II-1</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
Table 6. Asthma Control (All Ages)

<table>
<thead>
<tr>
<th>Components of Control</th>
<th>Assessing Asthma Control and Adjusting Therapy</th>
<th>All Ages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Controlled</td>
<td>Not Controlled</td>
</tr>
<tr>
<td>Impairment</td>
<td>Daytime Symptoms ≤ 2 brief symptomatic</td>
<td>&gt; 2 symptomatic episodes per week</td>
</tr>
<tr>
<td></td>
<td>Nighttime awakening ≤ 2 nights/month</td>
<td>&gt; 2 nights/month</td>
</tr>
<tr>
<td></td>
<td>Interference with normal activities None</td>
<td>Some Limitation</td>
</tr>
<tr>
<td>Normal</td>
<td>SABA use for symptom control ≤ 2 treatments/week</td>
<td>&gt; 2 treatments/week</td>
</tr>
<tr>
<td>FEV1/FVC:</td>
<td>Spirometry (if obtained) FEV1 ≥ 80% AND</td>
<td>FEV1 ≤ 80% OR abnormal FEV1/FVC</td>
</tr>
<tr>
<td>≤19 yr – 85%</td>
<td>FEV1/FVC normal</td>
<td></td>
</tr>
<tr>
<td>20-39 yr – 80%</td>
<td>Asthma Control Test (ACT) Score</td>
<td></td>
</tr>
<tr>
<td>40-59 yr – 75%</td>
<td>ages ≥ 4 years ≥ 20</td>
<td>≤ 19</td>
</tr>
<tr>
<td>Risk</td>
<td>Exacerbation requiring oral systemic steroids</td>
<td>0-1x/year</td>
</tr>
<tr>
<td></td>
<td>Progressive loss of lung function Evaluation requires long-term follow-up and is best assessed by spirometry conducted at regular intervals (at least every 1-2 years)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk</td>
<td></td>
</tr>
<tr>
<td>Action for Treatment</td>
<td>Maintain current therapy step</td>
<td>Step up therapy; Reevaluate in 2-6 weeks</td>
</tr>
<tr>
<td></td>
<td>Follow up every 1-6 months</td>
<td>Consider a 5 to 10-day course of oral steroids if acute exacerbation and reevaluate in 1-2 weeks</td>
</tr>
<tr>
<td></td>
<td>Consider step down</td>
<td>If persistently uncontrolled or worsening, consider referral to specialist</td>
</tr>
</tbody>
</table>

Modified from the NHLBI (2007) and GINA (2007) guidelines
6.2 Adjustment of Treatment

**BACKGROUND**

With routine monitoring, proper adjustments can be made to a patient’s asthma treatment plan. The goal is to ‘step up’ or ‘step down’ therapy based on the interim symptoms and current control of asthma. When it appears that the patient has optimal control of his/her asthma through routine monitoring, he/she may be able to ‘step down’ the medical management. Conversely, if it appears the patient is more symptomatic during reassessment, he/she may need to ‘step up’ asthma therapy in order to help control the asthma. Whenever there is any change made to a patient’s asthma therapy, closer follow-up should be implemented to assure the asthma remains under control.

**ACTION STATEMENT**

Adjust treatment using a step-wise approach to maximize asthma control.

**RECOMMENDATIONS**

1. Ongoing monitoring is essential to maintain control of asthma. Patients should be monitored at 2-6 week intervals after initial evaluation and treatment to re-evaluate their response and current symptoms.

2. Regular follow-up contacts at 1 to 6-month intervals, depending on level of control, are recommended to ensure that control is maintained. A closer follow-up and objective measurement of airway obstruction should be obtained whenever the patient’s asthma medication regimen is changed.

3. When adjusting medications: (see Table 7)
   a. If asthma is not controlled on current regimen, a ‘step up’ in therapy is indicated after assuring that the patient has good adherence and technique with the medication
   b. If asthma is partially controlled, the provider should consider ‘stepping up’ the patient’s medication until control is achieved
   c. If the patient is able to maintain control of asthma symptoms for at least 3-6 months on their medicine regimen, a ‘step down’ or decrease in their asthma control medication may be considered.
### Table 7. Step Care for Medications Required to Maintain Long-Term Control

<table>
<thead>
<tr>
<th>Initial Sev.</th>
<th>Use of Quick relief</th>
<th>Activity limits</th>
<th>Symptoms</th>
<th>FEV1</th>
<th></th>
<th></th>
<th>Daily Medications[^a]</th>
<th>Daily Medications</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
<td>Intermittent</td>
<td>NONE</td>
<td>&lt; 2 days/week</td>
<td>&lt; 2 days/week</td>
<td>&lt; 2x/month</td>
<td>&gt; 80%</td>
<td>SABA PRN</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td><strong>Step 2</strong></td>
<td>Mild</td>
<td>Minor limitation</td>
<td>&gt; 2 days/week, not daily</td>
<td>&gt; 2x/month</td>
<td>&gt; 80%</td>
<td>Low-dose ICS</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Step 3</strong></td>
<td>Moderate</td>
<td>Minor limitation</td>
<td>&gt; 2 days/week, not daily [^c]</td>
<td>&gt; 1x/week, not nightly</td>
<td>60-80%</td>
<td>Age 0-4: Medium-dose ICS or Low-dose ICS + LTRA</td>
<td>Age ≥ 5 to Adult: Low-dose ICS + LABA or Medium-dose ICS</td>
<td>Low-dose ICS + LTRA</td>
<td></td>
</tr>
<tr>
<td><strong>Step 4</strong></td>
<td>Severe</td>
<td>Some limitations</td>
<td>Daily [^c]</td>
<td>Nightly</td>
<td>&lt; 60%</td>
<td>Age 0-4: Medium-dose ICS + LABA + LTRA</td>
<td>Age ≥ 5 to Adult: Medium-dose ICS + LABA</td>
<td>Medium-dose ICS + LTRA</td>
<td></td>
</tr>
<tr>
<td><strong>Step 5</strong></td>
<td>Severe</td>
<td>Extremely limited</td>
<td>Throughout the day [^c]</td>
<td>Nightly</td>
<td>&lt; 60%</td>
<td>Age 0-4: High-dose ICS + LABA</td>
<td>Age ≥ 5 to Adult: High-dose ICS + LABA + oral corticosteroids</td>
<td>Medium-dose ICS + LABA + LTRA</td>
<td>Consider referral to specialist</td>
</tr>
<tr>
<td><strong>Step 6</strong></td>
<td>Severe</td>
<td>Extremely limited</td>
<td>Several times a day [^c]</td>
<td>Nightly</td>
<td>&lt; 60%</td>
<td>Age 0-4: High-dose ICS + LABA + LTRA (Consider 5-10 day course of oral corticosteroids)</td>
<td>Age ≥ 5 to Adult: High-dose ICS + LABA + oral corticosteroids</td>
<td>High-dose ICS + LABA + LTRA</td>
<td>Refer to specialist</td>
</tr>
</tbody>
</table>

[^a] Every step: Patient education, environmental control, and management of co-morbidities.
Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma.
Steps 4-6: Consider referral to specialist for evaluation and/or management.
Steps 5-6: Consider Omalizumab for patients with allergies and elevated IgE.

[^b] Quick-relief medications for all patients:
SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20 minute-intervals, as needed. Short course of oral systemic corticosteroids may be needed.

[^c] More than 2 exacerbations per year (requiring oral systemic steroids) should prompt step up in therapy

The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs.
7. FOLLOW-UP OF PATIENT WITH STABLE ASTHMA

BACKGROUND

Appropriate follow-up visits and management for stable asthma patients should be arranged. Care should be focused on preventive visits rather than waiting for symptoms to arise or asthma getting out of control. The follow-up visits should include assessment of control, adherence to treatment and reinforcement of self-management skills. Patient education and written Action Plans should be reviewed and updated. Close follow-up may minimize need for emergency department visits and/or admissions, preventing progressive loss of lung function, and providing optimal pharmacotherapy with minimal adverse effects.

ACTION STATEMENT

Schedule routine follow-up visits for evaluating asthma control and monitoring disease progression and response to treatment.

RECOMMENDATIONS

1. Stable asthma patients with persistent mild, moderate, or severe asthma should be seen for a visit every 6 months unless symptoms warrant sooner follow-up.
2. Stable asthma patients with persistent mild, moderate, or severe asthma should receive spirometry at initial evaluation, after treatment and stabilization, if they experience worsening of symptoms, and at least every 1-2 years.
3. Aspects of the follow-up visit should include:
   a. An interim focused history, review of signs and symptoms, and physical exam
   b. Obtaining history of acute exacerbations
   c. Assessing the impact of co-morbid conditions affecting asthma control
   d. Identifying new environmental triggers
   e. Reviewing spirometry and peak flow monitoring
   f. Assessing adherence to treatment, spacer use or MDI technique
   g. Assessing indications for step-down or step-up therapy
   h. Reviewing and updating patient education and written Action Plans
   i. Preventive health maintenance, including smoking status of patients and family members
   j. Scheduling the next follow-up visit.

RATIONALE

Asthma is a chronic disease with significant morbidity and mortality if left untreated and unmonitored. Stable asthma patients require periodic follow-up visits to ensure acceptable asthma control.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency of follow-up visits</td>
<td>NHLBI 2007</td>
<td>III</td>
<td>Poor</td>
<td>I</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
7.1 Indications for Consultation/Referral to Specialist

RECOMMENDATIONS

1. Patients may benefit from referral for assistance in asthma management in the following circumstances:
   a. Patient has had a life-threatening asthma exacerbation
   b. Patient is not meeting the goals of asthma therapy after 3–6 months of treatment. An earlier referral or consultation is appropriate if the primary care provider concludes that the patient is unresponsive to therapy
   c. Patient requires step 4 care or higher (step 3 for children 0–4 years of age). Consider referral if patient requires step 3 care (step 2 for children 0–4 years of age)
   d. Patient required more than two bursts of oral corticosteroids in 1 year or had an exacerbation requiring hospitalization
   e. Other conditions that complicate asthma or its diagnosis (e.g., recurrent sinusitis, nasal polyps, aspergillosis, severe rhinitis, VCD, GERD, COPD) that do not respond to appropriate management
   f. Additional diagnostic testing is indicated (e.g., allergy skin testing, rhinoscopy, complete pulmonary function studies, bronchoscopy)
   g. Patient is being considered for immunotherapy or specialized medication such as omalizumab
   h. Patient requires additional education and guidance on complications of therapy, problems with adherence, or allergen avoidance (Asthma Educator)
   i. Patient / parent requests consultation with a subspecialist.

RATIONALE

Most patients with asthma can be successfully managed by the primary care provider but patients with asthma are in a continuum of severity and vary in their response to medications. Situations may arise in either establishing a diagnosis or selecting the best therapy, when the specialist will be of assistance.

EVIDENCE STATEMENT

Patients with asthma that do not respond to standard treatment may benefit from referral to an asthma specialist (BTS, 2008; NHLBI, 2007).
INTERVENTIONS

8. PHARMACOTHERAPY

8.1 Step Care Approach

BACKGROUND

While there are differences in the implementation of step care in children and adults, the basic principles are similar. The goal of asthma therapy is to maintain long-term control of asthma with the least amount of medication and minimal risk for adverse effects (NHLBI, 2007).

To achieve and maintain control of asthma, a stepwise approach to therapy is recommended, in which the dose and number of medications and frequency of administration are increased as necessary and decreased when possible. Assessing both domains (impairment and risk) emphasizes the need to separately consider asthma’s effects on quality of life and functional capacity on an ongoing basis (i.e., at present) and the risks asthma presents for adverse events in the future, such as exacerbations or progressive reduction in lung growth. These domains may respond differentially to treatment. For example, a large study of children with asthma revealed that 30 percent of the low-dose ICS treatment group, whose levels of impairment (symptoms, SABA use, lung function) improved, remained at risk for exacerbations requiring oral systemic corticosteroids (CAMP, 2000).

Deciding which step of care is appropriate for a patient depends on whether long-term control therapy is being initiated for the first time or whether therapy is being adjusted. The classification of asthma severity, which considers the severity of both impairment and risk domains, provides a guide for initiating therapy for patients who are not currently taking long-term control medications. Once therapy is initiated, or if the patient is already taking long-term control medication, the patient’s response to therapy will guide decisions about adjusting therapy based on the level of control achieved in both the impairment and risk domains. Therapy may be stepped up to regain control, or stepped down for patients who have maintained control for a sufficient length of time, to determine the minimal amount of medication required to maintain control and/or reduce the risk of side effects.

As indicated, a key to implementing step care involves assessing asthma control. Implementation involves assessing severity and monitoring response to therapy with appropriate follow-up. Determining the severity in response to treatment can be accomplished by assessment of the number of recent exacerbations, frequency of use of rescue medication, impairment of daily activities, nighttime symptoms, and pulmonary function levels. In children, this may mean questioning the child’s parents. Another monitoring activity involves determining the patient’s acceptance and adherence to the medication regimen and the avoidance of asthma triggers such as exposure to plants, pets, or cigarette smoke.

ACTION STATEMENT

Use the step-up and step-down approaches to initiate and adjust pharmacotherapy for the treatment of intermittent and persistent asthma (see Table 7: Step Care for Medications Required to Maintain Long-Term Control).

RECOMMENDATIONS

1. Always prescribe an inhaled short-acting bronchodilator for use as needed for intermittent symptoms.
2. Always prescribe an anti-inflammatory controller medication for use in persistent asthma.
3. Inhaled corticosteroids are the preferred anti-inflammatory controller.
4. Alternative anti-inflammatory controllers include anti-leukotriene, and cromolyn sodium medications.
5. Consider prescribing a long-acting bronchodilator controller medication for use in persistent asthma in addition to an anti-inflammatory controller.
6. The preferred long-acting bronchodilator controller is an inhaled long-acting beta2-agonist.
7. Alternative controller medications include oral theophylline, oral beta2-agonists, and anti-IgE antibody injections.
8. The dosage of inhaled corticosteroids and added use of combination controller therapy is determined by the degree of initial and ongoing impairment and risk.
9. Step-care includes both stepping up and stepping down the dosage and use of combination controller therapy. Stepping down therapy may be considered after a minimum period of stability (3-6 months).

8.2. Medication

8.2.1 Quick Relief

**Short Acting β2-adrenergic Agonists (SABAs)** are bronchodilators that relax smooth muscle and are the treatment of choice for relief of acute symptoms, exacerbations of asthma, and prevention of EIB. SABAs should only be used on an as-needed basis at the lowest dose and frequency required. Increasing use of SABA treatment or the use of SABA >2 days a week for symptom relief (not prevention of EIB) indicates inadequate asthma control and the need for initiating or intensifying anti-inflammatory therapy. Equally, failure to achieve a quick and sustained response during an exacerbation mandates medical attention. Regularly scheduled, daily, chronic use of SABA is not recommended.

**RECOMMENDATIONS**

1. All patients should have a SABA as needed for acute relief of symptoms. [A]
2. SABAs should not be used on a scheduled basis for maintenance therapy.
3. Providers should evaluate frequency of SABA use. Use of SABA more than 2 days/week for symptom control, increasing use, or lack of expected response may indicate inadequate asthma control and the need to intensify maintenance drug therapy.
4. Clinical efficacy and safety are comparable between racemic and non-racemic agents; therefore, the least costly agent may be selected.

**EVIDENCE STATEMENTS**

**Short Acting β2-adrenergic Agonists** (SABAs) have a rapid onset of effect and are safe, well tolerated and easy to use for relief of acute bronchospasm.

- The NHLBI reviewed several studies that showed regularly scheduled use of albuterol offered no clinical advantage over use on an as-needed basis.
- Randomized controlled trials in both chronic and acute asthma have shown no clear benefit for non-racemic over racemic SABAs in clinical efficacy or β-adrenergic mediated adverse effects such as tachycardia, tremor, and nervousness (Berger et al., 2006; Hamilos et al., 2007; Hardasmalani et al., 2005; Lotvall et al., 2001; Nowak et al., 2006; Qureshi et al., 2005). However, one study (Carl et al., 2003) suggested a decrease in hospitalization rate in the emergency department setting with the use of non-racemic SABAs.

**Systemic Corticosteroids** reduce airway hyperresponsiveness, inhibit inflammatory cell migration and activation, and block late-phase reaction to allergen. While not short acting, oral corticosteroids are used for
moderate to severe exacerbations in addition to SABAs to accelerate recovery and prevent recurrent exacerbations.

8.2.2 Long-term Controllers

Inhaled Corticosteroids

Inhaled Corticosteroids (ICS) reduce airway hyperresponsiveness, inhibit inflammatory cell migration and activation, and block late-phase reaction to an allergen. ICS do not appear to alter progression or underlying severity of asthma but do reduce impairment and risk of exacerbations. Currently, ICS are the most effective anti-inflammatory medications for long-term control of persistent asthma across all age groups and in all the therapy care steps.

RECOMMENDATIONS

1. ICS should be used as first-line therapy to control persistent asthma. [A]
2. ICS initial dosing should be based on the asthma severity.
3. ICS should be integrated into a step care approach. [A]
4. ICS treatment should be monitored for adverse effects and the patient/parent should be counseled regarding management adverse effects.
5. ICS delivery via nebulization should be administered using specific nebulizer equipment.

RATIONALE

Asthma is predominately a disease of inflammation of the airway that produces airway edema, smooth muscle hypertrophy, mucus gland hyperplasia, and airway remodeling such as basement membrane thickening. Control of the inflammatory process leads to improvement in airway size and function, typically resulting in relief of symptoms, reduction in asthma exacerbations, and improvement in quality of life.

EVIDENCE STATEMENTS

- The pathophysiology of asthma is characterized by a complex inflammatory response within the airways. Medications that target inflammation are the most effective agents in the long-term control of asthma.
- ICS are anti-inflammatory medications that are the most viable and effective options for long-term control of asthma.
- ICS are safe and well tolerated; however, adverse effects of the medications are possible, especially with escalating doses.
- Children with asthma require special monitoring for adverse effects of ICS therapy, particularly in the aspect of linear growth. ICS appears to affect linear growth in the first few months after initiation of therapy, and does not appear to affect final adult height. Poorly controlled asthma can affect linear growth.
**Evidence Table**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 ICS should be used as first-line therapy to control persistent asthma</td>
<td>Durchame et al., 2004</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Ng et al., 2004</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NHLBI, 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 ICS initial dosing should be based on asthma severity</td>
<td>NHLBI, 2007</td>
<td>III</td>
<td>Poor</td>
<td>Mod</td>
<td>I</td>
</tr>
<tr>
<td>3 ICS dosing should be integrated into a step care approach</td>
<td>Adams et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Gibson et al., 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NHLBI, 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Patient/parent counseling and monitoring for ICS adverse effects</td>
<td>NHLBI, 2007</td>
<td>III</td>
<td>Poor</td>
<td>Substantial</td>
<td>I</td>
</tr>
<tr>
<td>should be performed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

**Long Acting β2-adrenergic**

**Long Acting β2-adrenergics** (LABAs) do not have anti-inflammatory activity. LABAs are bronchodilators that act by increasing cyclic adenosine monophosphate in airway smooth muscle, thereby causing bronchodilation. A LABA is always used in combination with an anti-inflammatory agent, preferably an inhaled corticosteroid, in maintenance treatment of asthma.

**Recommendations (Adults)**

1. LABAs are not recommended for treatment of acute symptoms or exacerbations. [I]
2. LABAs must NOT to be used as monotherapy for maintenance treatment of asthma. [D]
3. LABAs are the preferred agents for add-on therapy to ICS. [A]
4. LABAs should be integrated into a step care approach: [A]
   a. For patients who are not adequately controlled on low-dose ICS, consider increasing the dose of ICS or adding a LABA. Strong preference should be given to increasing the dose of inhaled corticosteroid due to safety concerns, while recognizing that efficacy is greater with the addition of a LABA.
   b. For patients who are not adequately controlled on moderate/high-dose ICS, the addition of a LABA is preferred to further increasing the ICS dose.
   c. Combining a LABA + ICS is preferred to combining a LABA + leukotriene receptor antagonist (LTRA) for greater efficacy.
5. Patient/parent counseling and monitoring for LABA adverse effects should be performed.

**Evidence Statements**

- The onset of action of salmeterol is slower than SABAs; therefore, it is inappropriate for use in management of acute symptoms. While formoterol has an onset of action similar to SABAs, it is not approved in the U.S. for acute use.
- Monotherapy with LABAs should not be used for maintenance of asthma regardless of asthma severity.
- Several randomized controlled trials comparing LABA+ICS to same dose ICS or LABA alone have shown that LABA monotherapy was inferior to combination ICS +LABA for improvement in pulmonary
function and asthma symptoms, decrease in rescue SABA use and resulted in more episodes of asthma worsening and exacerbations. In these same studies, outcomes with monotherapy ICS was better than, or similar to LABAs (Corren et al., 2007; Kavuru et al., 2000; Murray et al., 2004; Nathan et al., 2006; Noonan et al., 2006; Pearlman et al., 2004; Shapiro et al., 2000).

- Discontinuation of ICS after initiation of LABA results in increased asthma exacerbations (Lazarus et al., 2001; Lemanske et al., 2001).
- The FDA has issued a Black Box warning regarding increased risk of severe asthma exacerbations and asthma-related deaths with use of LABAs. The reasons for increased risk are unknown, but may, in part, be explained by a lack of concomitant inhaled corticosteroid therapy, genetic factors, reliance on bronchodilators in the face of worsening airway inflammation, or the underlying severity of asthma (Castle et al., 1993; Nelson et al., 2006). These safety concerns have been reinforced by FDA advisory committees (2008), including the FDA safety committee, leading to a recommendation that the indication for LABAs as monotherapy for treatment of asthma be withdrawn.

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  LABAs are NOT recommended for treatment of acute symptoms or exacerbations</td>
<td>NHLBI, 2007</td>
<td>III</td>
<td>Poor</td>
<td>Zero/Neg</td>
<td>I</td>
</tr>
<tr>
<td>2  LABAs are NOT to be used as monotherapy for maintenance treatment of asthma</td>
<td>NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>D</td>
</tr>
<tr>
<td>3  LABAs are the preferred agents for add-on therapy to ICS</td>
<td>NHLBI, 2007 Adult</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Child Ducharme et al., 2004</td>
<td>III</td>
<td>Poor</td>
<td>Mod</td>
<td>I</td>
</tr>
<tr>
<td>4  LABAs should be integrated into a step care approach but should not be used as monotherapy</td>
<td>Gibson et al., 2007 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td>5  Patient/parent counseling and monitoring for LABA adverse effects should be performed</td>
<td>NHLBI, 2007</td>
<td>III</td>
<td>Poor</td>
<td>Substantial</td>
<td>I</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

**Leukotriene Modifiers**

**Leukotriene Modifiers** interferes with the pathway of leukotriene mediators released from mast cells, eosinophils, and basophils. Leukotriene modifiers have a small and variable bronchodilator effect and reduce airway inflammation. These drugs can be further classified as leukotriene receptor antagonists (LTRA) (montelukast, zafirlukast) and 5-lipoxygenase inhibitors (zileuton). In children with allergies, there may be some benefit for the use of Leukotriene.

**RECOMMENDATIONS**

1. Monotherapy with leukotriene modifiers may be considered as an alternative (not preferred) to ICS for mild persistent asthma. [A]
2. Leukotriene modifiers may be used as an alternative (not preferred) to LABA for add-on therapy to ICS.  [A]
3. Zileuton is NOT recommended for use in children < 12 years of age, and is discouraged from use in adults due to safety concerns (liver toxicity).  [D]
4. Leukotriene modifiers should be integrated into a step care approach.  [B]

EVIDENCE STATEMENTS

- Several randomized controlled trials have shown that monotherapy with leukotriene modifiers improve pulmonary function, asthma symptoms, as needed SABA use, nighttime awakening due to asthma, and asthma exacerbations compared to placebo (Altman et al., 1998; Baumgartner et al., 2003; Busse et al., 2001; Fish et al., 1997; Malmstrom et al., 1999; Nelson et al., 2007; Noonan et al., 1998; Reiss et al., 1998).
- A Cochrane meta-analysis showed that monotherapy with leukotriene modifiers is less effective than monotherapy with ICS for improvement in pulmonary function, symptoms, rescue SABA use, quality of life, and exacerbations (Ducharme et al., 2004). This finding was also supported in a 1-year trial comparing montelukast and low-dose ICS (Zeiger et al., 2005).
- There are limited data comparing the leukotriene modifiers to theophylline or mast cell stabilizers as monotherapy; therefore, selection of one of these agents as non-preferred should take into account safety and patient-specific variables (Nathan et al., 1999; Schwartz et al., 1998; Yurdakul et al., 2003).
- Serum alanine aminotransferase (ALT) concentrations should be monitored before treatment with zileuton is initiated - monthly for the first 3 months, every 2-3 months for the reminder of the first year, and then periodically thereafter. Periodic monitoring may be considered for zafirlukast.
- In clinical trials using zileuton immediate-release, the overall rate of elevation in ALT > 3 x ULN was 3.2%. One patient developed symptomatic hepatitis with jaundice (Zyflo product labeling).
- In a 12-month safety surveillance study, 4.4% of patients receiving zileuton immediate-release had elevation in ALT ≥ 3 x ULN compared to 1% in the usual care group. Elevation in ALT ≥ 8 x ULN occurred in 1.3% and 0.2% respectively. Two-thirds of the cases in the zileuton group occurred in the first 3 months. No patient in this study developed jaundice or hepatic failure (Lazarus et al., 1998; Watkins et al., 2007).
- In a 6-month trial using zileuton controlled-release, 1.8% of patients had an elevation in ALT ≥ 3 x ULN compared to 0.7% of those receiving placebo. Eighty-two percent of the cases occurred within the first 3 months. There were no cases of jaundice or hepatic failure in this study (Wenzel et al., 2007).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Monotherapy with leukotriene modifiers may be considered as an alternative (not preferred) to ICS for mild persistent asthma</td>
<td>NHLBI, 2007 Ducharme et al., 2004</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td>2. Leukotriene modifiers may be used as an alternative (not preferred) to LABA for add-on therapy to ICS</td>
<td>NHLBI, 2007 Adult Ducharme et al., 2004</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>NHLBI, 2007 Child Ducharme et al., 2004</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td></td>
</tr>
</tbody>
</table>

Clinical Practice Guideline for the Management of Asthma in Children and Adults

Algorithms and Annotations - Page 59
Zileuton may be less preferable than the LTRA due to the need for liver function monitoring and drug interactions. Watkins et al., 2007

Zileuton is not recommended for use in children < 12 years of age. NHLBI, 2007

Leukotriene modifiers should be integrated into a step care approach. NHLBI, 2007

Cromolyn sodium stabilizes mast cells and interferes with chloride channel function. Its anti-inflammatory effect is weak and considered less effective than low-dose ICS. Mast cell stabilizers for the long-term treatment of asthma are considered as an alternative medication (not preferred) for mild persistent asthma (step 2). It can be used before unavoidable exposure to known allergens or as preventative treatment before exercise. Cromolyn is no longer available in a metered-dose inhaler; however, it remains available as a solution for nebulizer use.

**RECOMMENDATIONS**

1. Cromolyn may be considered as an alternative for mild persistent asthma when other preferred options have not been successful. [A]

2. Consult a specialist if the use of cromolyn is being considered. [I]

**EVIDENCE STATEMENTS**

- A Cochrane Systematic Review found that ICS were superior to cromolyn for improvement in pulmonary function, symptoms scores, and exacerbation rates in children and adults with asthma (Guevara et al., 2006).

- There are insufficient data directly comparing cromolyn to leukotriene inhibitors (Nathan et al., 1999); however, the leukotriene inhibitors are the preferred second-line agents based on the relative volume of literature supporting their use compared to cromolyn for maintenance monotherapy. Furthermore, adherence to cromolyn is expected to be poor due to its four times daily administration.

- There are insufficient data evaluating cromolyn as add-on therapy to other agents. The NHLBI recommends that cromolyn not be used as add-on therapy.

**EVIDENCE TABLE: CROMOLYN SODIUM**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Monotherapy with cromolyn may be considered as an alternative (not preferred) to ICS for mild persistent asthma</td>
<td>Guevara et al., 2006; NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
</tr>
<tr>
<td>2</td>
<td>Cromolyn should not be used as add-on therapy</td>
<td>NHLBI, 2007</td>
<td>III</td>
<td>Poor</td>
<td>Small</td>
</tr>
</tbody>
</table>

**LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)**
Xanthine

**Xanthine** derivatives are mild to moderate bronchodilators and may have mild anti-inflammatory effects. Patient-specific variables should be reviewed due to potential toxicity and significant interactions with other drugs. When reference is made to theophylline, it is to the long-acting/slow-release formulations, unless otherwise stated.

**RECOMMENDATIONS**

1. Theophylline may be considered as an alternative for maintenance of mild persistent asthma when other preferred options have not been successful. Consult a specialist if maintenance therapy with theophylline is being considered.

2. Theophylline may be considered as an adjunctive therapy with ICS for maintenance of moderate or persistent asthma.

3. Patients on theophylline should be maintained at a serum level of 5-15 mcg/ml with routine monitoring of serum level.

**EVIDENCE TABLE: XANTHINE (THEOPHYLLINE)**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Consult a specialist if maintenance therapy with theophylline is being considered</td>
<td>Working Group Consensus</td>
<td>III</td>
<td>Poor</td>
<td>Zero/Neg</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*

Immunomodulators anti-IgE (Omalizumab)

**Immunomodulators anti-IgE** (Omalizumab) is a monoclonal antibody that prevents binding of IgE to high-affinity receptors on basophils and mast cells. Omalizumab may be used as adjunctive therapy for severe persistent asthma (step 5 or 6) in patients with sensitivity to a relevant allergen (e.g., dust mite, cockroach, cat, or dog). Anaphylaxis may occur, therefore clinicians administering omalizumab (prescribed by a specialist) should be prepared and equipped to identify and treat anaphylaxis.

**RECOMMENDATIONS**

1. Omalizumab may be considered, in consultation with a specialist, as adjunctive therapy for severe persistent asthma (step 5 or 6) in patients with sensitivity to relevant allergens. [I]

**EVIDENCE TABLE: IMMUNOMODULATORS ANTI-IGE (OMALIZUMAB)**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Consult Specialist for use of this agent in allergic asthma</td>
<td>Working Group Consensus</td>
<td>III</td>
<td>Poor</td>
<td>Zero/Neg</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*
Oral systemic Corticosteroids

**Oral Systemic Corticosteroids** reduce airway hyperresponsiveness, inhibit inflammatory cell migration and activation, and block late-phase reaction to allergen.

**RECOMMENDATIONS**

1. Consult a specialist if maintenance therapy with an oral corticosteroid is being considered.

**EVIDENCE TABLE: ORAL SYSTEMIC CORTICOSTEROIDS**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Consult a specialist on the use of an oral corticosteroid for maintenance</td>
<td>Working Group Consensus</td>
<td>III</td>
<td>Poor</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*

8.2.3 Combination

**BACKGROUND**

Combination therapy is used to take advantage of the different mechanisms of action of each drug class. When single-agents do not provide adequate control, combining agents from different therapeutic classes may result in added efficacy.

**RECOMMENDATIONS**

1. Combination ICS with LABA is preferred over ICS and LTRA, or zileuton or theophylline for the treatment of moderate persistent asthma. [A]

2. Combination of low-dose ICS with LABA may be considered equivalent to medium dose ICS for the treatment of moderate persistent asthma. [C]

3. Combination of high-dose ICS with LABA is the preferred therapy for severe persistent asthma. [A]

4. Addition of LABA is preferred to further increasing the ICS dose for patients who are not adequately controlled on medium-dose ICS. [A]

**EVIDENCE STATEMENTS**

- A number of studies as summarized in the NHLBI 2007 report provide evidence from randomized controlled trials that combining a LABA and ICS provide greater benefits with respect to pulmonary function, reduction in exacerbations and improvement in asthma symptoms compared to any dose of ICS alone in adults. Compared to a combination of ICS with a leukotriene modifier or theophylline, a LABA and ICS provided greater benefit with respect to pulmonary function and improvement in asthma symptoms. There were inconsistent findings with respect to a reduction in asthma exacerbations with the trend toward improvement. These combinations have not been well studied in children ages 5 to 11 and not at all in children age 4 and under (NHLBI 2007).

- Although evidence supports a greater efficacy of adding a LABA to low-dose ICS over medium-dose ICS, the two approaches are considered equal due to the concern for potential adverse effects from a LABA (NHLBI, 2007 p. 230). In addition, a meta-analysis by Greenstone et al. (2005) indicated that there was no difference between a LABA and ICS (400 beclomethasone equivalent) compared to 1000 ICS beclomethasone equivalent (non-HFA equivalent). In patients with steroid-naïve mild to
moderate asthma, a LABA and low to medium-dose ICS is equivalent to ICS alone with respect to exacerbations, and slightly inferior with respect to symptom-free days and pulmonary function (Greenstone et al., 2005). However, a meta-analysis by Masoli et al. indicated that the addition of a LABA to a medium ICS dose provided greater efficacy than doubling the dose of ICS in symptomatic asthma patients (Masoli et al., 2005).

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Combination ICS with LABA is preferred over ICS and LTRA or zileuton or theophylline for treatment of moderate persistent asthma</td>
<td>NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
</tr>
<tr>
<td>2</td>
<td>Combination of low-dose ICS with LABA may be considered equivalent to medium-dose ICS for the treatment of moderate persistent asthma</td>
<td>NHLBI, 2007 Greenstone et al., 2005</td>
<td>I</td>
<td>Good</td>
<td>Small Mod</td>
</tr>
<tr>
<td>3</td>
<td>High-dose ICS with LABA is the preferred therapy for severe persistent asthma</td>
<td>NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
</tr>
<tr>
<td>4</td>
<td>Addition of a LABA is preferred to further increasing the ICS dose for patients who are not adequately controlled on moderate/high-dose ICS</td>
<td>Adults: NHLBI, 2007 Greenstone et al., 2005 Masoli et al., 2005</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
</tr>
<tr>
<td></td>
<td>Children:</td>
<td>III</td>
<td>Poor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*

### 8.3 Use of Devices (MDI without Chambers), Training Technique

**BACKGROUND**

Inhaled medications for the treatment of asthma are typically delivered through metered dose inhalers (MDIs), or air powered nebulizer units. The MDIs are used with or without valved holding chambers (VHC). The most effective delivery of inhaled medication via MDI is with a VHC. Use of a VHC should be the primary method of MDI delivery, especially for inhaled corticosteroids, in all patients. Optimal medication delivery is dependent upon the patient’s ability at the time of treatment to physically coordinate and manipulate the delivery device, the ability to reproduce optimal delivery technique, and the availability of any additional required resources (i.e., electrical power). Additional considerations include the patient’s attitude and compliance with the need to properly clean and maintain the selected device.

Regardless of the delivery device selected, detailed education on the use, care and maintenance of the delivery device is essential. The patient should demonstrate proper technique initially and with each follow-up visit to ensure proper (optimal) medication delivery.

The use of a VHC eliminates most physical coordination and manipulation issues associated with MDI-only therapy and can be carried easily by the patient. MDIs with VHC do not require filters, batteries, or access to electrical power. This delivery combination requires little cleaning and maintenance and is easily replaced. Studies show that when compared to nebulized medication delivery, the use of MDIs in conjunction with VHC demonstrated a reduced admission rate in pediatrics (over age 5) and no negative impact on adults (Castro et
al., 2004, Cates et al., 2006). These same studies suggest that severity scores by patients improved when using the MDIs with VHC in both adults and pediatrics (Castro et al., 2004). MDIs with VHC are recommended as the primary delivery system for inhaled medications in the treatment of asthma (see Table 8: Comparison of Inhaler Devices).

**ACTION STATEMENT**

Metered Dose Inhalers (MDIs) in conjunction with Valved Holding Chambers (VHC) are recommended as the primary delivery system for inhaled medications in both pediatric and adult patients.

**RECOMMENDATIONS**

1. Metered Dose Inhalers with Valved Holding Chambers are as effective as nebulizer therapy for delivery of aerosolized medications (quick relief) in the adult and pediatric patient. [B]

**Table 8. Comparison of Inhaler Devices**

<table>
<thead>
<tr>
<th>Device</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
</table>
| **Metered Dose Inhaler (MDI)** | • Portable – compact  
• Little or no preparation time  
• Short treatment time  
• High dose-to-dose reproducibility  
• No content contamination | • Requires significant breath and actuation coordination  
• Physical dexterity for actuation required  
• Not all inhaled medications available in this form  
• Few with dose counters |
| Beta2–Agonists  
Corticosteroids  
Cromolyn Sodium  
Anticholinergics | See above | |
| **Metered Dose Inhaler (MDI) with Valved Holding Chamber (VHC)** | • Portable  
• Little or no preparation time  
• Short treatment time  
• High dose-to-dose reproducibility  
• Less pharyngeal deposition vs. MDI  
• Reduced coordination vs. MDI  
• No content contamination | • Less compact vs. MDI only  
• Physical dexterity for actuation required  
• Not all inhaled medications available in this form  
• Few with dose counters |
| See above | | |
| **Dry Powder Inhaler (DPI)** | • Portable – compact  
• Little or no preparation time  
• Short treatment time  
• Breath actuated  
• Less patient coordination  
• Propellant not required  
• Most have dose counters | • Requires 30-60 lpm inspiratory flow for optimal delivery  
• Some units require loading with each dose  
• Not all medications available in this form |
| Beta2–Agonists  
Corticosteroids  
Anticholinergics | | |
| **Small Volume Jet Nebulizer** | • Patient coordination minimal  
• Effective with tidal breathing  
• Can be used with supplemental oxygen | • Lengthy treatment time  
• Contamination possible  
• Device cleaning required  
• Pressurized gas source required  
• Limited portability  
• Not all medications available in this form  
• Device preparation required  
• Performance variability |
| Beta2–Agonists  
Corticosteroids  
Cromolyn Sodium  
Anticholinergics | | |

*Adapted from Dolovich et al., 2005*
9. ENVIRONMENTAL CONTROL

9.1 Inhaled Allergens

BACKGROUND

There is an important association between inhaled allergens and asthma. The presence of IgE-mediated sensitization to inhaled allergens is a risk factor for the development of asthma. Furthermore, allergic sensitization and exposure to elevated levels of inhaled allergens have been linked to airway hyperreactivity and a variety of adverse asthma outcomes including fatal asthma. These links have been shown for indoor environmental allergens such as dust mites, animal dander, cockroaches and molds as well as outdoor allergens including grass, ragweed, and molds. As a result, the approach to every patient with asthma should include a thorough history to assess for associations between inhaled allergens and their asthma symptoms.

A thorough history and knowledge of specific sensitizations can be used to determine the relevant inhaled allergen exposures and serve as the foundation for patient education on triggers, avoidance, and possibly immunotherapy. The role of specific strategies for avoidance of indoor inhaled allergens is controversial.

Understanding potential triggers and associations of symptoms with inhaled allergen exposure can also serve an important role in patient selection for consideration of immunotherapy.

RECOMMENDATIONS

1. For all patients with asthma at any level of severity [B]:
   a. Use the patient’s medical history to identify allergen exposures that may trigger the patient’s asthma
   b. Use the patient’s history to assess sensitivity to seasonal allergens
   c. Educate the patient and consider measures to reduce exposure to the identified inhaled allergen(s).

2. For patients with persistent asthma and indoor-related symptoms, the investigation of the potential role of allergens should be considered [C]:
   a. Allergy testing should be performed to reliably determine sensitivity to common inhalant allergens to which the patient is exposed (skin testing or serum-specific IgE [i.e., RAST] testing)
   b. The patient’s history should be used to assess the significance of positive allergen-specific IgE tests
   c. Educate the patient and consider measures to reduce exposure to the identified allergens.

3. A comprehensive approach to inhaled allergen avoidance in sensitized patients should be employed rather than implementing a single specific environmental avoidance strategy or regimen. [C]

4. Consider allergen immunotherapy when there is clear evidence of a relationship between symptoms and exposure to an allergen to which the patient is sensitive. [B]

DISCUSSION

While there is insufficient evidence to recommend any single specific environmental avoidance strategy or regimen for the varied inhaled allergens, the NHLBI 2007 report outlined a set of sensible strategies for common inhaled allergens based on existing literature (see Appendix E).

Several studies demonstrate the ability to significantly lower the levels of several indoor inhaled allergens using differing methods requiring differing levels of cost and effort. However, there are limited and contradictory findings in the literature that examine improvement in asthma outcomes with avoidance.
measures for indoor inhaled allergens. Strategies that take comprehensive approaches to avoidance of inhaled allergens such as dust mites, cockroaches, and animal dander have shown clinical benefit in some smaller well-designed studies. Limited and/or single strategy approaches to indoor inhaled allergens, such as bedding covers alone for dust mites, or HEPA filtration alone in a home where the pet remains, are not reliably effective. A Cochrane analysis (Gøtzsche et al., 2007) concluded that dust mite interventions were not effective in improving asthma outcomes. However, this meta-analysis included negative trials with limited approaches and non-sensitized individuals while it excluded some well designed, though smaller, positive trials with multiply sensitized patients.

Patients with persistent symptoms or prolonged seasonal symptoms who have sensitization to relevant inhaled allergens have been shown to benefit from immunotherapy. Controlled studies have demonstrated improved asthma outcomes when treated for symptoms caused by grass, ragweed, house dust mites, cats and molds. A meta-analysis (Abramson et al., 2003) and the updated NHLBI 2007 Guidelines support the role for immunotherapy in asthma.

For more details on allergens, see Appendix E.

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Exposure to inhaled allergens in sensitized individuals results in airway inflammation and asthma symptoms</td>
<td>Call et al., 1992 &amp; 1994 Custovic et al., 1998 GINA, 2007 Gruchalla, 2002 Huss et al., 2001 NHLBI, 2007 Pulimood et al., 2007 Rosenstreich et al., 1997 Sporik et al., 1990</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>2 Limited avoidance measures to reduce inhaled indoor allergens do not reduce allergen levels or improve asthma outcomes</td>
<td>De Blay et al., 1991 Francis et al., 2003 GINA, 2007 Gotzche et al., 2007 Luszczynska et al., 2003 NHLBI, 2007 Terreehorst et al., 2002 Woodcock et al., 2003</td>
<td>I</td>
<td>Fair</td>
<td>Small</td>
<td>C</td>
</tr>
<tr>
<td>3 Comprehensive measures to reduce inhaled indoor allergens improve airway inflammation and asthma outcomes</td>
<td>Carter et al., 2001 Halken et al., 2003 Morgan et al., 2004 NHLBI, 2007 Peroni et al., 2002 Platts-Mills et al., 2000 Popplewell et al., 2000 Van der Heide et al., 1997</td>
<td>II-1</td>
<td>Fair</td>
<td>Small</td>
<td>C</td>
</tr>
<tr>
<td>4 Immunotherapy is effective for patients with persistent asthma who have symptoms consistent with identified inhaled allergen sensitivities</td>
<td>Abrahamson et al., 2003 NHLBI, 2007</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
9.2 Inhaled Irritants

BACKGROUND

There are convincing links and concerning associations between a variety of environmental irritants and asthma. Understanding possible associations between asthma and the environmental tobacco smoke, particulate air pollution, nitrogen dioxide (NO2), sulfur dioxide (SO2), diesel exhaust, volatile organic compounds, formaldehyde, fumes from wood burning stoves and fireplaces, and gas appliances can be important in developing plans for avoidance and treatment of patients with asthma.

RECOMMENDATIONS

1. Patients who have asthma at any level of severity should: [C]
   a. Avoid exposure to environmental tobacco smoke and other respiratory irritants, including smoke from wood-burning stoves and fireplaces and, if possible, substances with strong odors
   b. Avoid exertion outdoors when levels of air pollution are high.
2. There is insufficient evidence to recommend any specific environmental strategies to prevent the development of asthma.

EVIDENCE STATEMENT

- Other guidelines (NHLBI, 2007 and GINA, 2007) have suggested that irritant identification and avoidance could be beneficial in controlling asthma in susceptible patients.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Avoid respiratory irritants</td>
<td>I</td>
<td>Good</td>
<td>C</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; SR = Strength of Recommendation (See Appendix A)

9.3 Occupational Exposure

BACKGROUND

Certain occupations may expose patients to inhaled allergens, inhaled irritants, or other unique substances that may contribute to or even be the proximate cause of their asthma. Early diagnosis and intervention can be important to reduce the risk of worsening or inducing a more persistent/permanent element to the patient’s asthma. History to include exposures to allergens, irritants, chemicals, dusts and the links of the workplace with symptoms and/or objective measures of lung function can be crucial.

RECOMMENDATIONS

1. Patients who have asthma and are employed, particularly those who have new-onset disease, should be queried about possible occupational exposures that may include allergens, irritants, or other exposures.[C]
2. Specialist care management over a period of time, or co-management with the primary care provider, should be considered when history suggests that an occupational or environmental inhalant or ingested substance is provoking or contributing to asthma. Treatment or intervention may be required in the work environment.
RATIONALE

Identification of occupational exposures and modification of work environment can be beneficial in controlling asthma symptoms.

EVIDENCE STATEMENT

- “Early recognition and control of exposures are particularly important in occupationally induced asthma, because the likelihood of complete resolution of symptoms decreases with time (Pisati et al., 1993). Occupational asthma is suggested by a correlation between asthma symptoms and work, as well as with improvement when away from work for several days. The patient may fail to recognize the relationship with work, because symptoms often begin several hours after exposure. Recently, common jobs—such as domestic cleaner, laboratory technician, and house painter—have been associated with the disease (Moscato et al., 1995). Serial peak flow records at work and away from work can confirm the association between work and asthma (Nicholson et al., 2005).” (NHLBI 2007 Page 175)

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Occupational exposures</td>
<td>GINA, 2007, NHLBI 2007</td>
<td>I</td>
<td>Good</td>
<td>C</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; SR = Strength of Recommendation (See Appendix A)*
10. OTHER INTERVENTIONS

10.1 Smoking Cessation

BACKGROUND

Personal use of tobacco products and exposure to environmental tobacco smoke (ETS) is common in the United States and directly affects asthma management. Second hand smoke exposure in all asthma patients is associated with increased asthma severity and poorer outcomes, including a decreased responsiveness to some asthma medications. Exposure to maternal smoking has been shown to be a risk factor for the development of asthma in infancy and childhood.

RECOMMENDATIONS

1. All patients should be asked about tobacco use and should have their tobacco use status documented on a regular basis. [A]
2. All providers should strongly advise every patient who smokes to quit. [A] (See the VA/DoD Clinical Practice Guideline for Tobacco Use.)
3. Asthma patients and their families and/or caregivers should be instructed to avoid ETS. [A]
4. All pregnant patients should be instructed not to smoke and to avoid exposure to ETS. [A]

RATIONALE

The negative effects of tobacco use and exposure to ETS in the general population are well documented in the medical literature. Particularly in patients with asthma, there is a marked decrease in lung function with tobacco use. All patients should be queried about tobacco use and/or ETS and instructed to stop smoking and/or avoid exposure at each encounter. Refer to the VA/DoD clinical practice guideline for tobacco use, for specific information on counseling and tobacco cessation interventions.

EVIDENCE

- Evidence has shown that clinic-screening systems, such as expanding the vital signs to include tobacco use status or the use of other reminder systems such as chart stickers or computer prompts, significantly increase rates of clinician intervention (PHS, 2008). [A]
- Evidence analysis shows that brief physician advice significantly increases long-term smoking abstinence rates. Additional studies show that advice to quit given by healthcare providers in general does significantly increase quit rates (PHS, 2008). [A]
- Tobacco smoking is associated with accelerated decline of lung function in patients with asthma and increases in asthma severity (GINA, 2007).
- Exposure to ETS is associated with increased symptoms, decreased lung function, decreased quality of life, and increased risk of asthma-related ED visits and hospitalizations in patients with asthma (GINA, 2007; NHLBI, 2007).
- Tobacco use during pregnancy and ETS exposure postnatally increases the risk of childhood recurrent wheezing and asthma (GINA, 2007; NHLBI, 2007). Of particular concern are the effects of tobacco exposure in utero and in early infancy because of the increased incidence of recurrent wheezing and asthma (NHLBI, 2007; GINA, 2007; DiFranza, 2004).
10.2 Nutrition

BACKGROUND

A well-balanced diet that includes a variety of foods promotes general good health. In brief, most Americans need to consume diets with more fruits, vegetables, and whole grains, and eat less solid fats (saturated fat, transfat), salt, and added sugars. While food allergies are rarely an aggravating factor, some asthma patients are sensitive to sulfites in foods and are at higher risk for severe reactions to foods to which they are sensitized.

RECOMMENDATIONS

1. Advise patients who have asthma symptoms associated with consuming foods to which they are sensitized and/or foods high in sulfites (e.g., processed potatoes, shrimp, dried fruit, beer or wine) to avoid these products. [C]

RATIONALE

There is no evidence to support using restrictive diets to control asthma except in the cases of patients with proven food sensitivities, to include sulfite-containing products. Asthma patients should follow the same dietary recommendations as the rest of the population (NHLBI, 2007).

EVIDENCE STATEMENTS

- Evidence shows that in certain patients with asthma, consuming sulfite-containing products or other foods to which they are sensitized can contribute to worsening asthma symptoms.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Avoid sulfite-containing foods or those to which a patient is sensitized</td>
<td>NHLBI, 2007</td>
<td>II</td>
<td>Fair</td>
<td>C</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
10.3 Weight loss

BACKGROUND

Obesity has been associated with asthma persistence and severity in both children and adults, with a correlation between excess weight and selected inflammatory mediators that may negatively impact asthma control. Weight loss in adults can result in improved FEV1, reductions in exacerbations, and improved quality of life.

RECOMMENDATIONS

1. Advise patients with asthma who are overweight or obese that excess body weight may have negative effects on asthma control and that weight loss may be associated with improvement of symptoms. [B]

2. Encourage all patients with asthma to attain and maintain healthy body weight (see the VA/DoD Guidelines for Overweight and Obesity). [B]

RATIONALE

Weight loss in obese patients with asthma can result in improvement in pulmonary mechanics, symptoms and quality of life, but the actual mechanisms are unclear. However, there is insufficient evidence to recommend severely limited caloric diets and/or bariatric surgery to control asthma.

EVIDENCE STATEMENTS

- A prospective study of obese women enrolled in an intensive weight loss program showed that while FVC and FEV1 improved, bronchial reactivity did not significantly change nor did methacholine responsiveness (Aaron et al, 2004).

- The evidence shows that children with high body weight, either at birth or later in childhood, are at increased risk for future asthma (Flaherman et al., 2006).

- There is compelling evidence that overweight and obese adults have a higher incidence of asthma (Beuther & Sutherland, 2007).

- Weight reduction in obese asthma patients has been demonstrated to improve lung function and health status (NHLBI, 2007).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Calorie controlled diets in chronic asthma improve FEV1 and FVC</td>
<td>Cheng et al., 2003</td>
<td>I</td>
<td>Fair</td>
<td>B</td>
</tr>
<tr>
<td>2 High body weight in children increases risk for future asthma</td>
<td>Flaherman et al., 2006</td>
<td>I</td>
<td>Fair</td>
<td>B</td>
</tr>
<tr>
<td>3 Overweight and obesity in adults are associated with increased incidence of asthma</td>
<td>Beuther &amp; Sutherland, 2007</td>
<td>I</td>
<td>Fair</td>
<td>B</td>
</tr>
<tr>
<td>4 Weight loss in adults results in improvement in pulmonary mechanics</td>
<td>NHLBI - 2007</td>
<td>II</td>
<td>Good</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
10.4 Complementary and Alternative Medicine (Meditation, Acupuncture)

**BACKGROUND**

Increasing numbers of the U.S. population are exploring options in complementary and alternative medicine (CAM), which includes chiropractic therapy, acupuncture, meditation, breathing or relaxation techniques, hypnosis, homeopathy, herbal products and nutritional supplements. While some cultural beliefs and practices may be incorporated into evidence-based asthma management, patients and caregivers must be educated on the potential dangers associated with utilizing unproven therapies.

**RECOMMENDATIONS**

1. In the process of interviewing the patient and reconciling medications, query every patient for the use of complementary and alternative medicine (CAM). [I]

2. Discourage patients and caregivers from substituting alternative therapies for evidence-based conventional asthma management by providing evidence-based information. [D]

**DISCUSSION**

The Joint Commission for the Accreditation of Healthcare Organizations includes alternative products in the definition of a drug and mandates full reconciliation and communication to all providers involved in patients’ care. Complementary and alternative therapies include acupuncture, homeopathy, herbal medicine, Ayurvedic medicine, ionizers, osteopathy and chiropractic manipulation and dietary supplements. The evidence for these therapies is limited by the small number, and size, of well-designed trials, and the lack of clinically significant differences between intervention and control groups. The few trials showing benefits were not reproducible and the potential side effects can be problematic and, in some cases, life-threatening if these therapies are used in place of conventional treatment.

**EVIDENCE STATEMENTS**

- There are many accounts of deleterious effects associated with the use of alternative therapies because of product interactions, overlap and/or duplication of effects, or contaminated products.

- There is substantial evidence showing that using CAM in place of traditional therapy causes loss of asthma control and, in some cases, serious medical symptoms (NHLBI, 2007; GINA, 2007).

- A meta-analysis of 15 trials (Markham et al., 2004) and a subsequent systemic review (Passalacqua et al., 2006) found insufficient evidence to recommend any of these therapies.

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Use of CAM is not proven to be effective and can be dangerous</td>
<td>NHLBI, 2007 GINA, 2007</td>
<td>II</td>
<td>Good</td>
<td>D</td>
</tr>
<tr>
<td>2 Treating asthma with omega-3 fatty acids</td>
<td>Reisman et al., 2006</td>
<td>I</td>
<td>Poor</td>
<td>I</td>
</tr>
<tr>
<td>3 Manual therapy for asthma (manipulation or massage)</td>
<td>Hondras et al., 2005</td>
<td>I</td>
<td>Poor</td>
<td>I</td>
</tr>
<tr>
<td>Lack of evidence for the use of CAM to improve asthma control</td>
<td>Markham et al., 2004 Passalacqua et al., 2006</td>
<td>I</td>
<td>Poor</td>
<td>D</td>
</tr>
</tbody>
</table>

*LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)*
11. SELF-MANAGEMENT/PATIENT EDUCATION

Providing limited asthma education to patients and families does not improve clinical outcomes. There is strong evidence that practice models incorporating comprehensive education on asthma self-management, including self-adjustment of medications in response to worsening symptoms, regular medical review and provision of a written action plan, significantly improve asthma control and quality of life.

11.1 Patient and Family Education (Self-Management)

BACKGROUND

Asthma self-management education is essential to provide patients and their caregivers with the skills necessary to control asthma, improve outcomes, and maintain a healthy lifestyle. Patient and family involvement is central to optimal asthma control and self-management education must be tailored to literacy levels and sensitive to diverse cultural beliefs and backgrounds. Asthma education is most effective when initiated at the time of diagnosis and reinforced at every encounter, and when it includes information on daily and acute management with self-adjustment of medications. By establishing joint treatment goals and demonstrating responsiveness to patient concerns, the primary care manager builds the foundation of a strong partnership in asthma management.

RECOMMENDATIONS

1. Assess patient and/or family for educational needs as well as for preferences and/or barriers to learning, which may include limited medical and/or English literacy, physical, developmental, emotional or psychological challenges as well as specific cultural and/or spiritual beliefs. [A]
2. Provide asthma self-management education at all points of care where health professionals interact with patients and their families. [A] Education may be effective at other points of care such as pharmacies, hospitals, schools, and emergency departments. [B]
3. Teach and review core asthma education and self-management concepts at every visit with return demonstration when appropriate. [B]
4. Encourage a varied diet that is consistent with the Dietary Guidelines for Americans. [B]
5. Encourage asthma patients to participate in regular exercise to maintain general health and improve pulmonary conditioning. [B]

DISCUSSION

The Joint Commission (TJC) mandates that all patients be assessed for cultural and spiritual requirements. Exercising and eating a variety of foods are safe for asthma patients and they should be encouraged to embrace a healthy lifestyle that includes good nutrition and regular exercise to improve pulmonary conditioning (Ram et al., 2005). Evidence is now abundant that asthma self-management education is effective in improving asthma outcomes (NHLBI, 2007). It is important to integrate asthma self-monitoring and management education into all aspects of asthma care, beginning at the time of diagnosis and continuing through follow-up care. The principal clinician should introduce the key educational messages and negotiate agreements about the goals of treatment, specific medications, and the actions patients will take to reach the agreed-upon goals to control asthma. These core concepts should be emphasized by all members of the healthcare team at every encounter.
Table 9. Core Education and Self-Management Concepts

<table>
<thead>
<tr>
<th>Core Education and Self-Management Concepts</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Basic information about asthma (inflammation vs. bronchoconstriction, chronicity of disease, definition of good control)</td>
</tr>
<tr>
<td>- Components and utility of a written asthma action plan, including recognition of worsening conditions along with actions to take at home (monitoring and medication adjustment)</td>
</tr>
<tr>
<td>- Triggers, allergen avoidance and environmental controls</td>
</tr>
<tr>
<td>- School/daycare-specific instructions</td>
</tr>
<tr>
<td>- Medications’ mechanisms of action, roles in management, and possible side effects</td>
</tr>
<tr>
<td>- Specific instructions for emergency situations</td>
</tr>
<tr>
<td>- Delivery devices and their appropriate use emphasizing that MDI/HFA with spacer device is equally effective for administration of nebulized medication.</td>
</tr>
<tr>
<td>- Contact names and telephone numbers for professional support to answer questions about home management</td>
</tr>
<tr>
<td>- Method of routine monitoring (symptoms and/or peak flow)</td>
</tr>
<tr>
<td>- Appointment information for the next visit</td>
</tr>
</tbody>
</table>

EVIDENCE STATEMENTS

- The Joint Commission requires comprehensive cultural and spiritual assessment of all patients entering a healthcare system (CAMH, 2008).
- The evidence supports the provision of individualized culturally sensitive patient and/or caregiver education (NHLBI, 2007).
- Strong evidence supports ensuring that asthma self-management education be initiated at the time of diagnosis and be repeated and reinforced at every patient encounter with healthcare providers (NHLBI, 2007).
- The evidence shows that regular physical exercise improves pulmonary conditioning and does not worsen lung function in patients with asthma (Ram et al., 2005).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Perform cultural and spiritual assessment</td>
<td>CAMH, Provision of Care 6.10, 2008</td>
<td>I</td>
<td>Good</td>
</tr>
<tr>
<td>2</td>
<td>Individualized culturally sensitive asthma education improves outcomes</td>
<td>Bailey et al., 2008 NHLBI, 2007</td>
<td>I</td>
<td>Fair</td>
</tr>
<tr>
<td>3</td>
<td>Self-management asthma education must be initiated at the time of diagnosis and be repeated and reinforced</td>
<td>NHLBI EPR-3, 2007</td>
<td>I</td>
<td>Good</td>
</tr>
<tr>
<td>4</td>
<td>A varied diet promotes good health</td>
<td>DHHS – Dietary Guidelines for Americans, 2005</td>
<td>II</td>
<td>Good</td>
</tr>
<tr>
<td>5</td>
<td>Physical training in asthma improves cardiopulmonary fitness while lung function and wheeze are not worsened</td>
<td>Ram et al., 2005</td>
<td>I</td>
<td>Fair</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
11.2 Strategies to Deliver Patient and Family Education

BACKGROUND

Effective patient and/or caregiver education can be accomplished using a variety of instructional methods. Comprehensive disease management programs may rely on interdisciplinary teams for patient education and include physicians, physician assistants, nurse practitioners, nurses, respiratory therapists, pharmacists and asthma educators. Many patients and families may benefit from the myriad of easily accessible emerging technologies that include audiovisual materials and internet-based programs.

RECOMMENDATIONS

1. Utilize a variety of educational strategies to include frequent appointments with asthma educators, individualized case management, and/or patient age-appropriate standard curriculums. [B]
2. Consider utilizing interactive, multi-media resources in providing asthma education. [B]
3. Consider providing information on web-based comprehensive education sites that may include journaling, bulletin boards, support systems, electronic symptom questionnaires, and/or quality of life surveys to track and reinforce patient self-monitoring and management skills. [B]

DISCUSSION

Many patients will benefit from interactive computer games and multi-faceted internet programs that provide basic asthma-related information and reinforce self-management techniques and environmental controls. There is increasing evidence that incorporating technology into asthma self-management education can augment and enhance traditional methods of instruction. In children, Cicutto demonstrated that using games, puppetry and model building decreased school absenteeism and activity limitation (Cicutto et al., 2005), while Runge showed that adding an internet-based education program improved health outcomes (Runge et al., 2006). Rasmussen demonstrated a similar effect in adult patients utilizing an internet-based asthma management tool (Rasmussen et al., 2005). Compared to both specialty and general practice, these patients had significantly fewer asthma symptoms, higher quality of life and better FEV1. Based on patient skill, access to and interest in using interactive multi-media tools and web-based information and decision tools can improve outcomes.

EVIDENCE STATEMENT

- Utilization of a variety of educational techniques has demonstrated improvement in outcomes (NHBLI, 2007; Cicutto et al., 2005).
- Emerging evidence suggests the potential for incorporating internet-based programs into asthma education and management (Runge et al., 2006; Rasmussen et al., 2007).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Innovative educational methods that include technology improve outcomes in children</td>
<td>Cicutto et al., 2005</td>
<td>I</td>
<td>Good</td>
<td>B</td>
</tr>
<tr>
<td>2 Incorporating internet-based asthma education improves outcomes in children</td>
<td>Runge et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>B</td>
</tr>
<tr>
<td>3 Using an internet-based asthma management tool decreased symptoms and increased quality of life in adults</td>
<td>Rasmussen et al., 2007</td>
<td>I</td>
<td>Good</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
11.3 Optimal Self-Management Tools (Use of Symptom or Peak Flow and/or Symptom-Based Action Plans)

**BACKGROUND**

Programs providing limited asthma education (transfer of information only without self-management techniques/written action plans) have not had positive effects on clinical outcomes with the exception of some possible benefit in the emergency department. Since all individuals diagnosed with asthma are susceptible to asthma exacerbations, patients with asthma should know how to prevent and manage these episodes. Optimal self-management includes self-monitoring (symptoms or symptoms and peak flow), regular medical review and the provision of a written action plan. Previous guidelines emphasized the use of peak flow meters, but the most recent evidence shows that symptom-based plans are also effective. In patients with asthma, training programs that enable patients and/or caregivers to adjust medication using a written plan leads to improved health outcomes.

**RECOMMENDATIONS**

1. Ensure optimal self-management by providing education on self-monitoring, use of a written asthma action plan and regular medical review. [A]

2. Develop asthma action plans that include instructions for daily management and recognition of worsening conditions along with actions to take at home (monitoring and medication adjustment) based on symptoms or peak expiratory flow (PEF) measurements and symptoms as appropriate. [A]

**DISCUSSION**

Education that is limited to information transfer does not significantly impact outcomes (Gibson et al., 2002). However, there is strong evidence that optimal asthma self-management, which includes education, regular medical review and use of a written asthma action plan, clearly leads to improved health outcomes in adults (Gibson et al., 2003). Agrawal demonstrated similar results in a pediatric population (Agrawal et al., 2005). As described in Bhogal, the need for active participation of the patient and/or caregiver to prevent exacerbation has resulted in the universal recommendation by national and international guidelines to provide written asthma action plans to all asthma patients (Bhogal et al., 2006; GINA, 2007; NHLBI, 2007). The action plan must include information on daily management, recognizing and handling worsening symptoms, including self-adjustment of medications when necessary.
Table 10. Information Included in Written Asthma Action Plans

<table>
<thead>
<tr>
<th>Personal Information and Daily Management</th>
<th>Worsening Symptoms and Actions to Take at Home</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient name</td>
<td>Patient-specific asthma symptoms/peak flow values requiring action:</td>
</tr>
<tr>
<td>Provider/clinic name and contact number</td>
<td>- Acute asthma symptoms (e.g., cough, wheeze, shortness of breath, chest tightness, etc.)</td>
</tr>
<tr>
<td>Personal best peak flow (when applicable)</td>
<td>- Daytime symptoms &gt; 2 times/week</td>
</tr>
<tr>
<td>Monitoring method and frequency (symptoms or symptoms and peak flow)</td>
<td>- Nighttime wakenings &gt; 2 times/month</td>
</tr>
<tr>
<td>Description of optimal control (e.g., no coughing, wheezing, shortness of breath, chest tightness, interference with activities or sleep, peak flow &gt; 80% of personal best)</td>
<td>- Increased limitation of normal activity</td>
</tr>
<tr>
<td>Trigger recognition, mitigation and/or avoidance (consider pollen count, air quality, etc.)</td>
<td>- Increased use of bronchodilator (&gt; 2 times/week)</td>
</tr>
<tr>
<td>Medications (quick relief, long-term controller, adjunctive therapies)</td>
<td>- Peak flow value &lt; 80% of personal best</td>
</tr>
<tr>
<td>Guidance on prophylactic medication prior to trigger exposure (exercise, environmental allergens or irritants)</td>
<td>Initial response to increased symptoms</td>
</tr>
<tr>
<td></td>
<td>- Stop the provoking activity/move away from trigger(s)</td>
</tr>
<tr>
<td></td>
<td>- Evaluate symptom severity/peak flow value</td>
</tr>
<tr>
<td></td>
<td>Appropriate use of quick-relief medication</td>
</tr>
<tr>
<td></td>
<td>When to reassess effectiveness of treatment through symptoms/peak flow</td>
</tr>
<tr>
<td></td>
<td>When and how to modify medication regimen (add and/or increase)</td>
</tr>
<tr>
<td></td>
<td>How to continue self-monitoring</td>
</tr>
<tr>
<td></td>
<td>How to identify a failure of home treatment if increased use of rescue medication is required until symptoms and peak flow stabilize</td>
</tr>
<tr>
<td></td>
<td>When to call the healthcare provider for evaluation</td>
</tr>
<tr>
<td></td>
<td>What symptoms/peak flow values require emergency medical treatment:</td>
</tr>
<tr>
<td></td>
<td>- Lack of response to quick-relief medication</td>
</tr>
<tr>
<td></td>
<td>- Inability to talk in complete sentences</td>
</tr>
<tr>
<td></td>
<td>- Extreme shortness of breath</td>
</tr>
<tr>
<td></td>
<td>- Retractions, lips/fingernails are blue</td>
</tr>
<tr>
<td></td>
<td>- Increased respiration rate</td>
</tr>
<tr>
<td></td>
<td>- Peak flow &lt; 50% of personal best</td>
</tr>
<tr>
<td></td>
<td>Directions for accessing emergency care (e.g., 911)</td>
</tr>
</tbody>
</table>

**EVIDENCE STATEMENT**

- Patients with optimal asthma management, including comprehensive asthma education that addresses self-monitoring, regular medical review and a written action plan have better outcomes. The action plan must include instructions on daily management and how to recognize and handle worsening asthma by self-adjustment of medications (Agrawal et al., 2005; Cicutto et al., 2005; Gibson et al., 2003).
Both symptom or symptom and peak flow-based written action plans can be effective (Bhogal et al., 2006).

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Education in self-management that includes self-monitoring, regular medical review and a written action plan improves health outcomes for adults</td>
<td>Gibson et al., 2003</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>2 Comprehensive asthma education that includes action plan use decreases urgent care visits, school absenteeism and activity limitation in children</td>
<td>Cicutto et al., 2005</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>3 Comprehensive self-management programs that include written asthma action plans decrease asthma events, missed days of school, nocturnal awakenings and symptoms</td>
<td>Agrawal et al., 2005</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>4 Symptom or symptom and peak flow-based asthma action plans are effective</td>
<td>Bhogal et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
<tr>
<td>5 Limited asthma education does not decrease hospitalizations, asthma therapy or time lost from work</td>
<td>Gibson et al., 2002</td>
<td>I</td>
<td>Good</td>
<td>A</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
12. ACUTE EXACERBATION

BACKGROUND

Exacerbations are characterized by decreases in expiratory airflow that should be documented and quantified by simple measurement of lung function (either spirometry, if readily available, or peak expiratory flow). Objective measures are a more reliable indicator of the severity of an exacerbation than reported symptoms. In general, milder exacerbations may be managed at home without requiring an office visit, whereas exacerbations that are more serious may require an office visit, referral to the emergency department, or a hospital admission. The most severe exacerbations require admission to the intensive care unit (ICU) for optimal monitoring and treatment. Although assessment and treatment of young children, especially infants, pose unique challenges, the management of asthma exacerbations in older children and adults is fairly similar.

12.1 Indication for Immediate Triage

BACKGROUND

Patients at high risk for asthma-related death should be managed with special attention. These patients should be advised to seek medical attention early during acute exacerbations. In general, primary care providers without expertise in asthma management should not attempt to manage these patients at home or in the office; they should instead be referred for more intensive treatment and monitoring in an emergency department. In the pediatric setting, infants seen by a primary care provider should also be referred immediately for acute management.

ACTION STATEMENT

Patients at high risk for hospitalization or complications related to an asthma exacerbation should be referred to the nearest emergency department for management.

RECOMMENDATIONS

1. Patients are considered high risk for complications from an acute exacerbation in the following situations: [C]
   a. Previous severe exacerbation (e.g., intubation or ICU admission for asthma)
   b. Two or more hospitalizations or greater than three Emergency Department visits in the past year
   c. Use of greater than two canisters of short-acting beta-agonist per month
   d. Difficulty perceiving airway obstruction or the severity of worsening asthma
   e. Recent use of oral glucocorticoids for exacerbation
   f. Major psychosocial problems or psychiatric disease (including illicit drug use)
   g. Co-morbidities such as cardiovascular disease or other chronic lung disease
   h. History of non-compliance with asthma medication plan.

2. Patients in respiratory failure, or at imminent risk of respiratory failure, should be treated very aggressively and transported immediately to the emergency department. Treatment using continuous nebulized bronchodilators (albuterol or levoalbuterol) and/or systemic bronchodilators (subcutaneous epinephrine or terbutaline) should be initiated in the office setting pending transport.
RATIONALE

- Patients with prior intubations or ICU admissions are at higher risk for repeat episodes due to poor perception of asthma severity or rapid decline in airway function with an exacerbation.
- Evidence suggests that near-fatal asthma is found in a higher proportion of patients with recent hospitalizations, increased beta-agonist use and recent glucocorticoid use.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Patients with asthma at high risk for death or hospitalization</td>
<td>Abramson et al., 2001 Suissa et al., 1994 Turner et al., 1998</td>
<td>II</td>
<td>Fair</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; SR = Strength of Recommendation (See Appendix A)

12.2 Assessing Severity of Exacerbation

BACKGROUND

One of the essential steps in managing an acute exacerbation of asthma is to determine the severity of the exacerbation. There are several indicators based on history, physical examination, and objective measurements of lung function that may guide whether a patient can be effectively managed in a primary care setting or should be referred to a higher level of care. Likewise, severity may indicate how quickly a patient should be transferred for acute management.

ACTION STATEMENT

An overall assessment of the severity of an asthma exacerbation should guide the location (home, office or hospital) and rapidity of treatment.

RECOMMENDATIONS

1. The severity of acute exacerbation should be determined by assessing specific characteristics of the symptoms, signs, and by objective measurement of SaO2 and PaCO2 (see Table 11).

RATIONALE

- The primary step in defining treatment options for any asthma exacerbation is to determine the severity of the exacerbation.
- Severity will guide the rapidity of treatment (urgent vs. non-urgent), location (home, office or acute care setting), and treatment options.
- Many primary care locations are not equipped to deal with a sudden worsening of an acute exacerbation and may not have availability of medications or monitoring capability.
Table 11. Classification of Acute Exacerbation: Severity and Treatment

<table>
<thead>
<tr>
<th>Severity of Asthma Exacerbation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild</strong></td>
</tr>
<tr>
<td><strong>Moderate</strong></td>
</tr>
<tr>
<td><strong>Severe</strong></td>
</tr>
<tr>
<td><strong>Respiratory Arrest Imminent</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIGNS / SYMPTOMS</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Respiratory Arrest Imminent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity Level:</td>
<td>Walks briskly</td>
<td>Walks slowly</td>
<td>Walks with assistance</td>
<td>Unable to walk</td>
</tr>
<tr>
<td>Feeding (infant):</td>
<td>Normal</td>
<td>Difficulty feeding</td>
<td>Unable to feed</td>
<td>Unable to suck</td>
</tr>
<tr>
<td>Talks in:</td>
<td>Sentences</td>
<td>Phrases</td>
<td>Words</td>
<td>Too dyspneic to speak; perspiring</td>
</tr>
<tr>
<td>Sounds (infant):</td>
<td>Normal cry, cooing</td>
<td>Short, clipped cry</td>
<td>Faint cry, grunting</td>
<td></td>
</tr>
<tr>
<td>Alertness:</td>
<td>May be agitated</td>
<td>Usually agitated</td>
<td>Usually agitated</td>
<td>Drowsy or confused</td>
</tr>
<tr>
<td>Respiratory rate:</td>
<td>Increased</td>
<td>Increased</td>
<td>Often &gt; 30/min</td>
<td></td>
</tr>
</tbody>
</table>

**Normal rates of breathing in awake children:**

<table>
<thead>
<tr>
<th>Age</th>
<th>Normal rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 2 months</td>
<td>&lt; 60/min</td>
</tr>
<tr>
<td>2-12 months</td>
<td>&lt; 50/min</td>
</tr>
<tr>
<td>1-5 years</td>
<td>&lt; 40/min</td>
</tr>
<tr>
<td>6-8 years</td>
<td>&lt; 30/min</td>
</tr>
</tbody>
</table>

**Retractions & accessory muscle use:**

<table>
<thead>
<tr>
<th>Usually not</th>
<th>Usually</th>
<th>Usually</th>
<th>Paradoxical thoraco-abdominal movement (see-saw breathing)</th>
</tr>
</thead>
</table>

**Wheeze:**

<table>
<thead>
<tr>
<th>Moderate, often only end expiratory</th>
<th>Loud expiratory</th>
<th>Usually loud, may be biphasic (inspiratory and expiratory)</th>
<th>Absence of wheeze</th>
</tr>
</thead>
</table>

**Pulse/min. > 8 yrs:**

<table>
<thead>
<tr>
<th>&lt; 100</th>
<th>100-120</th>
<th>&gt;120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline limits of normal pulse rate in children:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infants (2-12 months):</td>
<td>&lt; 160/min</td>
<td></td>
</tr>
<tr>
<td>Preschool (1-2 years):</td>
<td>&lt; 120/min</td>
<td></td>
</tr>
<tr>
<td>School age (2-8 years):</td>
<td>&lt; 110/min</td>
<td></td>
</tr>
</tbody>
</table>

**Pulsus paradoxus:**

<table>
<thead>
<tr>
<th>Absent &lt; 10 mm Hg</th>
<th>May be present 10-25 mm Hg</th>
<th>Often present &gt; 25 mm Hg (adult) 20-40 mm Hg (child)</th>
<th>Absence suggests respiratory muscle fatigue</th>
</tr>
</thead>
</table>

**TESTS**

<table>
<thead>
<tr>
<th>SaO2% (on room air)</th>
<th>&gt; 95%</th>
<th>91-95%</th>
<th>&lt; 90%</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEF after initial bronchodilator treatment</td>
<td>Over 80%</td>
<td>Approx. 60-80%</td>
<td>&lt; 60% predicted</td>
</tr>
<tr>
<td>PaO2 (on room air)</td>
<td>Normal Test not usually necessary</td>
<td>&gt; 60 mm Hg</td>
<td>&lt; 60 mm Hg Possible cyanosis</td>
</tr>
<tr>
<td>PaCO2</td>
<td>&lt; 45 mm Hg</td>
<td>&lt; 45 mm Hg</td>
<td>&gt; 45 mm Hg</td>
</tr>
</tbody>
</table>

*Note: Hypercapnea (hypoventilation) develops more readily in young children than in adolescents and adults.*

**INTERVENTION**

<table>
<thead>
<tr>
<th>Response to inhaled Short-Acting Bronchodilator (SABA)</th>
<th>Prompt relief</th>
<th>Complete relief after multiple treatments</th>
<th>Partial relief after multiple treatments. Requires continuous inhaled SABA</th>
<th>Minimal or no relief from inhaled SABA. Requires systemic bronchodilator (subcutaneous epinephrine, terbutaline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location of care</td>
<td>Home Management</td>
<td>Office or emergency department</td>
<td>Emergency department; possible hospitalization</td>
<td>Hospitalization following stabilization in emergency department</td>
</tr>
</tbody>
</table>

*Note: The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation.*
12.3 Non-Urgent Management of Acute Exacerbations (Home or Office)

**BACKGROUND**

The general principles and goals for managing asthma exacerbations (AE) defined by the 2007 NHLBI asthma guidelines include early treatment of exacerbations, and identification of patients who are at high risk for asthma-related deaths, with special attention to infants. In those patients who are not at high-risk for hospitalization or death, beginning treatment at home avoids treatment delays, prevents exacerbations from becoming severe, and adds to patients’ sense of control over their asthma. The degree of care provided in the home depends on the patient’s (or parents’) abilities and experience, and on the availability of emergency care.

**ACTION STATEMENT**

Patients with mild to moderate asthma and without significant risk factors may be able to manage their asthma exacerbation at home or during a routine office visit without requiring management in an urgent care or emergency department setting.

**RECOMMENDATIONS**

1. Early treatment of exacerbations is best; patients (or parents) should be able to recognize early indicators of an exacerbation to include cough and/or worsening peak expiratory flow.
2. All patients should be provided with – and instructed on how to use – a written asthma action plan that includes an individualized daily management plan and instructions on recognizing and handling worsening asthma. It should also include self-adjustment of medications in response to acute symptoms or changes in peak flow measures in the event of an exacerbation.
3. Initial adjustments in medication should include an increase in frequency of SABA. [B] [For mild - moderate AE, up to 3 treatments within an hour (i.e., to 2-6 puffs per treatment); for severe AE, 4-8 puffs and seek medical care.]
4. Addition of a short course of oral systemic corticosteroids may be considered for 4-7 days following frequent use of SABA. [A]
5. The dose of inhaled corticosteroids should NOT be doubled [D] and patients should contact their healthcare provider before instituting a course of oral systemic corticosteroids.
6. Patients should be advised to withdraw from any environmental allergens or irritants that may contribute to the exacerbation.
7. Response to treatment should be monitored and communicated to the provider to determine if an office visit or referral to the emergency department is warranted.

**RATIONALE**

- Early treatment of asthma exacerbations by patients at home is warranted, as this is associated with a decrease in hospitalizations.
- In many instances, a peak flow-based plan may be useful for patients with difficulty perceiving airflow obstruction and who may be unable to recognize an exacerbation based on symptoms.
- Treatment of an exacerbation in which there is acute bronchoconstriction is best treated by inhaled SABA. Once initiated, oral steroids will treat the underlying inflammation leading to acute bronchoconstriction.
- Early treatment of acute asthma symptoms with oral steroids in children with a pattern of recurrent acute asthma may decrease the severity of acute asthma episodes and reduce the likelihood of subsequent relapses. (Rachelefsky, 2003; Rowe 2001 [Cochrane])
o There is no role for home remedies such as increased consumption of liquids, breathing warm, moist air, or taking over-the-counter antihistamines or cold remedies.

o In patients who regularly take an inhaled corticosteroid, doubling daily ICS dose alone is not effective for the treatment of mild to moderately severe exacerbations of asthma in adults (Harrison et al., 2004; FitzGerald et al., 2004, Rice-McDonald et al., 2005).

### EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Administer albuterol by emergency teams out of hospital</td>
<td>Markenson et al., 2004 Richmond et al., 2005</td>
<td>IIa</td>
<td>Fair</td>
</tr>
<tr>
<td>2</td>
<td>Initiate oral corticosteroids treatment</td>
<td>McFadden, 2003 Rachelefsky, 2003 Rowe et al., 2001 (SR)</td>
<td>III</td>
<td>I</td>
</tr>
<tr>
<td>3</td>
<td>Doubling dose of ICS is NOT sufficient</td>
<td>FitzGerald et al., 2004 Harrison et al., 2004 Rice-McDonald et al., 2005</td>
<td>I</td>
<td>Good</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

12.4. Management of Exacerbation in the Emergency Department

### BACKGROUND

The emergency department is the best place for managing moderate to severe asthma exacerbations and for patients with a high-risk past medical history. Primary care physicians should notify the closest emergency department and arrange for patient ACLS transport. Once in the emergency department, patients will be cared for according to their asthma severity. Emergency department interventions for moderate exacerbations may include continuous or separate albuterol nebulized treatments, nebulized anticholinergics, and systemic steroids. Severe exacerbations may need magnesium, subcutaneous adrenergic agents or possibly full airway support. The majority of patients will be sent home on a 5-day course of oral steroids and SABA. Following all emergency department visits, patients should be seen by their primary care physician within 1-2 days for outpatient evaluation and review of long-term asthma control medications.

### RECOMMENDATIONS

1. A brief history and physical examination pertinent to the exacerbation should be conducted concurrently with the prompt initiation of therapy.

2. The history should include:
   a. Severity and duration of symptoms, including exercise limitation and sleep disturbance
   b. All current medications, including dose (and device) prescribed, dose usually taken, dose taken in response to the deterioration, and the patient’s response (or lack thereof) to this therapy
   c. Time of onset and cause of the present exacerbation
   d. Risk factors for asthma-related death.

3. The physical examination should assess exacerbation severity by evaluating pulse rate, respiratory rate, use of accessory muscles, the patient’s ability to complete a sentence, and other signs.

4. Any complicating factors should be identified (e.g., pneumonia, atelectasis, pneumothorax, or pneumomediastinum).
5. Without unduly delaying treatment, a baseline PEF or FEV1 measurement should be made before treatment is initiated.

6. Subsequent measurements should be made at intervals until a clear response to treatment has occurred.

7. Oxygen saturation should be closely monitored, preferably by pulse oximetry. This is especially useful in children because objective measurements of lung function may be difficult. Oxygen saturation in children should normally be greater than 95%, and oxygen saturation less than 92% is a good predictor of the need for hospitalization [C].

8. A chest X-ray (CXR) is not routinely required unless there are signs of infection such as fever or cough productive of purulent sputum. A patient presenting for the first time with signs and symptoms of asthma may require a CXR to rule out other causes of airway hyperreactivity. Additionally, if the clinician suspects secondary complications such as pneumothorax based on history and physical examination, a CXR should be obtained.

12.5 Follow-up in Primary Care after Discharge from Emergency Department

**BACKGROUND**

Most patients who fail outpatient therapy after discharge from the emergency department will return to the emergency department or make an unscheduled clinic visit within 72 hours. Therefore, patients should be evaluated by the primary care provider or asthma specialist after emergency department treatment to assess for clinical and subjective improvement or deterioration.

**RECOMMENDATIONS**

1. Patients discharged from the emergency department should contact the primary care provider within 1-2 days and schedule a follow-up visit as considered appropriate by the provider.

2. An acute exacerbation episode may indicate a lack of control of the patient’s chronic asthma. A step-up adjustment of the patient’s routine care and/or a consultation with a specialist may be considered.

**DISCUSSION**

Some data suggest that patients discharged from the emergency department do better with follow-up by a specialist rather a primary care physician (GINA, 2007).
13. EXERCISE-INDUCED BRONCHOSPASM

BACKGROUND

Exercise-induced bronchospasm (EIB), commonly referred to in the medical literature as exercise-induced asthma or exercise-induced bronchoconstriction, can be diagnosed in two distinct groups of patients. The first group consists of those patients with established asthma who, during exercise, have a component of bronchospasm that limits their activities. It is reported to occur in up to 80% of patients with asthma and is usually a self-limited process that resolves with cessation of exercise (see Section 13.1: EIB in the Patient with Asthma).

There is a separate group of patients who do not have underlying asthma but may develop symptomatic bronchospasm with prolonged exercise. These patients are generally competitive athletes or active duty military who exercise on a regular basis. The evaluation of these patients always demonstrates normal resting spirometry but airway hyperreactivity with bronchoprovocation testing (see Section 13.2: EIB in the Athlete).

13.1 EIB in the Patient with Asthma

BACKGROUND

Exercise-induced bronchospasm (EIB) should be anticipated in all asthma patients. It is frequently referred to as exercise-induced asthma in the medical literature. A history of cough, shortness of breath, chest pain or tightness, wheezing, or endurance problems during exercise suggests EIB in the patient with asthma. An exercise challenge (in which there is a 15 percent decrease in PEF or FEV1) can help establish the diagnosis. An important dimension of adequate asthma control is a patient’s ability to participate in any activity he or she chooses without experiencing asthma symptoms. EIB should not limit either participation or success in vigorous activities.

ACTION STATEMENT

Consider the diagnosis of exercise-induced bronchospasm (EIB) in the patient with asthma who has significant symptoms associated with exercise. Optimal treatment for such a patient may consist of an increase in long-term controller medications or prophylactic beta-agonist use prior to exercise.

RECOMMENDATIONS

1. All patients with asthma should have a regular exercise program and be asked about any limitations to exercise.
2. Bronchoprovocation testing (exercise spirometry) should be considered if the patient notes increased symptoms suggestive of EIB during or immediately following exercise. [C]
3. Primary treatment is a warm-up period prior to exercise and pretreatment with short-acting beta-agonists is recommended. [A]
4. Alternative treatments include LTRAs, which can attenuate EIB in up to 50 percent of patients. [C]
5. Cromolyn sodium or nedocromil taken shortly before exercise is an alternative treatment, but it is not as effective as SABAs. [C]
6. Consideration for increasing controller medications may be indicated to control or alleviate increased asthma symptoms during exercise.
RATIONALE

- Exercise-induced bronchospasm (EIB) can be diagnosed in up to 80% of all patients with asthma.
- A regular exercise program is indicated in patients with asthma to avoid deconditioning and improved cardiovascular health.
- Exercise spirometry is the easiest and most reliable method recommended by the ATS for bronchoprovocation testing.
- Short-acting beta-agonists are the most investigated and proven method of decreasing EIB in the patient with asthma. SABA used shortly before exercise may be helpful for 2–3 hours.
- Frequent or chronic use of LABA as pretreatment for EIB is discouraged, as it may disguise poorly controlled persistent asthma.

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Regular exercise program</td>
<td>NHLBI, 2007 page 38</td>
<td>III</td>
<td>Poor</td>
<td>Small</td>
<td>I</td>
</tr>
<tr>
<td>2 Bronchoprovocation testing</td>
<td>Randolph, 1997</td>
<td>III</td>
<td>Fair</td>
<td>Small</td>
<td>C</td>
</tr>
<tr>
<td>3 Short-acting beta-agonist</td>
<td>Pearlman et al., 2007</td>
<td>I</td>
<td>Good</td>
<td>Substantial</td>
<td>A</td>
</tr>
<tr>
<td>4 LTRA use</td>
<td>Pearlman et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>C</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

Annotation E-2  Consider Bronchoprovocation Testing

13.2 EIB in the Athlete

BACKGROUND

Exercise-induced bronchospasm (EIB) in the athlete is a common pulmonary disease diagnosed primarily in competitive athletes at all levels. EIB may also be common in the active duty military population given the nature of their duties and requirements for aerobic conditioning. These patients are defined in the following manner: 1) symptoms (dyspnea, cough, wheezing, or chest tightness) only associated with exercise with no other resting or nocturnal symptoms; 2) normal resting baseline spirometry and examination; 3) nonspecific airway hyperreactivity with bronchoprovocation testing; and 4) response to treatment. Optimal treatment for these patients has not been well delineated. Treatment usually consists of prophylactic beta-agonist use prior to exercise. There is little indication for controller medications as the pathophysiology is strikingly different from asthma and resolves spontaneously after cessation of exercise.

ACTION STATEMENT

In competitive athletes and active duty military with symptoms of exertional dyspnea and a normal baseline spirometry, the diagnosis of exercise-induced bronchospasm (EIB) should be actively pursued.

RECOMMENDATIONS

1. The patient’s history should focus on the correlation of symptoms (dyspnea, wheezing, cough, or chest tightness) with exertion during or immediately after prolonged exercise such as running.
2. Normal baseline resting spirometry (no evidence of obstruction or restriction with a normal flow volume loop) should prompt referral for bronchoprovocation testing.
3. The preferred method for bronchoprovocation testing is histamine and methacholine challenge testing or eucapneic hyperventilation as other methods are less sensitive for detecting airway hyperreactivity.

**RATIONALE**

Exercise-induced bronchospasm is caused by osmotic drying of the airways due to a decrease of humidified air inhaled during exercise. It resolves rapidly with the cessation of exercise and should not cause rest or nocturnal symptoms.

Spirometry may be abnormal if performed immediately post-exercise, but the rapid reversal of osmotic changes causes no chronic inflammation or persistent changes in spirometry.

Bronchoprovocation testing can document the predisposition to airway hyperreactivity usually present in these patients even when not actively exercising.

**EVIDENCE TABLE**

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Prevalence of EIB</td>
<td>Sonna et al., 2001</td>
<td>II-2</td>
<td>Fair</td>
<td>Small</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Wilber et al., 2000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Method of bronchoprovocation</td>
<td>Dickinson et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>A</td>
</tr>
<tr>
<td>testing</td>
<td>Morris et al., 2002</td>
<td>II</td>
<td>Fair</td>
<td>Mod</td>
<td></td>
</tr>
</tbody>
</table>

**13.3 Bronchoprovocation Testing**

**BACKGROUND**

Bronchoprovocation testing is a useful adjunct in establishing the presence or absence of airway hyperreactivity in patients being evaluated for asthma or exercise-induced bronchospasm (EIB). Indications for testing include patients with asthma symptoms with normal spirometry who are suspected of having mild asthma or EIB. There are numerous methods established to include methacholine, histamine, cold air, eucapneic hyperventilation, and exercise challenge. The indications for using each specific type of bronchoprovocation test depend on the availability of equipment and clinical indication.

**ACTION STATEMENT**

Bronchoprovocation testing should be considered for 1) patients with symptoms suggestive of asthma with normal spirometry or 2) to establish the diagnosis of exercise-induced bronchospasm in patients with asthma who exhibit exertional symptoms.

**RECOMMENDATIONS**

1. Methacholine or histamine challenge testing is indicated to establish the presence of airway hyperreactivity in patients with exertional symptoms (cough, wheezing, dyspnea, chest tightness) and normal resting spirometry. [C]

2. Exercise challenge testing is indicated to establish the diagnosis of exercise-induced bronchospasm (or exercise-induced asthma) in known patients with asthma who exhibit exertional symptoms. [B]

3. Eucapneic hyperventilation or cold air testing are equivalent to methacholine or histamine challenge testing but should be used in laboratories experienced in these techniques. [B]
RATIONALE

Methacholine or histamine challenge testing has been shown to be more sensitive in establishing the presence of nonspecific airway hyperreactivity when compared to exercise challenge testing.

A positive methacholine challenge test does not specifically establish the diagnosis of asthma (may be positive in allergic rhinitis, cystic fibrosis or COPD), but a negative test excludes the diagnosis of asthma.

Exercise challenge testing is the least sensitive test for airway hyperreactivity and is best utilized to establish EIB in known patients with asthma.

Bronchoprovocation testing should be performed and interpreted by trained individuals.

EVIDENCE STATEMENTS

- “Bronchoprovocation with methacholine, histamine, cold air, or exercise challenge may be useful when asthma is suspected and spirometry is normal or near normal. For safety reasons, bronchoprovocation should be carried out only by a trained individual in an appropriate facility and is not generally recommended if the FEV1 is <65 percent predicted. A positive test is diagnostic for airway hyperresponsiveness, which is a characteristic feature of asthma but can also be present in other conditions. Thus, a positive test is consistent with asthma, but a negative test may be more helpful to rule out asthma.” (NHLBI 2007, page 45)

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Histamine or methacholine for EIB in athletes</td>
<td>Brown et al., 2004</td>
<td>II-2</td>
<td>Fair</td>
<td>Mod</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>Eliasson et al., 1992</td>
<td>II-1</td>
<td>Fair</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>2 Exercise spirometry for EIB in patients with asthma</td>
<td>ATS Guidelines, 1999</td>
<td>III</td>
<td>Fair</td>
<td>Mod</td>
<td>B</td>
</tr>
<tr>
<td>3 Eucapneic hyperventilation</td>
<td>Dickinson et al., 2006</td>
<td>I</td>
<td>Good</td>
<td>Mod</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Mannix et al., 1999</td>
<td>II-1</td>
<td>Good</td>
<td>Mod</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)

Annotation E-3  Manage Exercise-Induced Bronchospasm (EIB)

13.4. EIB Treatment

BACKGROUND

Optimal treatment for EIB patients has not been well delineated but usually consists of prophylactic beta-agonist use prior to exercise. There is little indication for controller medications as the pathophysiology is strikingly different from asthma and resolves spontaneously after cessation of exercise.

ACTION STATEMENT

EIB in the athlete should be treated prior to exercise to improve exercise tolerance and decrease post-exercise symptoms related to airway hyperreactivity.

RECOMMENDATIONS

1. The initial treatment regimen should consist of a warm-up period (gradual increase in exercise) and short-acting beta-agonist use 15-20 minutes prior to exercise. [C]
2. The use of LTRA or inhaled cromolyn prior to exercise may be considered. [C]
3. Lack of symptomatic improvement to inhaled beta-agonists or continued poor exercise tolerance should prompt referral for further evaluation by a specialist.

RATIONALE

Exercise-induced bronchospasm (EIB) is caused by osmotic drying of the airways due to a decrease of humidified air inhaled during exercise. EIB can resolve rapidly with the cessation of exercise and should not cause rest or nocturnal symptoms.

Documentation of decreased symptoms or improved exercise tolerance with treatment is critical in establishing the diagnosis of EIB in the athlete.

EVIDENCE STATEMENTS

- Commonly accepted and long-standing treatment for EIB is short-acting beta-agonist use prior to exercise. Beta-agonist use has been shown to decrease symptoms both during and post-exercise (Parsons & Mastronarde, 2005).
- There are no studies that have specifically examined the use of LTRA or cromolyn in patients with EIB without underlying asthma. Studies performed in asthma patients with EIB have shown benefit in decreasing exercise symptoms (Pearlman et al., 2006).

EVIDENCE TABLE

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Source</th>
<th>LE</th>
<th>QE</th>
<th>NE</th>
<th>SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Beta-agonists prior to exercise</td>
<td>Parsons &amp; Mastronarde, 2005</td>
<td>III</td>
<td>Fair</td>
<td>Mod</td>
<td>C</td>
</tr>
<tr>
<td>2 LTRA or cromolyn use</td>
<td>Pearlman et al., 2006</td>
<td>III</td>
<td>Fair</td>
<td>Mod</td>
<td>C</td>
</tr>
</tbody>
</table>

LE = Level of Evidence; QE = Quality of Evidence; NE = Net Effect; SR = Strength of Recommendation (See Appendix A)
14. MILITARY (ACTIVE DUTY)-SPECIFIC ISSUES

RECOMMENDATIONS

Evaluation for possible asthma

1. Active duty service members should be diagnosed with asthma or exercise-induced bronchospasm on the basis of the following criteria:
   a. Chronic symptoms of cough, dyspnea, or wheezing
   b. Associated decrease in tolerance of exercise and/or running
   c. Normal chest radiograph (should be obtained in all active duty patients)
   d. Demonstration of persistent airway hyperreactivity
      • Baseline spirometry with reversible airflow obstruction post-bronchodilator
      OR
      • Reactive bronchoprovocation testing or lower dose of methacholine (preferred method of bronchoprovocation testing).

See Appendix C - DoD Service-Specific Regulation Concerning Asthma

Deployment issues

2. Guidelines for deploying or redeploying service members with asthma to/from a theater of operations:
   a. In general, service members should be able to perform all required duties, wear protective gear, and have stable disease not requiring frequent treatments or oral corticosteroids
   b. Failure to meet these criteria should prompt consideration for redeployment
   c. See Appendix C – DoD Service-Specific Regulation Concerning Asthma
   d. Army; AR 40-501, Section 5–14. Medical fitness standards for deployment and certain geographical areas:
      “Asthma. See paragraph 3–27a for profile guidance and for MEB/PEB processing criteria. If it is determined that the Soldier can be returned to duty, the Soldier should not deploy if he/she cannot wear protective gear, has experienced recent emergency room visits, or requires repetitive use of oral corticosteroids.”
   e. Navy, Air Force, Coast Guard – No specific regulatory guidance.
APPENDICES

Appendix A
Guideline Development Process

The development update of the VA/DoD Clinical Practice Guideline for Management of Asthma in Primary Care followed the steps described in “Guideline for Guidelines,” an internal working document of the VA/DoD Evidence-Based Practice Working Group, that requires an ongoing review of the work in progress. The Asthma Working Group of the VA/DoD was charged to update the evidence-based recommendations.

The Offices of Quality and Performance and Patient Care Services, in collaboration with the network Clinical Managers, the Deputy Assistant Under Secretary for Health, and the Medical Command of the DoD identified clinical leaders to champion the guideline development process. During a preplanning conference call, the clinical leaders defined the scope of the guideline and identified a group of clinical experts from the VA and DoD that formed the Management of Asthma Working Group. Working Group members included representatives of the following specialties: Family Practice, Pulmonology, Nursing, Emergency Medicine, Internal Medicine, Pediatrics, Allergy Medicine, Respiratory therapy, Pharmacology, and Nutrition.

The Working Group defined a set of clinical questions within the area of the guideline. This ensured that the guideline development work focused on issues that practitioners considered important, and generated criteria for conducting a systematic review of the literature.

The Working Group participated in an initial face-to-face meeting to reach consensus about the guideline algorithms and recommendations, and to prepare a draft update document. The draft continued to be revised by the Working Group at-large through numerous conference calls and individual contributions to the document. Following the initial effort, an editorial panel of the Working Group convened to further edit the draft document. Recommendations for inclusion of specific procedures or services were derived through a rigorous methodological approach that included the following:

- Determining appropriate criteria, such as effectiveness, efficacy, population benefit, or patient satisfaction
- Reviewing the literature to determine the strength of the evidence in relation to these criteria
- Formulating the recommendations and grading the level of evidence supporting the recommendation
- Reviewing of the final draft by independent experts and incorporating their feedback into the final document.

This update of the Asthma Guideline is the product of many months of diligent effort and consensus building among knowledgeable individuals from the VA, DoD, and academia. An experienced moderator facilitated the multidisciplinary Working Group. The list of participants is included in Appendix H.
Formulation of Questions

Literature searches were conducted on all topics identified in the algorithm or recommendations of the original guidelines. After reviewing the results of the initial search for systematic reviews and meta-analyses, the Working Group decided to focus the search for individual randomized controlled trials (RCTs) on specific interventions. The Working Group developed researchable questions and associated key terms for these interventions. The questions specified (adapted from the Evidence-Based Medicine toolbox, Center for Evidence-Based Medicine, [http://www.cebm.net]):

- **Population** – Characteristics of the target patient population
- **Intervention** – Exposure, diagnostic, prognostic, or therapeutic interventions
- **Comparison** – Intervention, exposure, or control used for comparison
- **Outcome** – Outcomes of interest

These specifications served as the preliminary criteria for selecting studies. (For list of questions, see Appendix F.)

Selection of Evidence

The evidence selection was designed to identify the best available evidence to address each key question and ensure maximum coverage of studies at the top of the hierarchy of study types. Published, peer-reviewed RCTs, as well as meta-analyses and systematic reviews that included randomized controlled studies were considered to constitute the strongest level of evidence in support of guideline recommendations. This decision was based on the judgment that RCTs provide the clearest, scientifically sound basis for judging comparative efficacy. The Working Group made this decision recognizing the limitations of RCTs, particularly considerations of generalizability with respect to patient selection and treatment quality. When available, the search sought out critical appraisals already performed by others that described explicit criteria for deciding what evidence was selected and how it was determined to be valid. The sources that have already undergone rigorous critical appraisal include Cochrane Reviews, Best Evidence, Technology Assessment, and AHRQ systematic evidence reports.

In addition to Medline/PubMed, the following databases were searched: Database of Abstracts of Reviews of Effectiveness (DARE) and Cochrane Central Register of Controlled Trials. For Medline/PubMed searches, limits were set for language (English), and type of research (RCT, systematic reviews and meta-analysis).

As a result of the literature reviews, articles were identified for possible inclusion. These articles formed the basis for formulating the guideline recommendations. The following inclusion criteria were used for studies:

- English-language only of studies performed in United States, United Kingdom, Europe, Australia, Japan, New Zealand
- Full articles only
- Randomized controlled trials or prospective studies
- Published from 2004 to February 2008

Admissible evidence (study design and other criteria):

- Original research studies that provide sufficient detail regarding methods and results to enable use and adjustment of the data and results.
- Randomized controlled trials (RCTs), systematic reviews (including EPC and HTA reviews), and meta-analyses.
- Relevant outcomes must be able to be abstracted from data presented in the articles.
Sample sizes must be appropriate for the study question addressed in the paper. RCTs will be included if they are initiated with 30 or more participants.

**Preparation of Evidence Tables (Reports) and Evidence Rating**

The results of the search were organized and evidence reports as well as copies of the original studies were provided to the Working Group for further analysis. Each study was appraised by a group of research analysts for scientific merit, clinical relevance, and applicability to the populations served by the federal healthcare system. The body of evidence was rated for quality and level of evidence.

**Recommendation and Overall Quality Rating**

Evidence-based practice involves integrating clinical expertise with the best available clinical evidence derived from systematic research. The Working Group received an orientation and tutorial on the evidence USPSTF 2001 rating process, reviewed the evidence and independently formulated Quality of Evidence ratings (see Table A-1), a rating of Overall Quality (see Table A-2), and a Strength of Recommendation (see Table A-3).

### Table A-1: Quality of Evidence (QE)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>At least one properly done RCT</td>
</tr>
<tr>
<td>II-1</td>
<td>Well-designed controlled trial without randomization</td>
</tr>
<tr>
<td>II-2</td>
<td>Well-designed cohort or case-control analytic study, preferably from more than one source</td>
</tr>
<tr>
<td>II-3</td>
<td>Multiple time series evidence with/without intervention, dramatic results of uncontrolled experiment</td>
</tr>
<tr>
<td>III</td>
<td>Opinion of respected authorities, descriptive studies, case reports, and expert committees</td>
</tr>
</tbody>
</table>

### Table A-2: Overall Quality

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>High-grade evidence (I or II-1) directly linked to health outcome.</td>
</tr>
<tr>
<td>Fair</td>
<td>High-grade evidence (I or II-1) linked to intermediate outcome; or Moderate-grade evidence (II-2 or II-3) directly linked to health outcome.</td>
</tr>
<tr>
<td>Poor</td>
<td>Level III evidence or no linkage of evidence to health outcome.</td>
</tr>
</tbody>
</table>

### Table A-3: Net Effect of the Intervention

<table>
<thead>
<tr>
<th>Substantial</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>More than a small relative impact on a frequent condition with a substantial burden of suffering; or A large impact on an infrequent condition with a significant impact on the individual patient level.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Moderate</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A small relative impact on a frequent condition with a substantial burden of suffering; or A moderate impact on an infrequent condition with a significant impact on the individual patient level.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Small</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A negligible relative impact on a frequent condition with a substantial burden of suffering; or A small impact on an infrequent condition with a significant impact on the individual patient level.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zero or Negative</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative impact on patients; or No relative impact on either a frequent condition with a substantial burden of suffering, or an infrequent condition with a significant impact on the individual patient level.</td>
<td></td>
</tr>
</tbody>
</table>
Table A-4: Final Grade of Recommendation

<table>
<thead>
<tr>
<th>Quality of Evidence</th>
<th>Substantial</th>
<th>Moderate</th>
<th>Small</th>
<th>Zero or Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>A</td>
<td>B</td>
<td>C</td>
<td>D</td>
</tr>
<tr>
<td>Fair</td>
<td>B</td>
<td>B</td>
<td>C</td>
<td>D</td>
</tr>
<tr>
<td>Poor</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
</tbody>
</table>

**Strength of Recommendations Rating System**

A
A strong recommendation that the clinicians provide the intervention to eligible patients.
*Good evidence was found that the intervention improves important health outcomes and concludes that benefits substantially outweigh harm.*

B
A recommendation that clinicians provide (the service) to eligible patients.
*At least fair evidence was found that the intervention improves health outcomes and concludes that benefits outweigh harm.*

C
No recommendation for or against the routine provision of the intervention is made.
*At least fair evidence was found that the intervention can improve health outcomes, but concludes that the balance of benefits and harms is too close to justify a general recommendation.*

D
Recommendation is made against routinely providing the intervention to patients.
*At least fair evidence was found that the intervention is ineffective or that harms outweigh benefits.*

I
The conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention.
*Evidence that the intervention is effective is lacking, or poor quality, or conflicting, and the balance of benefits and harms cannot be determined.*

**Lack of Evidence – Consensus of Experts**

Where existing literature was ambiguous or conflicting, or where scientific data was lacking on an issue, recommendations were based on the clinical experience of the Working Group.

**Algorithm Format**

The goal in developing the guideline for management of Asthma was to incorporate the information into a format that would maximally facilitate clinical decision-making. The use of the algorithmic format was chosen because of the evidence that such a format improves data collection, diagnostic and therapeutic decision-making and changes patterns of resource use. However, few guidelines are published in such a format.

The algorithmic format allows the provider to follow a linear approach to critical information needed at the major decision points in the clinical process, and includes:

- An ordered sequence of steps of care
- Recommended observations
• Decisions to be considered
• Actions to be taken

A clinical algorithm diagrams a guideline into a step-by-step decision tree. Standardized symbols are used to display each step in the algorithm (Society for Medical Decision-Making Committee, 1992). Arrows connect the numbered boxes indicating the order in which the steps should be followed.

Rounded rectangles represent a clinical state or condition.

Hexagons represent a decision point in the guideline, formulated as a question that can be answered Yes or No. A horizontal arrow points to the next step if the answer is Yes. A vertical arrow continues to the next step for a negative answer.

Rectangles represent an action in the process of care.

Ovals represent a link to another section within the guideline.

A letter within a box of an algorithm refers the reader to the corresponding annotation. The annotations elaborate on the recommendations and statements that are found within each box of the algorithm. Included in the annotations are brief discussions that provide the underlying rationale and specific evidence tables. Annotations indicate whether each recommendation is based on scientific data or expert opinion. A complete bibliography is included in the guideline.

REFERENCES


Appendix B-1
Details of a Comprehensive History

1. The history should focus on the characterization of symptoms related to airway obstruction or airway hyperresponsiveness:
   - Cough
   - Wheezing
   - Shortness of breath
   - Chest tightness
   - Sputum production.

2. The pattern of symptoms should be characterized:
   - Onset
   - Duration
   - Frequency
   - Diurnal variation
   - Seasonality.

3. Precipitating and aggravating factors should be explored:
   - Viral infections
   - Exercise
   - Environmental indoor allergens:
     - Mold
     - House dust mites
     - Cockroaches
     - Pets
     - Rodents
   - Environmental outdoor allergens:
     - Pollens
     - Molds
   - Secondary tobacco exposure
   - Occupational chemicals, irritants, or allergens
   - Irritants:
     - Strong odors
     - Air pollution
     - Chemicals
     - Dusts/particulates
     - Vapors, gases, and aerosols
   - Emotions and/or stress
   - Drugs (i.e., aspirin, NSAIDs)
   - Sulfites in food
   - Cold air
   - Characteristics of the home and/or office:
     - Carpets
     - Wood burning stoves
     - Chemicals
   - Co-morbid conditions (sinusitis, rhinitis, GERD).
4. The development of disease and prior symptoms, diagnosis and treatment should be explored:
   - Age of onset and/or diagnosis
   - Early life airway injury such as BPD or pneumonia
   - Present or recent management
     - Frequency of SABA use and response
     - Requirement for oral steroids, frequency, and response.

5. Family history:
   - Asthma
   - Allergy
   - Rhinitis
   - Sinusitis
   - Nasal polyps
   - Eczema.

6. Social history:
   - Daycare, workplace, school characteristics
   - Social factors interfering with adherence such as substance abuse
   - Social support networks
   - Level of education
   - Employment.

7. History of prior exacerbations:
   - Prodrome
   - Rapidity of onset
   - Duration
   - Frequency
   - Severity (hospitalizations, ICU admissions, intubations)
   - Life-threatening exacerbations (intubation, ICU)
   - Number and severity of exacerbations in last 12 months
   - Usual pattern and management.

8. Impact of the disease on the patient and family:
   - Unscheduled care (Emergency Department, urgent care, hospitalization)
   - Missed school days
   - Limitations in activity including work, sports, and play
   - Nocturnal awakenings
   - Effect on growth, development, behavior
   - Economic impact.

9. The history should include an assessment of the patient’s and family’s perceptions of disease:
   - Patient’s, parent’s, spouse’s, partner’s knowledge of and belief in disease and treatment
   - Ability of patient and family/support system to cope with disease
   - Level of support
   - Economic resources
   - Sociocultural beliefs.
Appendix B-2
Details of a Comprehensive Physical Exam

Physical examination of the upper respiratory tract, neck, chest, heart and skin may support the diagnosis of asthma. However, the absence of supportive findings does not exclude the diagnosis of asthma.

(*) May suggest an alternative diagnosis or co-morbid condition.

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1. | Vital signs | Hypertension*  
|   |   | Increased Body Mass Index* |
| 2. | Eyes | Erythema of the conjunctive |
| 3. | Nasopharynx | Increased nasal secretions  
|   |   | Mucosal swelling  
|   |   | Nasal polyps |
| 4. | Oropharynx | Enlarged tonsils*  
|   |   | Cobblestoning of the posterior pharynx  
|   |   | Evidence of upper airway obstruction* |
| 5. | Ears | Evidence of otitis media in children |
| 6. | Neck | Adenopathy or mass*  
|   |   | Increased intravenous pyelogram (IVP)*  
|   |   | Stridor* |
| 7. | Chest | Wheezing at rest  
|   |   | Prolonged phase of forced exhalation  
|   |   | Hyperexpansion of the thorax  
|   |   | Use of accessory muscles  
|   |   | Chest deformity  
|   |   | Crackles*  
|   |   | Dullness to percussion* |
| 8. | Heart | Rate  
|   |   | Rhythm  
|   |   | Presence of murmurs  
|   |   | Presence of gallops |
| 9. | Abdomen | Organomegaly* |
| 10. | Skin | Presence of atopic dermatitis |
| 11. | Extremities | Edema*  
|   |   | Clubbing*  
|   |   | Pulses* |
### Physical Findings in Review of Systems

<table>
<thead>
<tr>
<th>Physical Findings</th>
<th>Asthma</th>
<th>Co-morbid Conditions</th>
<th>Alternative diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ears</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>Normal</td>
<td>Cobblestoning</td>
<td>Evidence of upper airway obstruction</td>
</tr>
<tr>
<td>Neck</td>
<td>Normal</td>
<td></td>
<td>Mass, stridor increased JVP</td>
</tr>
<tr>
<td>Chest</td>
<td>Wheeze, prolonged expiration</td>
<td>Crackles, dullness to percussion</td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>Normal</td>
<td></td>
<td>Murmurs or gallops</td>
</tr>
<tr>
<td>Abdomen</td>
<td></td>
<td></td>
<td>Organomegaly mass or bruit</td>
</tr>
<tr>
<td>Skin</td>
<td>Atopic dermatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extremities</td>
<td></td>
<td></td>
<td>Edema, clubbing</td>
</tr>
</tbody>
</table>
Appendix C
DoD Service-Specific Regulation Concerning Asthma

PPG-TAB A: AMPLIFICATION OF THE MINIMAL STANDARDS OF FITNESS FOR DEPLOYMENT TO THE CENTCOM AOR; TO ACCOMPANY MOD 7 TO USCINCENT INDIVIDUAL PROTECTION AND INDIVIDUAL/UNIT DEPLOYMENT POLICY

1. General. This tab accompanies MOD 7 Para 15.g., and provides amplification of the minimal standards of fitness for deployment to the CENTCOM AOR, including a list of medical conditions that should usually be sufficient basis to deny medical clearance for or to disapprove deployment of a civilian employee, volunteer, or contractor’s employee. The list of conditions is not comprehensive; there are many more conditions that could be cause to deny medical clearance for deployment. Possession of one or more of the conditions listed in this chapter does not automatically mean that the individual may not deploy. Rather, it imposes the requirement to obtain a knowledgeable physician’s opinion as to the deployable status of the individual. “Medical conditions” as used here also includes those health conditions usually referred to as dental, oral, psychological and/or emotional conditions. (Uniformed service members will be evaluated for fitness according to service regulations and policies, in addition to the guidance in the parent PPG Modification (MOD). The services’ parent regulations are as follows.

- Army: AR 40-501, Standards of Medical Fitness, February 2004;
- Air Force: AFI 48-123, 22 MAY 2001, Medical Examinations And Standards;
- Navy: NAVMED P-117, The Manual of the Medical Department;
- Marine Corps: NAVMED P-117, article 15-5;
- Coast Guard: Medical Manual, COMDTINST M6000.1B)

Deployment Issues

Documented medical conditions usually precluding medical clearance. While a list of all possible diagnoses and their severity that should not be approved would be too expansive to list here, the following conditions, in general, should usually not be approved. The medical evaluator must carefully consider whether there is any question whether the climate, the altitude, the nature of available food and housing, the availability of medical, behavioral health, dental, and surgical services, or whether other environmental and operational factors may be hazardous to the deploying person’s health because of a known physical condition.

Usually, medical clearance to deploy for persons with any of the following documented medical conditions should be granted only after consultation with theater medical authority. The theater medical authority can determine if adequate treatment facilities and specialist support is available at the duty station.

A. Conditions resulting in inability to wear personal protective equipment, including protective mask, ballistic helmet, body armor, and chemical/biological protective garments, regardless of the nature of the condition that causes the inability.

Service-specific regulations regarding medical standards of fitness for asthma or other deployment issues are available on the asthma CPG homepage under resource material at:
https://www.qmo.amedd.army.mil/asthma/Asthfr.htm
### Table D1: Drugs Used in Treatment of Asthma

<table>
<thead>
<tr>
<th>Drug Class§</th>
<th>Uses</th>
<th>Cautions and Monitoring‡</th>
</tr>
</thead>
</table>
| **Inhaled Corticosteroids (ICS)** | Considered first line agents for maintenance treatment of asthma | • Local adverse effects include oral candidiasis, dysphonia, and reflex cough/bronchospasm  
  ○ Use of a spacer or holding chamber (for non-breath activated inhalers) and rinsing mouth after inhalation can reduce the incidence of oral candidiasis  
  ○ Use of a spacer or holding chamber (for non-breath activated inhalers) is used as a measure to prevent dysphonia. To treat dysphonia, temporarily reducing the dose of ICS, or rest for vocal stress has been used  
  ○ Use of a spacer or holding chamber (for non-breath activated inhalers), slower inspiration, or pretreatment with a SABA may be tried for reflex cough/bronchospasm |  
  • Higher doses have been associated with adrenal suppression, glaucoma, cataracts, skin thinning, and bruising  
  • Smoking may decrease the effectiveness of ICS; regardless, patients with asthma should be encouraged to stop smoking |
| Beclomethasone |  |  |
| Budesonide |  |  |
| Ciclesonide |  |  |
| Flunisolide* |  |  |
| Fluticasone |  |  |
| Mometasone |  |  |
| Triamcinolone* |  |  |

(See Table D2 for Dosage)

*CFC MDIs are being phased out and will no longer be available in the near future

| **Short-acting Beta-agonists (SABA)** |  |  |
| Albuterol |  |  |
| Levalbuterol |  |  |
| Pirbuterol |  |  |

**Long-acting Beta-agonists (LABA)**

| Formoterol | Long-acting agents are used as the preferred add-on agents to inhaled corticosteroid |  |
| Salmeterol |  |  |

Note: Formoterol and arformoterol are available in a nebulizer solution approved for maintenance therapy for COPD; at present, they are not approved for use in asthma.

Short-acting agents are used for acute relief of bronchospasm and prevention of exercise-induced bronchospasm

May cause palpitations, chest pain, rapid heart rate, increased blood pressure, tremor, nervousness

Decreases in potassium levels or hyperglycemia have occurred

Frequent use of SABA (>2 days/week) may indicate uncontrolled asthma and the need to intensify maintenance drug therapy

2 to 6 puffs of SABA may be used in accordance with the asthma action plan. Patients who do not experience relief after 3 doses in a one hour period OR who need a dose more frequently than every 4 hours should seek medical care

Long-acting beta-agonists are CONTRAINDICATED AS MONOTHERAPY for maintenance treatment of asthma. If a long-acting beta-agonist is used, an inhaled steroid must also be prescribed and used by the patient on a daily basis.

Long-acting beta-2 agonist are not to be used for the acute treatment of bronchospasm

Formoterol: Capsules are for oral inhalation only (capsules should not be swallowed). Administer using supplied inhalation device (Aerolizer) only
<table>
<thead>
<tr>
<th>Drug Class§</th>
<th>Uses</th>
<th>Cautions and Monitoring‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Combination ICS/LABA</strong>&lt;br&gt; Budesonide/formoterol&lt;br&gt; Fluticasone/salmeterol</td>
<td>Monotherapy may be considered as an alternative (not preferred) to ICS for mild persistent asthma</td>
<td>• See comments for inhaled corticosteroids and beta-agonists</td>
</tr>
<tr>
<td><strong>Leukotriene Modifiers</strong>&lt;br&gt; Montelukast&lt;br&gt; Zafirlukast&lt;br&gt; Zileuton extended-release</td>
<td>Montelukast may be used for prevention of exercise-induced bronchospasm (zafirlukast and zileuton are not FDA approved)&lt;br&gt; May be used as an alternative (not preferred) to a LABA for add on therapy to ICS</td>
<td>• Rare cases of Churg-Strauss have occurred with montelukast and zafirlukast; however, the association is unclear&lt;br&gt; • Zafirlukast should be taken at least 1 hour before or 2 hours after meals due to decreased bioavailability when taken with meals.&lt;br&gt; • Zafirlukast and zileuton can inhibit the metabolism of warfarin. INRs should be monitored during co-administration&lt;br&gt; • Zileuton can inhibit the metabolism of theophylline; therefore, monitoring of theophylline levels is recommended&lt;br&gt; • Zileuton is contraindicated in patients with active liver disease or persistent hepatic function enzyme elevation (&gt; 3x ULN)&lt;br&gt; • Asses hepatic function enzymes prior to initiation of zileuton, monthly for the first 3 months, every 2-3 months for the remainder of the first year, and periodically thereafter&lt;br&gt; • Postmarketing surveillance of zafirlukast has reported cases of reversible hepatitis and, rarely, irreversible hepatic failure resulting in death and liver transplantation. Consider periodic hepatic enzymes (ALT) monitoring&lt;br&gt; • Patients and providers should be aware of the potential for neuropsychiatric events (e.g., suicidal ideation, depression, agitation, aggression, anxiousness, irritability, restlessness, dream abnormalities, hallucinations, and insomnia) with these medications. Patients should be told to contact their healthcare provider if these events occur. Consider discontinuing these medications if patients develop neuropsychiatric symptoms</td>
</tr>
<tr>
<td><strong>Mast cell stabilizer</strong>&lt;br&gt; Cromolyn Nebulizer solution</td>
<td>Monotherapy may be considered as an alternative (not preferred) to ICS for mild persistent asthma. May be used for prevention of exercise-induced bronchospasm; however, generally not as effective as SABA</td>
<td>• Generally well tolerated although may cause coughing and wheezing&lt;br&gt; • Improvement can occur in 1-2 weeks; however, maximal benefit may not be seen for 4-6 weeks&lt;br&gt; • Needs to be dosed four times daily (may be reduced to three times daily once symptoms have stabilized)&lt;br&gt; • Cromolyn is no longer available as a MDI; therefore, limiting the usefulness of this agent</td>
</tr>
</tbody>
</table>

---

*Note: Cromolyn is no longer available as a MDI*
<table>
<thead>
<tr>
<th>Drug Class§</th>
<th>Uses</th>
<th>Cautions and Monitoring‡</th>
</tr>
</thead>
</table>
| **Methylxanthines** | May be considered as an alternative for maintenance of mild persistent asthma when other preferred options have not been successful | – Monitor theophylline levels. The usual therapeutic range is 5-15mcg/mL but some toxicity may be noted at the upper end of this range.  
– Adverse reactions include stomach upset, nausea, insomnia, tremors, palpitations, and irritability which may be lessened by initiating the dose low and increasing gradually.  
– Serious adverse events including cardiac arrhythmias and seizures can occur at higher concentrations.  
– Instruct patient not to take extra doses of theophylline for acute asthma attack.  
– Sustained-release products should not be crushed or chewed.  
– Scored tablets may be split without affecting absorption characteristics.  
– Several drugs or other factors can influence theophylline concentration (list not intended to be inclusive of all interactions)  
  o Drugs or factors decreasing theophylline clearance: cimetidine, ciprofloxacin, clarithromycin, disulfiram, enoxacin, erythromycin, mexiletine, pentoxifylline, propranolol, ticlopidine, troleandomycin, zileuton, allopurinol (≥ 600 mg/day), fluvoxamine, interferon, propafenone, tacrine, verapamil, congestive heart failure, cor pulmonale, elderly (> 60 yrs.), hepatic insufficiency (cirrhosis, acute hepatitis, cholestasis), fever (> 24 hrs.).  
  o Drugs or factors increasing theophylline clearance: charcoal-broiled food; low carbohydrate, high protein diet; smoking (tobacco or marijuana); phenobarbital; phenytoin; rifampin, carbamazepine; isoniazid; moricizine. |
| **Theophylline** | May be considered as an adjunctive therapy with ICS for maintenance of moderate or persistent asthma. |  |
| **Aminophylline** | |  |
| **Immunomodulators anti-IgE** | Used as adjunctive therapy for severe persistent asthma (Step 5 or 6) who have a positive skin test or in vitro reactivity to a perennial aeroallergen | – Not to be used in patients who have had a prior allergic reaction to omalizumab.  
– Patient should have pre-treatment serum IgE 30-700IU/ml and positive skin test or in vitro reactivity to common aeroallergen (e.g., dust mites, pet dander, cockroach).  
– Give patient the omalizumab Medication Guide and instruct them to read it before each dose of omalizumab.  
– Educate patient on signs and symptoms of severe hypersensitivity and anaphylaxis.  
– Patients should carry and know how to initiate emergency self-treatment for anaphylaxis.  
– Observe patients for an appropriate amount of time after each injection. In clinical trials, patients were observed for 2 hours after the 1st dose and 1 hour for subsequent doses.  
– Healthcare professionals should be prepared to manage life-threatening anaphylaxis.  
– If a severe hypersensitivity reaction occurs, omalizumab should be discontinued. |
| **Omalizumab** | |  |

§ Refer to product package insert or other established resources for dosing recommendations and age specific use.

‡ Table is not intended to be inclusive of all cautions and monitoring, but rather to highlight some of the major points.
Table D2: Inhaled Steroids \(^{a,b}\)

<table>
<thead>
<tr>
<th>Inhaled steroid (dose/puff)</th>
<th>Dosage forms</th>
<th>Usual dosing interval</th>
<th>Low dose mcg/day (^{c})</th>
<th>Medium dose mcg/day (^{c})</th>
<th>High dose mcg/day (^{c})</th>
<th>PC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclomethasone</td>
<td>MDI (HFA)</td>
<td>12h</td>
<td>80-160</td>
<td>&gt;12 yrs 240-480</td>
<td>&gt;12 yrs &gt;480</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>40mcg</td>
<td></td>
<td>80</td>
<td>80-160</td>
<td>5-11 yrs &gt;160-320</td>
<td></td>
</tr>
<tr>
<td></td>
<td>80mcg</td>
<td></td>
<td>200-320</td>
<td>5-11 yrs &gt;240-480</td>
<td>5-11 yrs &gt;480</td>
<td></td>
</tr>
<tr>
<td>Budesonide</td>
<td>DPI</td>
<td>12h</td>
<td>&gt;12 yrs 200-600</td>
<td>&gt;12 yrs &gt;600-1200</td>
<td>&gt;12 yrs &gt;1200</td>
<td>B</td>
</tr>
<tr>
<td>200mcg (delivered dose 160mcg)</td>
<td></td>
<td></td>
<td>180-400</td>
<td>5-11 yrs &gt;400-800</td>
<td>5-11 yrs &gt;800</td>
<td></td>
</tr>
<tr>
<td>90mcg (delivered dose 80mcg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180mcg (delivered dose 160mcg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budesonide suspension</td>
<td>Nebulizer</td>
<td>24h or 12h</td>
<td>5-11 yrs 0.5</td>
<td>5-11 yrs 1.0</td>
<td>5-11 yrs 2.0</td>
<td></td>
</tr>
<tr>
<td>0.25, 0.5, 1mg/2mL ampule</td>
<td></td>
<td></td>
<td>0-4 yrs 0.25-0.5</td>
<td>0-4 yrs &gt;0.5-1.0</td>
<td>0-4 yrs &gt;1.0</td>
<td></td>
</tr>
<tr>
<td>Must use with PARI nebulizer or other high-efficiency nebulizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciclesonide</td>
<td>MDI (HFA)</td>
<td>24h</td>
<td>80-160</td>
<td>&gt;12 yrs &gt;160-320</td>
<td>&gt;12 yrs &gt;320-1280</td>
<td>C</td>
</tr>
<tr>
<td>80mcg</td>
<td></td>
<td></td>
<td>80-160</td>
<td>5-11 yrs 80-160</td>
<td>5-11 yrs &gt;160-320</td>
<td></td>
</tr>
<tr>
<td>160mcg</td>
<td></td>
<td></td>
<td>200-320</td>
<td>&gt;12 yrs &gt;320-1280</td>
<td>&gt;12 yrs &gt;1200</td>
<td></td>
</tr>
<tr>
<td>Flunisolide (^e)</td>
<td>MDI (CFC)</td>
<td>12h</td>
<td>&gt;12 yrs 500-1000</td>
<td>&gt;12 yrs &gt;1000-2000</td>
<td>&gt;12 yrs &gt;2000</td>
<td>C</td>
</tr>
<tr>
<td>250mcg</td>
<td></td>
<td></td>
<td>500-750</td>
<td>5-11 yrs 500-750</td>
<td>5-11 yrs &gt;1250</td>
<td></td>
</tr>
<tr>
<td>Fluticasone (MDI/DPI)</td>
<td>MDI (HFA)</td>
<td>12h</td>
<td>&gt;12 yrs 88-264</td>
<td>&gt;12 yrs &gt;264-440</td>
<td>&gt;12 yrs &gt;440</td>
<td>C</td>
</tr>
<tr>
<td>44mcg /50mcg</td>
<td>DPI</td>
<td></td>
<td>88-176</td>
<td>0-11 yrs 88-176</td>
<td>0-11 yrs &gt;352</td>
<td></td>
</tr>
<tr>
<td>110mcg /100mcg</td>
<td></td>
<td></td>
<td></td>
<td>12 yrs &gt;264-440</td>
<td></td>
<td></td>
</tr>
<tr>
<td>220mcg/250mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mometasone</td>
<td>DPI</td>
<td>24h or 12h</td>
<td>&gt;12 yrs 200</td>
<td>&gt;12 yrs 400</td>
<td>&gt;12 yrs &gt;400</td>
<td>C</td>
</tr>
<tr>
<td>220mcg (delivered dose 200mcg)</td>
<td></td>
<td></td>
<td>200</td>
<td>200</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>110mcg (delivered dose 110mcg)(^d)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triamcinolone (^e)</td>
<td>MDI with built-in spacer (CFC)</td>
<td>6-8h or 12h</td>
<td>&gt;12 yrs 300-750</td>
<td>&gt;12 yrs &gt;750-1500</td>
<td>&gt;12 yrs &gt;1500</td>
<td>C</td>
</tr>
<tr>
<td>100mcg (delivered dose 75mcg)</td>
<td></td>
<td></td>
<td>300-600</td>
<td>5-11 yrs 300-600</td>
<td>5-11 yrs &gt;600-900</td>
<td></td>
</tr>
</tbody>
</table>

PC = Pregnancy Category

\(^a\) Comparative daily doses adapted from the Global Initiative for Asthma 2007 and NHLBI Guidelines for the Diagnosis and Management of Asthma (EPR-3).

\(^b\) For dosing recommendations, refer to the manufacturer’s product package insert.

\(^c\) Doses for budesonide suspension shown in mg.

\(^d\) Dose of mometasone for children is 110mcg once daily.

\(^e\) CFC MDIs are being phased out and will no longer be available in the near future.
Appendix E
Environmental Control

House Dust Mite Allergen
The EPR-3 Panel recommends the following mite-control measures. Effective allergen avoidance requires a multifaceted approach:

- Recommended actions to control mites include:
  - Encase the mattress in an allergen-impermeable cover.
  - Encase the pillow in an allergen-impermeable cover or wash it weekly.
  - Wash the sheets and blankets on the patient’s bed weekly in hot water.
  - A temperature of >130 °F is necessary for killing house dust mites. Prolonged exposure to dry heat or freezing temperatures can also kill mites but does not remove allergen. If high-temperature water is not available, a considerable reduction in live mites and mite allergens can still be achieved with cooler water using detergent and bleach.

- Actions to consider to control mites include:
  - Reduce indoor humidity to 60 percent or below, ideally between 30 and 50 percent.
  - Remove carpets from the bedroom.
  - Avoid sleeping or lying on upholstered furniture.
  - Remove from the home carpets that are laid on concrete.
  - In children’s beds, minimize the number of stuffed toys, and wash them weekly.

Animal Allergens
The EPR-3 Panel recommends the following actions to control animal antigens:

- If the patient is sensitive to an animal, the treatment of choice is removal of the exposure from the home.
- If removal of the animal is not acceptable:
  - Keep the pet out of the patient’s bedroom.
  - Keep the patient’s bedroom door closed.
  - Remove upholstered furniture and carpets from the home, or isolate the pet from these items to the extent possible.
  - Mouse allergen exposure can be reduced by a combination of blocking access, low-toxicity pesticides, traps, and vacuuming and cleaning.

Cockroach Allergen
The EPR-3 Panel recommends that cockroach control measures be instituted if the patient is sensitive to cockroaches and infestation is present in the home:

- Patients should not leave food or garbage exposed.
Poison baits, boric acid, and traps are preferred to other chemical agents, because the latter can be irritating when inhaled by persons who have asthma.

- If volatile chemical agents are used, the home should be well-ventilated, and the person who has asthma should not return to the home until the odor has dissipated.
- Care should be taken so that young children do not have access to cockroach baits and poisons.

**Indoor Fungi (Molds)**

The EPR-3 Panel recommends consideration of measures to control indoor mold:

- Measures to control dampness or fungal growth in the home may be beneficial.

**Outdoor Allergens (Tree, Grass, and Weed Pollen; Seasonal Mold Spores)**

The EPR-3 Panel recommends that measures be taken to reduce exposure to outdoor allergens if the patient is sensitive to outdoor allergens and has symptoms that correlate with exposure:

- Patients who are sensitive to seasonal outdoor allergens should consider staying indoors, if possible, during peak pollen times—particularly midday and afternoon.
- Patients can reduce exposure during peak pollen season by staying indoors with windows closed in an air-conditioned environment, particularly during the midday and afternoon when pollen and some spore counts are highest.
- Conducting outdoor activities shortly after sunrise will result in less exposure to pollen.
- These actions may not be realistic for some patients, especially children.
Appendix F
Questions for Literature Search

KEY:  A & P – adults and pediatrics; A – adults only; P – pediatrics only

### DIAGNOSIS

1. In patients with asthma, does **consultation or referral** to a subspecialist (pulmonologist/allergist) at the time of diagnosis, when admitted to the emergency department with exacerbation or early in treatment vs. **no consultation/referral** improve symptom control, patient satisfaction and increased patient knowledge? [A & P]

2. In patients with asthma, does **routine allergy testing** (e.g., skin prick testing, aeroallergens, immunotherapy) vs. **no testing** or testing **HIGH RISK** (severe uncontrolled asthma, family history of allergies) improve outcomes in terms of QOL through allergen avoidance or immunotherapy, patient knowledge and adherence? [A & P]

3. In adults with exercise-related symptoms of asthma only and non-diagnostic spirometry, is **formal exercise testing** with pre- and post-PFTs compared to informal exercise testing (methacholine challenge test, bronchoprovocation test) better for establishing the diagnosis of EIB or exercise-induced asthma? [A]

4. Does the routine use of office-based **spirometry** compared to history and physical for both asthma diagnosis and monitoring improve outcomes? [P]

5. In adults with exercise-related asthma, is **peak flow monitoring** to assess variability of airway obstruction compared to spirometry a comparable way for diagnosing EIB or exercise-induced asthma? [A]

6. Do **biomarkers of inflammation** (e.g., total and differential cell count and mediator assays) in sputum, blood, urine, and exhaled air aid in the diagnosis and assessment of asthma in the primary care setting? [A & P]

7. Is a thorough history and physical, followed by a therapeutic challenge sufficient to identify **co-morbid GERD** compared to a diagnostic test in children with asthma? [P]

8. In **pregnant women** who were not previously diagnosed with asthma, but who develop symptoms consistent with asthma, does assessing PFT compared to a presumptive diagnosis (no PFT) improve patient outcome with no harm? [A]

### PROGNOSIS

9. In adults with asthma who present with an **acute exacerbation**, what clinical predictors are best at predicting successful outpatient management? [A]

10. In patients with difficult-to-control asthma (adults & children), how frequently does the **management of co-existing sinusitis** or GERD compared to no management improve the control of asthma? [A & P]

11. In patients with asthma who are obese, does **weight loss and exercise compared** to no weight loss/exercise improve the control of asthma symptoms? [A & P]

### MEDICATIONS

12. In children with **under-controlled asthma** on low-dose ICS, what is the best **step-up treatment / add-on therapy** to gain asthma control (search in age groups 1-5, 5-12, 12-17)? [P]

13. In active duty personnel with asthma in operational environments, is **one controller** compared to other controllers better apt to control asthma symptoms? [A]

14. In patients with **mild** persistent asthma and no evidence of allergies as triggers (adults & children), does **ICS** compared to **Montelukast or Tilade, Intal, or other pulmonary anti-inflammatories** lead to better outcome and minimize harm? [9]
15. In patients with moderate or severe uncontrolled asthma who are taking ICS (adults & children), does increasing the dose of ICS compared to adjunctive therapy (LABA, Singulair, Leukotriene) lead to better control of symptoms with no harm? [A]

16. In adult patients with asthma, does tiotropium (Spiriva) compared to long-acting inhaled bronchodilators lead to comparable improvement in PFT, peak flow measures, and safety? [A]

17. In patients with exercise-induced asthma (bronchospasm) (adults & children), does taking a preventive medication before exercise compared to continuous daily medication improve symptom control? [A&P]

18. In patients over age 65 with asthma, does the use of long-acting beta adrenergic drugs compared to not using the drug reduce adverse cardiovascular events (e.g., sudden death, acute MI, arrhythmias)? [A >65]

19. In patients over age 65 who require long-term systemic corticosteroids, does a reduced dose of corticosteroids compared to the regular dose reduce the risk for adverse complications (osteoporosis, DM, Vascular necrosis of the femoral head, cataracts)? [A >65]

20. In patients with asthma, how effective is aerosol delivery of asthma medications by pMDI + VHC compared to nebulization for quick relief aerosols? [A&P]

21. Do studies show there is an effective pharmacotherapy (PRN SABA, ICS Leukotrine) for the <5-year-old child with recurrent wheeze, but no asthma diagnosis? [P]

22. Do studies show an optimal systemic steroid preparation, dosage, and duration of treatment for managing asthma in pediatrics? [P]

23. Do studies show that routine initiating LTC ICS in children with persistent asthma at discharge from the emergency department is more effective? [P]

**MANAGEMENT**

24. Does the use of a home peak flow meter-based Asthma Action Plan compared to a symptom-based Asthma Action Plan result in better outcomes in patients with asthma? [A&P]

- Do patient questionnaires improve reporting of asthma symptoms and therefore improve asthma severity assessment and treatment?
- Do comprehensive approaches to environmental control and avoidance of allergens improve asthma outcomes?
- What evidence is there for poorer asthma outcomes related to specific inhaled irritants/pollutants such as tobacco smoke, particulate air pollution, NO2, SO2, diesel exhaust, volatile organic compounds, formaldehyde, and fumes?

25. Which strategy in the outpatient setting leads to better outcomes in terms of decreased frequency of exacerbations, emergency department visits, or hospitalization in patients with asthma? [A&P]

- Implementation of comprehensive asthma care (pt. education, action plans and asthma educators) compared to usual care
- Implementation of group visits compared to individual patient appointments
- Written action plans compared to not using a written action plan in usual care
- Providing patient education in modality other than written (e.g., media, computer-based, internet).
# Appendix G
## Acronym List

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABG</td>
<td>Arterial Blood Gas</td>
</tr>
<tr>
<td>ABPA</td>
<td>Allergic Bronchopulmonary Aspergillosis</td>
</tr>
<tr>
<td>ACT</td>
<td>Asthma Control Test</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine Aminotransferase</td>
</tr>
<tr>
<td>ATS</td>
<td>American Thoracic Society</td>
</tr>
<tr>
<td>BNP</td>
<td>Brain Natriuretic Peptide</td>
</tr>
<tr>
<td>BPD</td>
<td>Bronchopulmonary Dysplasia</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary Artery Disease</td>
</tr>
<tr>
<td>CAM</td>
<td>Complementary and Alternative Medicine</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>CPAP</td>
<td>Continuous Positive Airway Pressure</td>
</tr>
<tr>
<td>CT</td>
<td>Computed Tomography</td>
</tr>
<tr>
<td>CXR</td>
<td>Chest X-Ray</td>
</tr>
<tr>
<td>DLCO</td>
<td>Carbon Monoxide Diffusing Capacity</td>
</tr>
<tr>
<td>DPI</td>
<td>Dry Powder Inhaler</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency Department</td>
</tr>
<tr>
<td>EIB</td>
<td>Exercise-Induced Bronchospasm</td>
</tr>
<tr>
<td>ETS</td>
<td>Environmental Tobacco Smoke</td>
</tr>
<tr>
<td>FEV1</td>
<td>Forced Expiratory Volume in 1 Second</td>
</tr>
<tr>
<td>FVC</td>
<td>Forced Vital Capacity</td>
</tr>
<tr>
<td>GERD</td>
<td>Gastroesophageal Reflux Disease</td>
</tr>
<tr>
<td>ICS</td>
<td>Inhaled Corticoid Steroids</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>LABA</td>
<td>Long-Acting Beta Agonists</td>
</tr>
<tr>
<td>LTRA</td>
<td>Leukotriene Receptor Antagonist</td>
</tr>
<tr>
<td>MDI</td>
<td>Metered Dose Inhalers</td>
</tr>
<tr>
<td>NAEPP-3</td>
<td>National Asthma Education and Prevention Program Expert Panel Report 3</td>
</tr>
<tr>
<td>OSA</td>
<td>Obstructive Sleep Apnea</td>
</tr>
<tr>
<td>PEF</td>
<td>Peak Expiratory Flow</td>
</tr>
<tr>
<td>PFT</td>
<td>Pulmonary Function Test</td>
</tr>
<tr>
<td>Acronym</td>
<td>Definition</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>PND</td>
<td>Post Nasal Drip</td>
</tr>
<tr>
<td>PPI</td>
<td>Proton Pump Inhibitor</td>
</tr>
<tr>
<td>SABA</td>
<td>Short-Acting Beta Agonists</td>
</tr>
<tr>
<td>SOB</td>
<td>Shortness of Breath</td>
</tr>
<tr>
<td>VCD</td>
<td>Vocal Cord Dysfunction</td>
</tr>
<tr>
<td>VHC</td>
<td>Valved Holding Chamber</td>
</tr>
</tbody>
</table>
Appendix H
Participant List

Arthur Blain, MD, MBA
Naval Hospital Camp Pendleton
Department of Family Medicine
Camp Pendleton, CA 92055
Phone: 760-725-1176
Email: Arthur.blain@med.navy.mil

Deborah Bray, BSN, MSN
Pulmonary CNS, Asthma Nurse Educator
Brooke Army Medical Center
3851 Roger Brooke Drive
Fort Sam Houston, TX 78234-6200
Phone: 210-916-0945
Email: Deborah.bray@amedd.army.mil

Carla Cassidy, RN, MSN, NP
Director, Evidence-Based Practice Program
Department of Veterans Affairs
810 Vermont Avenue
Washington, DC 20420
Phone: 202-266-4502
Email: Carla.cassidy@va.gov

Christine Colluraburke, MD
LCDR, MD, USN
Pediatric Allergy
Naval Medical Center Portsmouth
620 John Paul Jones Circle
Portsmouth, VA 23708
Email: Christina.Colluraburke@med.navy.mil

Darrel W. Dodson, MD, DPM, MPH
LTC, USA
Chief, Department of Medicine
Carl R. Darnall Army Medical Center
36000 Darnall Loop
Fort Hood, TX 76544
Phone: (254) 288-8090
Email: darrel.w.dodson@us.army.mil

Donald Curran, MD
Veterans Administration
555 Willard Ave
Newington, CT 06111
Phone: 860-694-6393
Email: Donald.curran@va.gov
Trina Davenport
HM2
Respiratory Therapist
National Naval Medical Center
8901 Wisconsin Ave
Bethesda, MD 20889
Phone: 301-319-4857
Email: Trina.davenport@med.navy.mil

Ernest Degenhardt, RN, MSN, ANP-FNP
COL, USA
Chief, Evidence-Based Practice
Quality Management Division
U.S. Army Medical Command
2050 Worth Road, Suite 26
Fort Sam Houston TX 78234
Phone: 210-221-6527 or DSN 471-6527
Email: ernest.degenhardt@amedd.army.mil

Carlos Daughaday, MD
Chief, Pulmonary
915 North Grand Blvd
St. Louis VA Hospital
St. Louis, MO 63106
Phone: 314-652-4100, Ext. 4475
Email: Carlos.Daughaday@med.va.gov

Daniel P. Hsu, M.D., FS, FAAP
LTC, MC, USA
Flight Commander/Medical Director, Pediatric Subspecialty Clinic
Assistant Chief, Division of Pediatric Pulmonology and Tri-Services Cystic Fibrosis Center
San Antonio Military Pediatric Center

Rosalie Fishman, RN, MSN, CPHQ
President
Healthcare Quality Informatics, Inc.
2275 Shady Grove Rd, Suite 500
Rockville, MD 20850
Phone: 301-296-4542
Email Rosalie@hqinc.com

Deborah Khachikian, PharmD
Clinical Pharmacy Specialist
Department of Veterans Affairs
Pharmacy Benefits Management Services
1st Ave-1 Blk N of Cermak Rd Building 37, Room 138
Hines, IL 60141
Phone: 708-786-7874
Email: Debbie.khachikian@va.gov
Angela Klar, RN, MSN, ANP-CS  
Chronic Disease CPG Coordinator  
U.S. Army Medical Command  
2050 Worth Road, Building 2792, Suite 26  
Fort Sam Houston, TX 78234  
Phone: 210-221-8740  
Email: Angela.Klar@amedd.army.mil

Rees Lee, MD  
CDR, MC, USN  
Staff Pediatric Pulmonologist, NMCP  
Assistant Professor of Pediatrics, USUHS  
Naval Center Portsmouth  
Dept. of Pediatrics  
620 John Paul Jones Circle  
Portsmouth, VA 23708  
Phone: 757-953-0220 or 953-2955  
Email: Rees.Lee@med.navy.mil

Julie Liss, PharmD  
Clinical Pharmacy Specialist  
Department of Defense (PEC)  
2450 Stanley Road, Suite 208  
Fort Sam Houston, TX 78234  
Phone: 210-295-2787  
Email: Julie.Liss@amedd.army.mil

Michael Littner, MD  
Chief, Pulmonary Function laboratory  
VA Greater Los Angeles Healthcare System  
16111 Plummer Street  
Sepulveda, CA 91343  
Phone: 818-895-9388  
Email: mlittner@ucla.edu

John Manning, RN, MSN, BSN  
CDR, NC, USN  
Pediatric Nurse Practitioner, AE-C  
Naval Hospital  
100 Brewster Blvd  
Camp Lejeune, NC 28547  
Phone: 910-450-3192  
Email: John.Manning@med.navy.mil

Joanne Marko, MS, SLP  
Independent Consultant  
17816 Whimsey Court  
Olney, MD 20832  
Phone: 301-774-5812  
Email: nitojo@comcast.net
Michael Morris, MD  
COL, MC, USA  
Staff, Pulmonary Disease/Critical Care Service  
Brooke Army Medical Center  
3851 Roger Brooke Drive  
Fort Sam Houston, TX 78234  
Phone: 210-916-3027  
Email: micheal.morris@amedd.army.mil

Jack Markusfeld, MD  
COL, MC, USA  
Deputy Commander Clinical Services  
TF 1125th MED, Internal medicine  
TF 115th MED  
Camp Cropper  
APO AE 09342  
Email: Jack.markusfeld@us.army.mil

Kristina Orio, MD  
Maj, MC, USAF  
Emergency Department  
Wilford Hall Medical Center  
2200 Bergquist Dr.  
Lackland AFB, TX 78236  
Email: Kristina.Orio@LACKLAND.af.mil

Lawrence Potter, MD  
LCDR, MC, USN  
Pediatrician  
NH Jacksonville, FL  
2080 Child St  
Jacksonville, FL 32214  
Phone : 904-542-7302  
Email: Lawrence.potter@med.navy.mil

James Quinn, MD  
COL, MC, USAF  
Allergy Immunology Program Director  
Wilford Hall Medical Center  
2200 Bergquist Dr.  
Lackland AFB, TX 78236  
Phone: 210-292-7521  
Email: James.Quinn@lackland.af.mil

Nancy Radebaugh, BPharm  
Carl R Darnall Army Medical Center  
36000 Darnall Loop  
Ft. Hood, TX 76544  
Phone: 254-286-7069  
Email: Nancy.radenbaugh@amedd.army.mil
Patricia A. Rikli, Ph.D, MSN, BSN
Project Manager/Nurse Planner
VA Employee Education System
St. Louis EERC, VA Medical Center Bldg.2
1 Jefferson Barracks Drive
St. Louis, MO 63125-4199
Phone: 314-894-5742
Email: patricia.rikli@va.gov

Kristie Robson, MD
LCDR, MC, USN
Head of Naval Hospital Okinawa Emergency Dept
United States Navy
PSC 482 Box 2552
FPO, AP 96362
Phone: 405-808-8700
Email: Kristie.robson@med.navy.mil

Christopher Roach, RCP, CRT
HM2
Respiratory Therapist
NNMC Bethesda
8901 Wisconsin Ave
Bethesda, MD 20889
Phone: 301-319-8634
Email: Christopher.roach@med.navy.mil

Gregory Sees, RRT, RPSGT
Respiratory Therapist
Harry S. Truman Memorial Veterans Hospital
800 Hospital Dr.
Columbia MO, 65201
Tel: 573-814-6471
Email: Gregory.Sees@va.gov

Wayne Schriner, DO, MPH
Director, Population Health
Carl R. Darnall Army medical Center
36000 Darnall Loop
Fort Hood, TX 76544
Phone: 254-535-3426
Email: wayne.schimer@amedd.army.mil

Oded Susskind, MPH
Medical Education Consultant
Brookline MA 02446
Phone: 617- 232-3558
Email: oded@tiac.net
Mark Tucker, MD  
LCDR, MC, USN  
Allergist  
Naval Medical Center-San Diego  
2051 Cushing Road  
San Diego, CA 92106  
Phone: 619-524-1519  
Email: Mark.Tucker@med.navy.mil

Henry Wojczak, MD  
CAPT, MC, USN  
Pediatric Pulmonologist  
Naval Medical Center San Diego  
34800 Bob Wilson Drive  
San Diego, CA 92124-5000  
Phone: 619-532-6883  
Email: henry.wojczak@med.navy.mil

Jane Jacknewitz-Woolard, RN, MSN, P/FNP, CS  
Pediatric Nurse Practitioner  
Walter Reed Army Medical Center  
6900 Georgia Ave, NW  
Washington, DC 20307  
Phone: 202-682-4498/3405  
Email: jane.jacknewitz-woolard@amedd.army.mil
Appendix I
Bibliography


Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006 Aug;100:1297-1306


Bailey EJ, Kruske SG, Morris PS, Cates CJ, Chang AB. Culture-specific programs for children and adults from minority groups who have asthma, Cochrane Database Syst Rev 2008 Apr 16;(2):CD006580..


Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007;175:661-666.


Centers for Disease Control-Forecasted Data-Specific Estimate of self-reported asthma prevalence-US 1998; MMWR Morb-Mortal wkly; Rep 1998; 47; 1022-1025


Cheng J, Pan Tao, Ye GH, Liu Q. Calorie controlled diet for chronic asthma. Cochrane Database of Systematic Reviews 2003, Issue 2. CD004674


DiFranza JR; Aligne CR; Weitzman M. Prenatal and Postnatal Environmental Tobacco Smoke Exposure and Children’s Health Pediatrics, Apr 2004; 113: 1007 – 1015.


Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2002;(3):CD002314.


FDA advisory committees –Available at: http://www.fda.gov/AdvisoryCommittees/default.htm


Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database of Systematic Reviews 2007, Issue 4. CD001187

Greenstone IIIG, Ni Chroinin M, Lasserson TJ, Ducharme F. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews 2005, Issue 4.


Markham AW; Wilkinson JM Complementary and alternative medicines (CAM) in the management of asthma; an examination of the evidence. J Asthma 2004; 41:131

Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005 Sep;60(9):730-4.


Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;(2) CD002314.


Reddel H, Marks G, Jenkins C. When can personal best peak flow be determined for asthma action plans. Thorax 2004 Nov; 59: 922-924.


Sorkness CA. Traditional and new approaches to asthma monitoring. Respiratory Care 2008 May;53(5): 593-601.


